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Abstract
To cope with the dynamic range of stressful stimuli that a cell experiences within its lifetime, a
host of adaptive cell survival and cell stress response pathways have evolved. The antioxidant and
heat shock responses are two key cell stress response pathways primarily involved in the
detoxification and elimination of oxidative stress and the maintenance of protein integrity,
respectively. Traditionally, these responses are regarded and studied as two independent pathways.
In this exploratory work, we hypothesize that oxidative damage to Nrf2 and Keap1 and their
interactions with Hsp90 alter their function within the cellular antioxidant stress response. By
establishing and characterizing a novel yeast model for human Nrf2, the transcriptional master
regulator of the antioxidant response, a previously unexplored interaction was found between Nrf2
and the major heat shock response protein, Hsp90. Further investigation into this interaction using
mammalian and breast cancer cells reveals the co-involvement of these proteins in key aspects of
protein oxidation, protein misfolding, and cellular responses to cancer therapy. Additionally, Nrf2
and its regulating protein Keap1 were observed to misfold and form protein inclusions upon
exposure to oxidative stress, which might implicate a previously unknown mechanism of Nrf2
regulation by inclusion formation. These findings suggest that investigating the antioxidant and
heat shock responses in parallel may provide an additional layer of knowledge that is relevant to
both basic science and clinical research.

Keywords
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Summary for Lay Audience
All living things experience stress from the environment that can be harmful to cells within the
body. As a means of protection, cells have evolved numerous cell stress response pathways to
eliminate these insults. This includes the antioxidant response, which protects against harmful free
radicals, and the heat shock response, which protects cells from protein-damaging stress.
Traditionally, these responses are regarded and studied as two independent and separate pathways.
In this exploratory work, we hypothesize that oxidative damage to Nrf2 and Keap1 and their
interactions with Hsp90 alter their function within the cellular antioxidant stress response. Using
laboratory yeast, a new binding interaction was discovered between the key cell stress protein,
Nrf2, which regulates the antioxidant response, and Hsp90, which is a key player in the heat shock
response. Further investigation into these interactions using human cells (including cancer cells)
shows their co-involvement in important aspects of protein folding and cellular responses to cancer
therapy. Additionally, Nrf2 and its regulating protein Keap1 were observed to misfold and form
clusters known as inclusions inside the cell under certain stress conditions which could function
as a previously unknown “on/off switch” for their cellular activity. Since these two cell stress
response pathways overlap, these findings suggest that studying the antioxidant and heat shock
responses in parallel may provide important information that is relevant to both basic science and
clinical research.
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iv

Acknowledgements
My accomplishments in graduate school would not have been possible without all the people who
supported me throughout this important chapter of my academic career.
First, I would like to thank my supervisor, Dr. Martin Duennwald, for being there to support me
since day one. None of this work would have been possible without your invaluable mentorship. I
am grateful for everything we have done and accomplished together, from sharing ideas in your
office and learning how to culture cells, to all the experiments and discussions that led to the
writing of this dissertation. Thank you truly for encouraging me to work hard and for this
opportunity to learn and grow as a young scientist.
I would also like to thank my Graduate Advisory Committee, Dr. Wing-Yiu Choy, Dr. Christopher
Howlett, and Dr. Patrick Lajoie for their mentorship and guidance throughout the years. Your ideas
and suggestions have helped to shape my research in extremely important ways. An additional
thank-you to Dr. Lajoie for always providing me with helpful feedback whenever I did a practice
talk in lab meeting, Dr. Howlett for your help with the clinical aspects of my work, and Dr. Choy
for your assistance with editing my manuscripts during a very crucial time.
Thank you to my doctoral thesis examiners, Dr. Matthew Cecchini, Dr. Robert Cumming, and Dr.
Frederick Dick from the University of Western Ontario, and Dr. John Hayes from the University
of Dundee, for sharing their time to examine my work and provide me with helpful questions and
feedback. A special thank-you to Dr. Hayes for going above and beyond and providing me with
extensive questions and considerations that greatly helped to improve my work. Your expertise
and passion for the field are inspiring.
I would also like to thank our Department Chair, Dr. Zia Khan, for always having an open door
whenever I needed your assistance or advice. I appreciate your patience, kindness, and willingness
to help, and importantly, thank you for believing in me when I needed it the most. I would also
like to thank our previous Department Chair, Dr. Chandan Chakraborty for his guidance and
wisdom, and the administrative and technical staff from the Department of Pathology and
Laboratory Medicine for their assistance over the years.

v

To all the members of the Duennwald lab, past and present, thank you for sharing this experience
with me. Regardless of how big or small, I am grateful that we got to learn together and have fun
together both in and out of the lab. The good times we shared and the amazing things we
accomplished will never be forgotten. Thank you also to the members of the Lajoie lab for all the
good times in lab meeting and for their encouragement and support.
To all my friends and loved ones, thank you for always being there for me on both sunny days and
cloudy days. I appreciate each and every one of you and I am so grateful to have you in my life.
To those whom I met at Western, an extra thank-you for the reassurance and pep talks whenever
my experiments failed, and for celebrating with me whenever we achieved something great in our
degrees.
Finally, thank you to my family who has loved and supported me unconditionally. To my
wonderful brothers and sister, I honestly could not ask for better siblings to “che” at. To my mom
and dad, to whom I dedicate this work, words cannot express how grateful I am to both of you. I
got to where I am today because of your unwavering hard work and perseverance. From the bottom
of my heart, thank you for everything.

vi

Table of Contents
Abstract.......................................................................................................................................... i
Summary for Lay Audience.......................................................................................................... ii
Co-Authorships............................................................................................................................ iii
Dedication..................................................................................................................................... iv
Acknowledgements....................................................................................................................... v
Table of Contents........................................................................................................................ vii
List of Tables.............................................................................................................................. xiii
List of Figures............................................................................................................................. xiv
List of Supplementary Figures.................................................................................................. xvii
List of Abbreviations.................................................................................................................. xix
1

Introduction ........................................................................................................................... 1
1.1

Oxidative Stress and Antioxidant Enzymes ..................................................................... 1

1.1.1

Reactive Oxygen Species .......................................................................................... 1

1.1.2

Oxidative Stress ........................................................................................................ 4

1.1.3

Antioxidant Response Enzymes ............................................................................... 6

1.1.4

Antioxidant Response Element (ARE) ..................................................................... 8

1.2

Keap1-Nrf2 Antioxidant Pathway .................................................................................... 9

1.2.1

Nuclear factor erythroid 2-related factor 2 (Nrf2) .................................................. 10

1.2.2

Kelch-like ECH-associated protein (Keap1) .......................................................... 12

1.2.3

Keap1-Dependent Nrf2 Regulation ........................................................................ 14

1.2.4

Non-Canonical Nrf2 Regulation ............................................................................. 18

1.2.5

Nrf2-Interacting Proteins ........................................................................................ 20

1.2.6

Keap1-Interacting Proteins ..................................................................................... 21
vii

1.2.7
1.3

Other Mechanisms of Nrf2 Regulation ................................................................... 23

Nrf2 in Cell Physiology.................................................................................................. 24

1.3.1

Mitochondrial Redox Signaling .............................................................................. 24

1.3.2

Autophagy ............................................................................................................... 25

1.3.3

Inflammation ........................................................................................................... 25

1.3.4

ER Stress and the UPR ........................................................................................... 26

1.4

Nrf2 in Human Disease .................................................................................................. 27

1.4.1

Cardiovascular Disease ........................................................................................... 27

1.4.2

Neurodegeneration .................................................................................................. 27

1.4.3

Cancer ..................................................................................................................... 28

1.4.4

Nrf2 as a Therapeutic Target .................................................................................. 31

1.4.5

Ageing ..................................................................................................................... 32

1.5

Proteins and Oxidative Stress ......................................................................................... 33

1.5.1

Protein Folding and Quality Control....................................................................... 33

1.5.2

Molecular Chaperones ............................................................................................ 36

1.5.3

Heat shock protein 90 (Hsp90) ............................................................................... 37

1.5.4

Protein Degradation ................................................................................................ 42

1.5.5

Protein Sequestration .............................................................................................. 43

1.5.6

Autophagy ............................................................................................................... 44

1.5.7

Protein Oxidation .................................................................................................... 45

1.5.8

Cysteine Thiol Oxidation ........................................................................................ 46

1.6

Studying Protein Interactions ......................................................................................... 49

1.6.1

Genetic Interactions and Physical Protein-Protein Interactions.............................. 49

1.6.2

Yeast as a Model Organism to Study Protein Interactions ..................................... 50
viii

2

3

1.7

Hypothesis and Aims ..................................................................................................... 54

1.8

References ...................................................................................................................... 56

A novel yeast model detects Nrf2 and Keap1 interactions with Hsp90 .......................... 83
2.1

Introduction .................................................................................................................... 84

2.2

Results ............................................................................................................................ 86

2.2.1

Expression of human Nrf2 and associated proteins in yeast................................... 86

2.2.2

The split-ubiquitin system detects protein-protein interactions of Nrf2 ................. 94

2.2.3

Interaction between Nrf2 and Keap1 with Hsp90................................................... 97

2.3

Discussion .................................................................................................................... 103

2.4

Materials and Methods ................................................................................................. 105

2.4.1

Plasmids ................................................................................................................ 105

2.4.2

Yeast strains, culture conditions, and growth assays ............................................ 107

2.4.3

Spotting assay growth quantification .................................................................... 107

2.4.4

Yeast fluorescence microscopy............................................................................. 108

2.4.5

Electrophoresis and western blot analysis ............................................................ 108

2.4.6

Mammalian cell culture conditions and transfections .......................................... 109

2.4.7

Immunofluorescence microscopy ......................................................................... 109

2.4.8

Cell viability assays .............................................................................................. 110

2.4.9

Statistical analysis ................................................................................................. 110

2.5

Supplemental Figures ................................................................................................... 111

2.6

References .................................................................................................................... 121

Oxidative stress-induced misfolding and inclusion formation of Nrf2 and Keap1 ..... 126
3.1

Introduction .................................................................................................................. 127

3.2

Results .......................................................................................................................... 128
ix

3.2.1

Nrf2 is intrinsically disordered and Keap1’s high cysteine content is evolutionarily

conserved ............................................................................................................................ 128
3.2.2

Oxidative stress and Nrf2 and Keap1 expression in yeast .................................... 131

3.2.3

Nrf2 forms protein inclusions under oxidative stress conditions in HeLa cells ... 133

3.2.4

Nrf2 inclusion formation is oxidative stress-specific and prevented by certain

antioxidants ......................................................................................................................... 135
3.2.5

Keap1 forms protein inclusions under oxidative stress conditions in HeLa cells 137

3.2.6

Keap1 inclusion formation is oxidative stress-specific and cannot be prevented by

tested antioxidants............................................................................................................... 139
3.2.7

Oxidative stress-induced Keap1 inclusion formation in breast cancer cell lines .. 141

3.2.8

Purified proteins for Nrf2 and Keap1 form inclusions upon exposure to oxidative

stress.....................................................................................................................................142
3.3

Discussion .................................................................................................................... 144

3.4

Materials and Methods ................................................................................................. 146

3.4.1

Prediction of intrinsically disordered regions ....................................................... 146

3.4.2

Protein sequence alignment .................................................................................. 147

3.4.3

Yeast growth assays and microscopy ................................................................... 147

3.4.4

Cell lines and culture conditions ........................................................................... 147

3.4.5

Fluorescence and immunofluorescence microscopy ............................................ 148

3.4.6

Cell viability assays .............................................................................................. 148

3.4.7

SDS-PAGE and Coomassie blue gel staining ....................................................... 148

3.4.8

SDD-AGE (semi-denaturing detergent agarose gel electrophoresis) ................... 149

3.4.9

Combined SDD-AGE and fractionation assay ..................................................... 149

3.4.10 Statistical analysis ................................................................................................. 149
3.5

Supplementary Figures ................................................................................................. 150
x

3.6
4

References .................................................................................................................... 159

Hyperactive stress response pathways in HER2+ breast cancers ................................. 163
4.1

Introduction .................................................................................................................. 164

4.2

Results .......................................................................................................................... 166

4.2.1

HSP90AA1 is up-regulated in HER2-enriched breast cancers .............................. 166

4.2.2

Increased glutathione peroxidase mRNA expression levels following oxidative

stress and Hsp90 inhibition in HER2+ breast cancer cells ................................................. 169
4.2.3

Increased glutathione levels following oxidative stress and Hsp90 inhibition in

HER2+ breast cancer cells .................................................................................................. 172
4.2.4

Increased response to taxane-treatment and increased ROS levels in HER2+ cells

lines......................................................................................................................................175
4.2.5

HER2, Hsp90α, and Hsp90β protein expression levels in response to oxidative

stress and Hsp90 inhibition ................................................................................................. 178
4.2.6

Co-inhibition of Hsp90 and GPx in HER2+ breast cancer therapy ...................... 179

4.3

Discussion .................................................................................................................... 180

4.4

Materials and Methods ................................................................................................. 182

4.4.1

Cell lines and culture conditions ........................................................................... 182

4.4.2

Inhibitor treatment ................................................................................................ 183

4.4.3

RNA isolation and quantitative reverse transcription PCR (RT-qPCR) ............... 183

4.4.4

Preparation of protein lysates................................................................................ 185

4.4.5

Electrophoresis and western blot analysis ............................................................ 185

4.4.6

Cell viability, ROS, and glutathione assays .......................................................... 185

4.4.7

Bioinformatics analyses ........................................................................................ 186

4.4.8

Statistical analysis ................................................................................................. 187

4.5

Supplementary Figures ................................................................................................. 188
xi

4.6
5

References .................................................................................................................... 193

Discussion ........................................................................................................................... 201
5.1

Summary of Chapters ................................................................................................... 201

5.1.1

A novel yeast model for Nrf2 and Keap1 detects their interaction with Hsp90 ... 201

5.1.2

Oxidative stress-induced inclusion formation of Nrf2 and Keap1 ....................... 202

5.1.3

Hyperactive stress response pathways in HER2+ breast cancers ......................... 203

5.2

Exploring Nrf2 Interactions ......................................................................................... 204

5.3

Oxidative Damage and Nrf2 Regulation ...................................................................... 206

5.4

Reversibility of Cysteine Oxidation Inclusions ........................................................... 206

5.5

Cysteine Oxidation in Protein Regulation.................................................................... 207

5.6

Off-Target Effects and Crosstalk Between Cell Stress Pathways ................................ 208

5.7

Limitations ................................................................................................................... 209

5.7.1

Chapter 2 ............................................................................................................... 209

5.7.2

Chapter 3 ............................................................................................................... 210

5.7.3

Chapter 4 ............................................................................................................... 211

5.8

Future Directions .......................................................................................................... 212

5.9

Overall Significance ..................................................................................................... 213

5.10 Graphical Summary...................................................................................................... 214
5.11 References .................................................................................................................... 215
Curriculum Vitae ...................................................................................................................... 221

xii

List of Tables
Table 1.1: Major Reactive Oxygen and Reactive Nitrogen Species ............................................... 2
Table 1.2: Summary of Nrf2’s functional domains and their key binding proteins ..................... 11
Table 1.3: Examples of cytoprotective genes regulated by Nrf2 .................................................. 17
Table 1.4: Non-canonical Nrf2 regulation by direct protein interaction ...................................... 19
Table 1.5: Hsp90 isoforms in humans and yeast .......................................................................... 40
Table 2.1: Yeast expression plasmids created using Gateway cloning ...................................... 106
Table 2.2: Mammalian expression plasmids created using Gateway cloning ............................ 106
Table 2.3: Yeast split-ubiquitin plasmids created using restriction digest and ligation-based
cloning ................................................................................................................................ 107
Table 2.4: Antibodies for western blot analyses ......................................................................... 109
Table 4.1: Primer sequences utilized for RT-qPCR in mRNA studies ....................................... 184
Table 4.2: Publicly available datasets utilized for analysis ........................................................ 186

xiii

List of Figures
Figure 1.1: Sources of exogenous and endogenous ROS ............................................................... 4
Figure 1.2: Oxidative stress in human disease ................................................................................ 5
Figure 1.3: Activation of the ARE by Nrf2 .................................................................................... 8
Figure 1.4: The Keap1-Nrf2 pathway ........................................................................................... 10
Figure 1.5: Domain structure of human Nrf2 ............................................................................... 11
Figure 1.6: Domain structure of human Keap1 ............................................................................ 13
Figure 1.7: Stress-induced cysteine modification of Keap1 ......................................................... 14
Figure 1.8: Two-site substrate recognition model for Keap1-dependent Nrf2 regulation ............ 15
Figure 1.9: The aberrant Keap1-Nrf2 pathway in cancer ............................................................. 29
Figure 1.10: Nrf2 protects cancer cells from cancer therapy ........................................................ 31
Figure 1.11: Thermodynamics of protein folding ......................................................................... 34
Figure 1.12: Equilibrium between native and non-native protein folding conformations ............ 35
Figure 1.13: Cellular mechanisms of protein quality control ....................................................... 36
Figure 1.14: Domain structure of human Hsp90 .......................................................................... 38
Figure 1.15: Hsp90 chaperone activity ......................................................................................... 39
Figure 1.16: Hsps are regulated by Hsf1 ...................................................................................... 41
Figure 1.17: The role of Hsp90 in promoting tumourigenesis...................................................... 42
Figure 1.18: Forms of cysteine ..................................................................................................... 46
Figure 1.19: The sulfur oxidation pathway with oxidation by hydrogen peroxide (H2O2) .......... 47
Figure 1.20: Oxidative stress-induced cysteine oxidation ............................................................ 48
Figure 1.21: Using a yeast model to study protein interactions .................................................... 50
Figure 1.22: Yeast growth assay for detecting genetic interactions ............................................. 51
Figure 1.23: Yeast two-hybrid (Y2H) system for detecting PPIs ................................................. 52
xiv

Figure 1.24: The split-ubiquitin system for detecting PPIs .......................................................... 53
Figure 1.25: Investigating crosstalk between the antioxidant and heat shock responses ............. 55
Figure 2.1: Expression of human Nrf2 in yeast ............................................................................ 87
Figure 2.2: Nrf2 fragments expressed in yeast ............................................................................. 89
Figure 2.3: Co-expression of Nrf2 with other Nrf2-associated proteins ...................................... 92
Figure 2.4: Nrf2 mutant variants expressed in yeast..................................................................... 94
Figure 2.5: The yeast split-ubiquitin system for studying physical Nrf2 protein-protein
interactions ............................................................................................................................ 96
Figure 2.6: Interaction between Nrf2 and Keap1 with Hsp90 ...................................................... 98
Figure 2.7: Expression of Nrf2 in yeast Hsp90 and co-chaperone deletion strains and
overexpression constructs ................................................................................................... 100
Figure 2.8: Nrf2 and Keap1 expressed in HeLa cells with Hsp90 detection .............................. 103
Figure 3.1: Protein disorder analyses and cysteine analyses for Nrf2 and Keap1 ...................... 131
Figure 3.2: Oxidative stress and Nrf2 and Keap1 in yeast ......................................................... 132
Figure 3.3: Nrf2 forms inclusions upon exposure to oxidative stress in vitro ............................ 134
Figure 3.4: Further analyses of the oxidative stress-induced protein misfolding of Nrf2 .......... 136
Figure 3.5: Keap1 forms inclusions upon exposure to oxidative stress in vitro ......................... 138
Figure 3.6: Further analyses of Keap1 oxidative stress-induced protein misfolding ................. 140
Figure 3.7: Keap1 forms oxidative stress-induced inclusions in breast cancer cell lines ........... 141
Figure 3.8: Nrf2 and Keap1 purified proteins aggregate upon exposure to oxidative stress in vitro
............................................................................................................................................ 143
Figure 4.1: HSP90AA1 is up-regulated in HER2-enriched breast cancers ................................ 169
Figure 4.2: Relative mRNA expression levels for GPX2 and GPX3 are significantly upregulated
following oxidative stress with Hsp90 inhibition ............................................................... 172

xv

Figure 4.3: Glutathione levels and ratios in response to oxidative stress, Hsp90 inhibition, and
combined treatment ............................................................................................................. 175
Figure 4.4: Relative cell viability and ROS levels in response to oxidative stress, Hsp90
inhibition, or combined treatment ....................................................................................... 178
Figure 4.5: Protein expression levels in response to oxidative stress, Hsp90 inhibition, and
combined treatment ............................................................................................................. 179
Figure 5.1: Summary of the observed Nrf2 interactions in yeast ............................................... 202
Figure 5.2: Nrf2 and Keap1 misfold and form protein inclusions upon oxidative stress ........... 203
Figure 5.3: Hsp90 inhibition in HER2+ breast cancer leads to GPx overexpression during
oxidative stress .................................................................................................................... 204
Figure 5.4: Graphical summary of Chapters 2, 3, and 4 ............................................................. 214

xvi

List of Supplementary Figures
Figure S2.1: Nrf2 protein interactions ........................................................................................ 111
Figure S2.2: Propidium iodide assay for Nrf2 and Keap1 expressed in yeast ............................ 112
Figure S2.3: Fluorescence microscopy for all proteins of interest expressed in yeast ............... 113
Figure S2.4: Cell viability assay for wild-type Nrf2 and its fragmented variants expressed in
HEK293 cells ...................................................................................................................... 114
Figure S2.5: Liquid growth curve for the co-expression of Nrf2 and Keap1 in yeast ................ 115
Figure S2.6: p21 co-expressed with Nrf2 mutant variants in yeast ............................................ 116
Figure S2.7: Keap1 expressed in yeast Hsp90 deletion strains .................................................. 117
Figure S2.8: (A-E) Control plates for growth assay interaction studies ..................................... 118
Figure S2.9: (A-E) Control plates for split-ubiquitin interaction studies ................................... 119
Figure S2.10: (A-B) Control plates for Hsp90 deletion and overexpression studies.................. 120
Figure S3.1: Individual disordered profile plots for PrDOS, IUPred2U, and PONDR .............. 150
Figure S3.2: The 15 species observed in cysteine analysis studies ............................................ 151
Figure S3.3: Yeast oxidative stress gene deletion strains ........................................................... 152
Figure S3.4: Full panel of growth assays for Nrf2 expression in yeast oxidative stress deletion
strains .................................................................................................................................. 153
Figure S3.5: Full panel of growth assays for Keap1 expression in yeast oxidative stress deletion
strains .................................................................................................................................. 154
Figure S3.6: Growth assay control plates for all yeast oxidative stress deletion studies ........... 155
Figure S3.7: Optimization of hydrogen peroxide treatment concentration and duration ........... 156
Figure S3.8: GFP controls for protein oxidation studies in HeLa cells ...................................... 157
Figure S3.9: Cell viability following hydrogen peroxide treatment in HEK293 cells ............... 158
Figure S4.1: HSP90AA1 expression is associated with Nrf2 and Hsf1 signalling pathways in
HER2+ breast cancers ......................................................................................................... 188
xvii

Figure S4.2: List of Nrf2 and Hsf1 target genes evaluated by RT-qPCR................................... 189
Figure S4.3: Relative mRNA levels for NFE2L2 and HSF1 ...................................................... 190
Figure S4.4: Relative mRNA levels for GSS and GSR .............................................................. 191
Figure S4.5: STRING interaction of Nrf2 and Hsf1 target genes ............................................... 192

xviii

List of Abbreviations
5FOA

5-fluorouracil

AD

Alzheimer’s disease

AD

activating domain

ADP

adenosine diphosphate

Aha1

activator of hsp90 ATPase protein 1

ALS

amyotrophic lateral sclerosis

AP-1

activator protein 1

ARE

antioxidant response element

ATF6

activating transcription factor 6

Atg8

autophagy-related protein 8

ATP

adenosine triphosphate

Bach1

BTB domain and CNC homolog 1

Bach2

BTB domain and CNC homolog 2

BCA assay

bicinchoninic acid assay

BRCA1

breast cancer 1

BRCA2

breast cancer 2

BSA

bovine serum albumin

BSO

buthionine sulfoximine

BTB

broad complex, tramtrack, and bric à brac

bZIP

basic leucine zipper domain

CBP

CREB-binding protein

Cdc37

cell division cycle protein 37

Cdk2

cyclin-dependent kinase 2

CHD6

DNA-binding protein 6

CLIPS

chaperones linked to protein synthesis

CMA

chaperone-mediated autophagy

CNC

cap 'n' collar

CRL

Cullin-RING E3 ubiquitin ligases

CRU

Cub-R-URA3
xix

CTR

C-terminal region

Cub

C-ubiquitin

Cul3

Cullin 3

DBD

DNA-binding domain

DJ-1

protein deglycase DJ-1

DMEM

Dulbecco's Modified Eagle Medium

DMSO

dimethyl sulfoxide

DNA

deoxyribonucleic acid

dNTP

deoxynucleotide

DPP3

dipeptidyl-peptidase 3

DsRed

Discosoma red fluorescent protein

eIF2α

eukaryotic initiation factor 2 alpha

eNOS

endothelial isoform of nitric oxide synthase

EpRE

electrophile response element

ER

endoplasmic reticulum

ERAD

endoplasmic reticulum-associated protein degradation

FANCN

Fanconi anemia complementation group N

FBS

fetal bovine serum

GEO

Gene Expression Omnibus

GFP

green fluorescent protein

GKS-3

glycogen synthase kinase-3

GCL

glutamate-cysteine ligase

GCLC

glutamate-cysteine ligase catalytic subunit

GCLM

glutamate-cysteine ligase modifier subunit

GOF

gain of function

GPx

glutathione peroxidase

GSH

glutathione

GSSG

glutathione disulfide

GST

glutathione S-transferase

H2O2

hydrogen peroxide

HD

Huntington’s disease
xx

HER2

human epidermal growth factor receptor 2

HIF1α

hypoxia-inducible factor 1α

HO-1/HMOX1

heme oxygenase 1

Hop

Hsp70/Hsp90 organizing protein

Hsf1

heat shock factor 1

Hsp

heat shock protein

Hsp70

heat shock protein 70

Hsp90

heat shock protein 90

ICGC

International Cancer Genome Consortium

IDP

intrinsically disordered protein

IDR

intrinsically disordered region

IHC

immunohistochemistry

IL-1β

interleukin 1 beta

IL-6

interleukin 6

IPOD

insoluble protein deposit

ITC

isothermal titration calorimetry

IVR

intervening region

JUNQ

juxtanuclear quality control

Keap1

Kelch-like ECH-associated protein 1

KIR

Keap1-interacting region

KPNA6

karyopherin α6

LOF

loss of function

MG132

carbobenzoxy-l-leucyl-l-leucyl-l-leucinal

MTOC

microtubule-organizing centre

Miro2

mitochondrial Rho GTPase 2

Msr

methionine sulfoxide reductase

MS

multiple sclerosis

NAC

N-acetylcysteine

Neh

Nrf2-ECH homology

NF-ΚB

nuclear factor kappa B

NLS

nuclear localization signal
xxi

NMR

nuclear magnetic resonance

NQO1

NAD(P)H:quinone dehydrogenase 1

Nrf2/NFE2L2

nuclear factor (erythroid-derived 2)-like 2

NTR

N-terminal region

Nub

N-ubiquitin

OD600

optical density at 600 nm

OE

overexpression

PALB2

partner and localizer of BRCA2

PBST

phosphate-buffered saline with tween

PCR

polymerase chain reaction

PD

Parkinson’s disease

PEG

polyethylene glycol

PERK

protein kinase RNA-like endoplasmic reticulum kinase

PGAM5

phosphoglycerate mutase family member 5

Pgk1

phosphoglycerate kinase 1

PI

propidium iodide

PKC

protein kinase C

PPI

protein-protein interaction

ProTα/PTMA

prothymosin alpha

Rb

retinoblastoma

Rbx1

RING box protein 1

RNAseq

RNA sequencing

RNS

reactive nitrogen species

ROS

reactive oxygen species

RPMI 1640

Roswell Park Memorial Institute 1640

RT-qPCR

quantitative reverse transcription-polymerase chain reaction

RXRα

retinoid X receptor α

SD

selective dextrose

SDD-AGE

semi-denaturing detergent agarose gel electrophoresis

SDS

sodium dodecyl sulfate

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel electrophoresis
xxii

sHsp

small heat shock protein

sMaf

small musculoaponeurotic fibrosarcoma

SOD

superoxide dismutase

SQSTM1

sequestosome-1

Srx

sulfiredoxin

Sti1

stress-inducible protein 1

tBHQ

tertiary butylhydroquinone

TCGA

The Cancer Genome Atlas

TE

tris-ethylenediaminetetraacetic acid

TF

transcription factor

TPR

tetratricopeptide repeat

Trx

thioredoxin

TrxR

thioredoxin reductase

UAS

upstream activating sequence

UGT

uridine diphosphate (UDP)-glucuronosyltransferase

UPR

unfolded protein response

UPS

ubiquitin-proteasome system

v/v

volume/volume

WT

wild-type

Y2H

yeast two-hybrid

YFP

yellow fluorescent protein

YPD

yeast extract peptone dextrose

αMEM

alpha Minimum Essential Medium

βME

beta-mercaptoethanol

βTrCP

beta-transducin repeat-containing protein

γ-GCS

gamma-glutamylcysteine synthetase

xxiii

Chapter 1
1

Introduction

1.1

Oxidative Stress and Antioxidant Enzymes

Organisms are continually exposed to exogenous and endogenous sources of reactive oxygen
species (ROS) and other oxidants that have both beneficial and deleterious effects on the cell. ROS
have important roles in a wide range of biological processes; however, high levels are associated
with oxidative stress and disease progression. Antioxidant defence systems have thus been evolved
as a means of protection against oxidative stress.

1.1.1 Reactive Oxygen Species
Free radicals are unstable atoms, ions, or molecules containing one or more unpaired electrons in
the outermost electron shell. An unpaired valence electron is unstable and highly reactive. To attain
stability, free radicals attack and acquire electrons from other compounds or molecules within their
proximity. The attacked entity loses an electron to become oxidized and becomes a free radical
itself, thereby initiating a chain reaction cascade that can result in cellular damage (Halliwell &
Gutteridge, 2015). ROS and reactive nitrogen species (RNS) are unstable molecules containing
oxygen and/or nitrogen and include both free radical and non-radical species. The oxygen
molecule (O2••) is a weak free radical itself due to the presence of two unpaired electrons in its
valence shell; however, it is less reactive than other oxygen species due to the parallel spin of its
electrons (Apel & Hirt, 2004). Major ROS and RNS are outlined in Table 1.1.
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Table 1.1: Major Reactive Oxygen and Reactive Nitrogen Species.
Molecule Type

Radical Status

Name

Symbol

ROS

Radical

Molecular oxygen

O2••

Superoxide

O2•–

Hydroxyl

•OH

Alkoxyl

RO•

Peroxyl

ROO•

Hydroperoxyl

HO2•

Hydrogen peroxide

H2O2

Peroxide

ROOR

Singlet oxygen

O2

Ozone

O3

Hydroxyl ion

OH–

Peroxynitrite

ONOO−

Nitric oxide

•NO

Nitrogen dioxide

•NO2

Peroxynitrite

ONOO−

Alkyl peroxynitrites

ROONO

Nitronium cation

NO2+

Nitroxyl cation

NO+

Nitroxyl anion

NO−

Nitrogen oxides

NxOx

Non-radical

RNS

Radical

Non-radical

RNS is a family of nitrogen moieties associated with oxygen. They are produced when nitric oxide
(•NO) reacts with oxygen species. For example, nitric oxide can react with superoxide (O2•–) to
form peroxynitrite (ONOO−):
•NO + O2•−

→ ONOO−
2

Peroxynitrite is very reactive and readily attacks lipid molecules, resulting in lipid peroxidation
and lipoprotein oxidation (Radi, 2018). However, like ROS, low levels of RNS have important
roles in cellular processes. For example, nitric oxide produced by nitric oxide synthase (NOS)
regulates blood vessel dilation and is involved in synaptic transmission in the brain (O'Dell et al.,
1991; Schuman & Madison, 1991). On the other hand, high levels of RNS results in nitrosative
stress, macromolecule damage, and activation of transcription factors NF-ΚB and activator protein
1 (AP-1) involved in inflammation and other pathological pathways (Kröncke, 2003; Martínez &
Andriantsitohaina, 2009). RNS and ROS often act together to cause cellular damage (Valko et al.,
2006).
ROS are oxidants (i.e., a molecule that removes electrons from other molecules) predominantly
produced as byproducts of normal cellular metabolism and biochemical processes within the cell.
Mitochondria are a primary source of ROS produced by aerobic respiration (Muller, 2000; Turrens,
2003; Andreyev et al., 2005; Adam-Vizi & Chinopoulos, 2006), where the reduction of molecular
oxygen in the electron transport chain results in the leaking of superoxide radicals which are
readily detoxified to hydrogen peroxide (H2O2) by antioxidant enzymes such as catalase and
glutathione peroxidase. Hydrogen peroxide may react with transition metals such as iron (Fe2+) to
produce hydroxyl radicals via the Fenton reaction to further produce hydroxyl radicals (•OH)
which are highly reactive towards all components of DNA molecules as well as lipids (Imlay et
al., 1988). Peroxisomes also generate ROS from aerobic metabolism (Fransen et al., 2012), and
phagocytic neutrophils and macrophages produce ROS to eliminate invading pathogens (Roos et
al., 2003). At low to moderate levels, ROS plays an important role in normal cell physiology,
serving as secondary messengers in intracellular signalling cascades that mediate cell growth,
autophagy, inflammatory and immune function, and contribute to overall redox regulation (Bae et
al., 2011; Finkel, 2011). However, both radical and non-radical ROS can be powerful oxidants that
are detrimental to the cell upon high or chronic exposure. Toxic exogenous sources of ROS include
pollution, tobacco smoke, alcohol, ozone, environmental and industrial toxins, and radiation. Due
to their reactive nature, ROS production and elimination must be strictly regulated by the cell.
Figure 1.1 summarizes the major sources of exogenous and endogenous ROS.
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Figure 1.1: Sources of exogenous and endogenous ROS. ROS can come from toxic exogenous
sources in the environment, or be produced as by-products of normal cell metabolism,
inflammation, and immunity. ROS may also function as secondary messengers within cell
signalling pathways.

1.1.2 Oxidative Stress
Extensive or prolonged exposure to ROS results in oxidative stress, a deleterious process that
damages lipids, proteins, and nucleic acids in the cell, thereby inhibiting their normal function
(Apel & Hirt, 2004). In this scenario, there is an imbalance between the production of ROS and
cellular defence mechanisms against oxidative stress, i.e., the antioxidant defence systems.
Chronic oxidative stress and the resultant oxidative damage have been implicated in many human
diseases including cardiovascular disease, neurodegenerative diseases, diabetes, cancer, and the
ageing process (Barnham et al., 2004; Reuter et al., 2010; Alfadda & Sallam, 2012; Asmat et al.,
2016; Liguori et al., 2018) (Figure 1.2).
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Figure 1.2: Oxidative stress in human disease. A prolonged imbalance between ROS production
and cellular antioxidant defence systems leads to oxidative stress. Oxidative stress damages
cellular macromolecules and has been implicated in many human diseases.

The consequence of ROS or oxidants and the extent of oxidative stress is dependent on the
strength, duration, and context of exposure. In response to oxidative stress, cells typically undergo
cell cycle arrest and enter the G0 phase (i.e., a quiescent, non-dividing stage) due to activation of
the p53-regulated cyclin-dependent kinase inhibitor p21, which halts cell cycle progression and
inhibits DNA synthesis (Xiong et al., 1993; Gartel & Radhakrishnan, 2005). ROS can also trigger
the p53 and p21-mediated dephosphorylation and activation of the tumour-suppressor
retinoblastoma protein (Rb) resulting in further inhibition of cell cycle progression (Brugarolas et
al., 1999). It is interesting to note that p21 is also involved in the regulation of the antioxidant
response through its binding to the antioxidant transcription factor, Nrf2 (Chen et al., 2009b) (to
be discussed in Section 1.2.5). Depending on the nature of the exposure, cells can activate cell
survival pathways; however, chronic exposure or excessively high levels of ROS may result in the
induction of autophagic or apoptotic pathways (Chen et al., 2008; Redza-Dutordoir & AverillBates, 2016).
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To preserve the delicate balance between the beneficial and harmful effects of ROS, living
organisms have evolved cellular defence mechanisms against oxidative stress to maintain redox
homeostasis. Alterations in redox status can lead to the transcriptional activation of pathways and
enzymes involved in the detoxification, transport, and elimination of ROS.

1.1.3 Antioxidant Response Enzymes
Complex antioxidant defence systems have been evolved to protect cells and tissue against
oxidative stress. Halliwell and Gutteridge have defined antioxidants as “any substance that, when
present in low concentrations compared to that of an oxidizable substrate, significantly delays or
inhibits the oxidation of that substrate” (Halliwell & Gutteridge, 1995). Key antioxidant defences
include (1) antioxidants that directly scavenge ROS, such as glutathione, vitamin C, and vitamin
E, and (2) antioxidant enzymes including superoxide dismutase, catalase, and glutathione
peroxidase.
Superoxide dismutases (SOD) are a class of enzymes found within the cytosol and mitochondria
of nearly all aerobic cells and contain metal ion cofactors such as copper, zinc, manganese, or iron.
SOD isoenzymes include Cu,Zn SOD (SOD1), Mn SOD (SOD2), and extracellular (EC) SOD
(SOD3) (Zelko et al., 2002; Abreu & Cabelli, 2010). SODs are responsible for the dismutation
(simultaneous oxidation and reduction) and breakdown of superoxide radicals into molecular
oxygen and hydrogen peroxide:
SOD
2O2•– + 2H+ → O2 + H2O2
Molecular oxygen and hydrogen peroxide are weak oxidants that are relatively stable; however,
hydrogen peroxide can be converted into extremely reactive hydroxyl radicals and must therefore
be targeted for further breakdown. Two enzymes responsible for the decomposition of hydrogen
peroxide are catalase and glutathione peroxidase.
Catalase is found in nearly all living organisms and exists primarily within peroxisomes as well as
in the mitochondria and nucleus (Chelikani et al., 2004). Catalases catalyze the breakdown of
hydrogen peroxide to molecular oxygen and water:
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catalase
2H2O2 → O2 + 2H2O
Glutathione peroxidases (GPx) are a class of enzymes that also break down hydrogen peroxide but
do so specifically through the oxidation of a glutathione (GSH) cofactor:
GPx
2GSH + H2O2 → GSSG + 2H2O
GSH is a tripeptide comprised of three amino acids (cysteine, glutamic acid, and glycine) and is
the most abundant and important low molecular weight antioxidant synthesized in cells. GSH plays
a critical role in protecting cells from oxidative damage through direct antioxidant activity or
coupled to GPx enzymatic activity (Pompella et al., 2003; Forman et al., 2009). Enzymes in the
GPx family include GPx1 through 8, each with different expression patterns within the body
(Brigelius-Flohé & Maiorino, 2013). GPx1 is the most abundant isoform and is ubiquitously
expressed in the cytosol and mitochondria. GPx2 is an intestinal extracellular enzyme, while GPx3
is extracellular, and GPx4 prefers lipid peroxides. Four additional isoforms of GPx (GPx5-8) have
been identified in humans but are not well studied. GPx enzymes are part of a family of critical
proteins known as the phase II enzymes responsible for the conjugation of xenobiotics with
peptides and sugars for detoxification.
Xenobiotic metabolism consists of phase I, phase II, and phase III enzymes involved in oxidation,
conjugation/detoxification, and elimination, respectively (Xu et al., 2005; Nakata et al., 2006).
Phase II enzymes are particularly important in cellular responses to oxidative stress and include
GPx, glutathione S-transferase (GST), and UDP-glucuronosyltransferase (UGT). Other important
antioxidant enzymes include sulfiredoxin (Srx), thioredoxin (Trx), thioredoxin reductase (TrxR),
heme oxygenase 1 (HO-1), and NAD(P)H:quinone oxidoreductase 1 (NQO1). Activation of these
enzymes leads to robust xenobiotic detoxification and/or antioxidant effects. Early mechanistic
studies on the induction of the rat glutathione S-transferase subunit genes, GSTA1 and GSTA2, led
to the discovery of a specific enhancer sequence within their promoter region termed the
antioxidant response element (ARE) (Rushmore et al., 1991). Since then, AREs have been found
in many other antioxidant genes including, among others, NQO1 and HMOX1 (Rushmore et al.,
1991; Nioi et al., 2003).
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1.1.4 Antioxidant Response Element (ARE)
The ARE (Rushmore et al., 1991), also referred to as the electrophile response element (EpRE), is
a cis-acting enhancer sequence found within the promoter region of many cytoprotective
antioxidant and phase II enzyme genes. It has a core sequence of 5’-TGACnnnGC-3’ and is
involved in inducible gene expression in response to oxidative stress (Rushmore et al., 1991). The
ARE is also responsible for low-level basal gene expression to mitigate the ROS produced by
cellular respiration. Thus, the ARE is important for redox regulation under both stressed and nonstressed conditions. Using in vivo studies in mice, Itoh et al. discovered that the induction of phase
II enzymes through the ARE is mediated by a protein transcription factor called Nrf2 (Itoh et al.,
1997) (Figure 1.3). Nrf2-deficient mice showed marked reductions in the expression of the phase
II enzyme GST α1 subunit and the antioxidant enzyme NQO1 (Itoh et al., 1997), and ensuing
studies demonstrated increased sensitivity to carcinogens and impaired detoxification of
acetaminophen in Nrf2-/- mice (Chan et al., 2001; Enomoto et al., 2001; Ramos-Gomez et al.,
2001). This illustrates the important role of Nrf2 in the activation of ARE-regulated antioxidant
and phase II enzyme genes.

Figure 1.3: Activation of the ARE by Nrf2. Nrf2 heterodimerizes with sMaf proteins and binds
to the ARE found within the promoter region of antioxidant and phase II enzyme genes to activate
their transcription.
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1.2

Keap1-Nrf2 Antioxidant Pathway

Nuclear factor erythroid 2-related factor 2 (Nrf2) (Moi et al., 1994) is the transcriptional master
regulator of cellular responses against oxidative stress. Nrf2 regulates the expression of a multitude
of antioxidant and phase II enzyme genes and is negatively regulated by Kelch-like ECHassociated protein (Keap1) (Itoh et al., 1999), a substrate adaptor protein that binds to Nrf2 in the
cytosol to facilitate its polyubiquitination by the Cullin 3 (Cul3) E3 ubiquitin ligase for
proteasomal degradation (McMahon et al., 2003; Nguyen et al., 2003; Kobayashi et al., 2004).
Constitutive Nrf2 degradation allows for low basal expression under non-stressed conditions.
Upon oxidative stress, specific stress-sensing cysteine residues in Keap1 are modified (DinkovaKostova et al., 2002; Zhang & Hannink, 2003; Wakabayashi et al., 2004), leading to a
conformational change that prevents Keap1 from mediating the ubiquitination of Nrf2 by Cul3
(Kobayashi et al., 2006). This results in Nrf2 stabilization, accumulation, and nuclear translocation
where Nrf2 heterodimerizes with sMaf proteins and binds to the ARE for the robust induction of
cytoprotective genes for enzymes involved in the detoxication of ROS and other oxidants (Itoh et
al., 1997) (Figure 1.4).
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Figure 1.4: The Keap1-Nrf2 pathway. Under basal conditions, Keap1 is bound to Nrf2 and Nrf2
is ubiquitinated by the Cul3 E3 ubiquitin ligase for degradation by the proteasome. Upon oxidative
stress, sensor cysteines in Keap1 are modified by ROS, leading to Nrf2 stabilization, accumulation,
and translocation to the nucleus where Nrf2 heterodimerizes with sMaf and binds to the ARE to
activate the transcription of antioxidant genes.

1.2.1 Nuclear factor erythroid 2-related factor 2 (Nrf2)
Nrf2 (Moi et al., 1994) belongs to the cap 'n' collar (CNC) subfamily of basic leucine zipper
(bZIP) transcription factors together with NF-E2 p45-related factors 1 and 3 (Nrf1 and Nrf3),
NF-E2 p45, and transcriptional repressors BTB Domain and CNC homolog 1 and 2 (Bach1 and
Bach2) (Sykiotis & Bohmann, 2010). Nrf2 contains seven conserved regions that are referred to
as the Nrf2-ECH homology (Neh) domains, designated Neh1 through 7 (Figure 1.5). The key
function of each domain is summarized in Table 1.2.

10

Figure 1.5: Domain structure of human Nrf2. Nrf2 contains seven conserved Neh domains. The
Neh2 domain contains two motifs (29DLG31 and 79ETGE82) wherein Keap1 binds as a substrate
adaptor for the Cul3-mediated ubiquitination and degradation of Nrf2.

Table 1.2: Summary of Nrf2’s functional domains and their key binding proteins.
Domain

Key Associated Function

Binds to

Reference(s)

Neh1

DNA-binding via the ARE;
dimerization with sMaf proteins

sMaf, ARE

(Moi et al., 1994; Itoh et
al., 1997)

Neh2

Keap1-binding for negative
regulation

Keap1

(Itoh et al., 1999; Tong et
al., 2006a)

Neh3

Transactivation

CHD6

(Nioi et al., 2005)

Neh4, Neh5

Transactivation

CBP

(Katoh et al., 2001; Kim et
al., 2013a)

Neh6

βTrCP-binding for negative
regulation

βTrCP

(Rada et al., 2011;
Chowdhry et al., 2013)

Neh7

RXRα-binding for suppressed
transactivation

RXRα

(Wang et al., 2013a)

Neh1 is the DNA-binding domain that contains the CNC-bZIP region important for Nrf2’s
association with sMafs, binding to the ARE, and transcription factor activity (Moi et al., 1994; Itoh
et al., 1997). The N-terminal Neh2 domain is a redox-sensitive degron that negatively regulates
Nrf2 activity and contains two highly conserved

29

DLG31 and 79ETGE82 motifs to which Keap1

binds, as well as seven lysine residues that are targets for ubiquitination by the Cul3 E3 ubiquitin
ligase (Itoh et al., 1999; Tong et al., 2006b). The C-terminal Neh3 domain is a transactivation
domain responsible for the transcriptional activation (transactivation) of Nrf2 and has been shown
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to interact with chromodomain helicase DNA-binding protein 6 (CHD6) which plays a role in
chromatin remodelling (Nioi et al., 2005). Neh4 and Neh5 are also transactivation domains where
the binding of the CREB-binding protein (CBP) (Katoh et al., 2001) or various other cofactors
(Kim et al., 2013a) increases the rate of Nrf2 transcriptional activity. The Neh6 domain is a redoxinsensitive degron that provides Keap1-independent negative Nrf2 regulation. Similar to Neh2,
Neh6 contains two highly conserved

334

DSGIS338 and

373

DSAPGS378 motifs to which the β-

transducin repeat-containing protein (βTrCP) binds, and within the DSGIS motif, a
phosphorylation site for glycogen synthase kinase-3 (GSK3) that enhances βTrCP activity upon
GSK3-mediated phosphorylation of Nrf2 (Rada et al., 2011; Chowdhry et al., 2013). Neh7 is the
binding domain for retinoid X receptor α (RXRα), which upon RXRα binding impairs the
recruitment of cofactors to Neh4 and Neh5 necessary for transactivation, thereby suppressing
transcriptional activation (Wang et al., 2013a).

1.2.2 Kelch-like ECH-associated protein (Keap1)
Keap1 (Itoh et al., 1999) belongs to the BTB-Kelch family of proteins which includes about 50
members, all of which assemble with the Cul3 E3 ubiquitin ligase and RING box protein-1 (Rbx1)
to form the Cullin-RING E3 ubiquitin ligases (CRLs) involved in the ubiquitination of BTB-Kelch
proteins, such as Keap1 (Kobayashi et al., 2004; Zhang et al., 2004). Cul3 assembly requires a “3box” motif that is characteristic of BTB-Kelch proteins (Canning et al., 2013). Accordingly, Keap1
contains three functional domains (Figure 1.6). The N-terminal BTB (broad complex, tramtrack,
and bric à brac) domain mediates Keap1 homodimerization and contributes to its interaction with
Cul3 (Cleasby et al., 2014). Additional Cul3 interaction is provided by a 3-box motif found within
the proximal part of the intervening region (IVR) (Canning et al., 2013). The IVR contains key
reactive cysteine residues through which Nrf2 activity is regulated, including Cys226, Cys257,
Cys273, and Cys288 (Dinkova-Kostova et al., 2002; Zhang & Hannink, 2003; Wakabayashi et al.,
2004; McMahon et al., 2010). The C-terminal Kelch domain, also known as the double glycine
repeat (DGR) domain, is important for Nrf2 binding (Lo et al., 2006; Tong et al., 2006a).
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Figure 1.6: Domain structure of human Keap1. Keap1 contains 3 functional domains and a 3box motif within the proximal part of the IVR domain. The location of all cysteine (C) residues in
Keap1 is shown, and key stress-sensing cysteines are marked with an asterisk (*).

Dissociation of Nrf2 from Keap1 occurs through the oxidative modification of specific stresssensing cysteine residues of Keap1 (Figure 1.7) (Wakabayashi et al., 2004). Intriguingly, Keap1
contains a very high content of cysteines, with the 27 cysteine residues in human Keap1 accounting
for approximately 4% of its total amino acid content, which is notably greater than the 2% average
for the human proteome (Miseta & Csutora, 2000). Cys273 and Cys288 are required for sensing
oxidative stress under both basal and stress conditions, whereas Cys151 may be required only
during oxidative stress conditions (Dinkova-Kostova et al., 2002; Zhang & Hannink, 2003). These
three key cysteines may function independently or collaboratively depending on the class of Nrf2inducing compounds, characterized by Yamamoto et al. (Saito et al., 2016), who also found some
inducers to function independently of these three specific cysteines. Correspondingly, Cys226,
Cys613, Cys622 and Cys624 are specifically involved in sensing hydrogen peroxide through a
mechanism that is distinct from that used for sensing electrophilic Nrf2 inducers (Suzuki et al.,
2019). Additional cysteine residues that respond to redox-active agents include the Cys288 alkenal
sensor, the zinc sensor comprised of His225, Cys226, and Cys613, and the nitric oxide sensor
comprised of a cluster of basic amino acids (His129, Lys131, Arg135, Lys150, and His154) that
facilitate the S-nitrosylation of Cys151 within Keap1 (McMahon et al., 2010).
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Figure 1.7: Stress-induced cysteine modification of Keap1. Under oxidative stress conditions,
specific stress-sensing cysteine residues in Keap1 are modified, leading to a conformational
change in Keap1 that results in Nrf2 stabilization, accumulation, and nuclear translocation for the
induction of ARE-containing cytoprotective genes.

1.2.3 Keap1-Dependent Nrf2 Regulation
As previously mentioned, Nrf2-regulated genes contain an ARE in their regulatory region and
encode numerous antioxidant and phase II enzymes (Itoh et al., 1997). Transcriptional activation
of the ARE is primarily dependent on Nrf2 stabilization, accumulation, and nuclear translocation
through its dissociation from the cytoskeleton-associated Keap1 (Itoh et al., 1999). Thus, Nrf2
activity is tightly regulated by its interaction with Keap1.
Nrf2 association requires the homodimerization of Keap1 (Zipper & Mulcahy, 2002). Keap1
recruits Nrf2 firstly through the binding of one Keap1 molecule to the high-affinity ETGE motif
within the Nrf2’s Neh2 domain. Subsequent binding of the other Keap1 molecule at the lowaffinity DLG motif locks Nrf2 in place by orienting the lysine residues within Neh2 in the correct
position for ubiquitination by Cul3 and degradation by the 26S proteasome (Tong et al., 2006a;
Tong et al., 2006b). This is known as the two-site substrate recognition model and has been
accepted as the primary mechanism of Nrf2 regulation (Figure 1.8).
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Figure 1.8: Two-site substrate recognition model for Keap1-dependent Nrf2 regulation.
(A) A Keap1 homodimer binds to the Neh2 domain of Nrf2 at the DLG and ETGE motifs, allowing
for the ubiquitination of Nrf2 by Cul3. (B) Stress-sensing cysteine residue(s) in Keap1 are
modified by oxidative stress (ROS) causing a conformational change in Keap1 that impairs Nrf2binding. Nrf2 is stabilized and no ubiquitination occurs.

Notably, the ETGE motif has a binding affinity that is two orders of magnitude higher than that of
the DLG motif due to the presence of more electrostatic interactions (Tong et al., 2007). The DLG
motif utilizes hydrogen bonding whereas the ETGE motif utilizes both hydrophobic interactions
and hydrogen bonding (Fukutomi et al., 2014). Accordingly, stress-induced cysteine modifications
that alter the structural conformation of Keap1 result in the prompt dissociation of Keap1 from the
weak-binding DLG motif, thereby impairing Nrf2 ubiquitination. On the other hand, the Keap1Nrf2 association may remain intact via the tight-binding ETGE motif even though ubiquitination
is impaired without DLG binding (Kobayashi et al., 2006; Tong et al., 2006a). Taken together, the
DLG motif is particularly important in Keap1-dependent degradation of Nrf2 by functioning as an
“on/off switch” for Nrf2 ubiquitination. Under basal conditions, Nrf2 has a short half-life of only
10-30 minutes (Nguyen et al., 2003; Stewart et al., 2003).
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When Keap1-Nrf2 binding is impaired, Nrf2 may be stabilized and for accumulation and nuclear
translocation. Within the nucleus, Nrf2 cannot bind to the ARE as a monomer and must
heterodimerize with the small Maf protein (sMaf) family (MafF, MafG, MafK) for transcriptional
activation (Itoh et al., 1997). The Nrf2-sMaf complex binds, in a sequence-specific manner, to the
ARE present within the promoter region of antioxidant and phase II enzyme genes, leading to their
robust activation. Table 1.3 lists key examples of Nrf2 regulated genes and their associated protein
function.
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Table 1.3: Examples of cytoprotective genes regulated by Nrf2.
Primary Role

Gene

Protein

Redox
homeostasis

GPX2

Glutathione peroxidase 2 (GPx2) Reduces hydrogen peroxide
and lipid hydroperoxides at the
expense of glutathione

PRDX1

Peroxiredoxin 1 (Prdx1)

Reduces hydrogen peroxide
and alkyl hydroperoxides

TXN1

Thioredoxin 1 (Trx1)

Reduces oxidized protein thiols

SRXN1

Sulfiredoxin 1 (Srx1)

Contributes to the thioredoxin
system by reducing sulfinic
acid to thiols

GCLC

Glutamate-cysteine ligase
catalytic subunit
(GCLC)

The first rate-limiting enzyme
of glutathione synthesis
(heavy subunit)

GCLM

Glutamate-cysteine ligase
modifier subunit (GCLM)

The first rate-limiting enzyme
of glutathione synthesis
(light subunit)

GST

Glutathione S-transferase (GST)

Catalyzes the conjugation of
glutathione to electrophilic
compounds

NQO1

NAD(P)H:quinone
oxidoreductase-1 (NQO1)

Reduces quinone to
hydroquinone

CYP2A6

Cytochrome P450 2A6
(CYP2A6)

Involved in the hydroxylation
of some anti-cancer drugs

Drug
Excretion

ABCC2

Multidrug resistance protein 2
(MRP2)

Mediates hepatobiliary
excretion; implicated in
multidrug resistance

Heme
metabolism

HMOX1

Heme oxygenase 1 (HO-1)

Cleaves heme to form
biliverdin during heme
catabolism

Glutathione
biosynthesis

Detoxification

Function
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1.2.4 Non-Canonical Nrf2 Regulation
Apart from its regulation by Keap1, Nrf2 is subject to further non-canonical forms of regulation
by a series of other proteins, summarized in Table 1.4. Direct interaction of these proteins with
either Nrf2 or Keap1 results in competitive inhibition that disrupts the Keap1-Nrf2 complex,
decreases Nrf2 ubiquitination, and increases Nrf2 stabilization and stress-induced ARE activation.
Some of these non-canonical forms of Nrf2 regulation are discussed in further detail.
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Table 1.4: Non-canonical Nrf2 regulation by direct protein interaction.
Interacting Known Interaction
Protein
Motif(s)
Nrf2

βTrCP

334
373

DSGIS338 (Nrf2)
DSAPGS378 (Nrf2)

Nrf2
Domain

+ or – Nrf2
Regulation

Reference(s)

Neh6

– ; Nrf2 degradation

(Rada et al., 2011;
Chowdhry et al.,
2013)

RXRα

209

ETT…NGP316
(Nrf2)

Neh7

– ; ↓ transactivation

(Wang et al., 2013a)

p21

29

DLG31 (Nrf2)

Neh2

+ ; Nrf2 stabilization

(Chen et al., 2009b)

79

ETGE82 (Nrf2)

154

KRR156 (p21)

DJ-1

Currently unknown

---

+ ; Nrf2 stabilization

(Clements et al.,
2006)

BRCA1

79

Neh2

+ ; Nrf2 stabilization

(Gorrini et al.,
2013; Xu et al.,
2018)

Keap1
Domain

+ or – Nrf2
Regulation

Reference(s)

Kelch

+ ; Keap1 inhibition

(Copple et al., 2010;
Fan et al., 2010; Jain
et al., 2010; Komatsu
et al., 2010; Lau et
al., 2010)

ETGE82 (Nrf2)

BRCT domain
(1591-1784)
(BRCA1)
Interacting Interaction Motif(s)
Protein
Keap1

p62 /
SQSTM1

349

DPSTGE354 (p62)

ProTα /
PTMA

38

NANEENGE45
(ProTα)

Kelch

+ ; Keap1 inhibition

(Karapetian et al.,
2005)

DPP3

480

Kelch

+ ; Keap1 inhibition

(Hast et al., 2013)

WTX

286

SPETGE291
(WTX)

Kelch

+ ; Keap1 inhibition

(Camp et al., 2012)

PALB2 /
FANCN

91

BTB

+ ; Keap1 inhibition

(Ma et al., 2012)

Kelch

- ; Nrf2 degradation

(Sun et al., 2011)

ETGE483 (DPP3)

ETGE94 (PALB2)

KPNA6 /
ARM domain (108-563)
Importin α7 (KPNA6)
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1.2.5 Nrf2-Interacting Proteins
β-transducin repeat-containing protein (βTrCP) is involved in the negative regulation of Nrf2 at
the Neh6 domain in a similar manner to Keap1 at the Neh2 domain. βTrCP interacts with Neh6 at
two conserved sites,

334

DSGIS338 and

373

DSAPGS378, and acts as a substrate receptor for

degradation by the Skp1-Cul1-Rbx1/Roc1 E3 ubiquitin ligase complex (Rada et al., 2011;
Chowdhry et al., 2013). Deletion of either motif results in the loss of βTrCP-mediated
ubiquitination (Rada et al., 2011). Additionally, the DSGIS motif in Neh6 overlaps with a
phosphorylation site for GSK3, wherein phosphorylation of Nrf2 at this motif by GSK3 enhances
βTrCP activity (Rada et al., 2011; Chowdhry et al., 2013). Accordingly, when Keap1 activity is
impaired in Keap1-/- mouse embryonic fibroblasts or in an Nrf2 ETGE deletion mutant that cannot
bind to Keap1, treatment with GSK3 inhibitors leads to impaired βTrCP-regulation and results in
Nrf2 stabilization and accumulation (Rada et al., 2011). On the other hand, activation of GSK3 in
Keap1-/- mouse embryonic fibroblasts or human lung A549 cells reduces Nrf2 protein levels and
mRNA levels for Nrf2-regulated enzymes (Chowdhry et al., 2013).
Retinoid X receptor alpha (RXRα) is involved in numerous developmental and physiological
pathways and in mediating the biological effects of retinoids (Szanto et al., 2004). RXRα directly
interacts with the Neh7 domain of Nrf2 which impairs the recruitment of cofactors to Neh4 and
Neh5 that are required for transactivation (Wang et al., 2013a). Accordingly, RNAi-mediated
knockout of RXRα increases the induction of Nrf2-regulated antioxidant gene expression, and
overexpression of RXRα in non-small cell lung cancer A549 cells leads to Nrf2 downregulation
and increases sensitivity to therapeutic drugs (Wang et al., 2013a).
p21 (or p21CIP1/WAF1) is a p53-regulated cyclin-dependent kinase inhibitor involved in inhibiting
the activity of cyclin/cyclin-dependent kinase (Cdk) complexes for the negative regulation of cell
cycle progression (Xiong et al., 1993). The 154KRR156 motif within p21 directly binds to the DLG
and ETGE motifs in Nrf2, thereby competing with Keap1 for Nrf2 binding (Chen et al., 2009b);
but instead of Nrf2 degradation, p21-Nrf2 binding leads to Nrf2 stabilization and increased
response to oxidative stress (Chen et al., 2009b). Accordingly, p21-/- mice show reduced levels of
Nrf2 protein and Nrf2 target genes (Chen et al., 2009b). Importantly, p21-dependent protection
from oxidative stress requires Nrf2, as colorectal cancer HCT116 cells overexpressing p21
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demonstrate enhanced survival in response to hydrogen peroxide in Nrf2+/+ but not Nrf2-/- cells
(Chen et al., 2009b).
Protein deglycase DJ-1 (DJ-1) (also known as Parkinson disease protein 7, Park7) is a redoxdependent molecular chaperone that mediates protein folding and prevents the misfolding and
inclusion formation of neuronal proteins such as α-Synuclein (Zondler et al., 2014). DJ-1 inhibits
Keap1-mediated Nrf2 degradation by competitively binding to Nrf2 (Clements et al., 2006). In
both primary human cells and mice, loss of DJ-1 leads to deficits in the expression of Nrf2mediated stress response enzymes, particularly the detoxification enzyme NQO1, suggesting that
DJ-1 is required for Nrf2 stability and Nrf2-mediated transcription (Clements et al., 2006).
Notably, a mutation in the DJ-1 gene has been strongly implicated in early-onset Parkinson’s
disease (PD) (Bonifati et al., 2003), suggesting the role of impaired oxidative stress regulation in
neurodegenerative diseases, such as PD.
Breast cancer type 1 susceptibility protein (BRCA1) is a tumour suppressor protein primarily
responsible for DNA damage repair in cells of the breast and other tissue (Deng & Wang, 2003).
The BRCT domain of BRCA1 interacts with the ETGE motif in the Neh2 domain of Nrf2, which
inhibits Keap1-mediated ubiquitination and increases the response to oxidative stress (Gorrini et
al., 2013; Xu et al., 2018). Expression of BRCA1 in neurons confers protection from
ischemia/reperfusion injury through activation of the Nrf2-mediated antioxidant pathway (Xu et
al., 2018), and BRCA1-/- mouse primary mammary epithelial cells demonstrate low expression of
Nrf2 target genes and increased ROS levels associated with decreased survival (Gorrini et al.,
2013). Intriguingly, BRCA1 contains an ARE sequence in its promoter region and is thereby
regulated by Nrf2, creating a positive feedback loop (Wang et al., 2013b).

1.2.6 Keap1-Interacting Proteins
p62 (also known as sequestosome-1, SQSTM1) is a stress-inducible scaffold protein involved in
numerous signalling pathways, including the targeting of proteins for selective autophagy (Lin et
al., 2013; Bitto et al., 2014). In 2010, five independent groups discovered the interaction between
p62 and Keap1 (Copple et al., 2010; Fan et al., 2010; Jain et al., 2010; Komatsu et al., 2010; Lau
et al., 2010). This interaction is mediated by a

349

DPSTGE354 motif in p62’s Keap1-interacting

region (KIR) that resembles the ETGE motif in the Keap1-binding domain of Nrf2 (Jain et al.,
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2010; Komatsu et al., 2010; Lau et al., 2010). p62 sequesters Keap1 into inclusion bodies for
autophagy-mediated degradation, thereby disrupting the Keap1-Nrf2 interaction and inhibiting
Nrf2 ubiquitination. Additionally, the binding affinity between p62 and Keap1 is significantly
increased when Ser351 in p62 is phosphorylated, leading to increased Nrf2 transcriptional activity
(Ichimura et al., 2013). Notably, p62 contains ARE sequences in its promoter and is thereby
regulated by Nrf2, indicating a positive feedback loop (Jain et al., 2010).
Prothymosin α (ProTα/PTMA) is a small, highly charged protein involved in cell proliferation and
survival through chromatin remodelling and pro-apoptotic activity (Malicet et al., 2006; George
& Brown, 2010). ProTα interacts with the Kelch domain of Keap1 and shuttles it into the nucleus,
thereby preventing its association with Nrf2 (Karapetian et al., 2005). The 38NANEENGE45 motif
in ProTα is required for its interaction with the Kelch domain (Khan et al., 2013). HeLa cells
overexpressing ProTα show increased Nrf2-mediated HMOX1 gene expression; however,
overexpression of a mutant variant of ProTα that impairs Keap1-binding fails to upregulate
HMOX1 (Karapetian et al., 2005), thereby demonstrating the role of ProTα in the expression of
certain antioxidant genes.
Dipeptidyl-peptidase 3 (DPP3) is involved in the cleavage and degradation of bioactive peptides
generated by the proteasome during protein degradation (Shimamori et al., 1988; Prajapati &
Chauhan, 2011). DPP3, which contains an

480

ETGE483 motif, interacts with Keap1 by binding to

the Kelch domain, thereby inhibiting the Keap1-Nrf2 interaction (Hast et al., 2013). Estrogen
receptor-positive MCF7 breast cancer cells demonstrate overexpression of DPP3 that is associated
with increased Nrf2 gene expression and poor prognosis (Lu et al., 2017).
WTX is a tumour suppressor and regulator in the canonical Wnt signalling pathway, which
mediates critical aspects of embryonic development by promoting the ubiquitination and
degradation of β-catenin (Major et al., 2007; Komiya & Habas, 2008). WTX is also involved in
oxidative stress regulation through its competitive binding to the Keap1, which inhibits Nrf2
ubiquitination (Camp et al., 2012). siRNA knockdown of WTX in HEK293T cells reduces the
activation of Nrf2 target genes in response to tBHQ, a potent Nrf2-activating compound (Camp et
al., 2012). WTX contains a 286SPETGE291 motif that is similar to the ETGE motif in Nrf2, which
allows for interaction with the Kelch domain in Keap1; however, this interaction requires the
22

phosphorylation of Ser286 to attain a sufficient binding affinity between the two proteins (Camp
et al., 2012).
Partner and localizer of BRCA2 (PALB2) (also known as Fanconi anemia complementation group
N, FANCN), is a protein that co-localizes with the breast cancer 2 early onset protein (BRCA2) to
regulate its stabilization, nuclear localization, and involvement in DNA repair (Xia et al., 2006).
siRNA knockdown of PALB2 in bone-derived U2OS cells results in reduced Nrf2 activity and
increased ROS levels (Xia et al., 2006). Like the WTX protein, PALB2 contains a 91ETGE94 motif
that permits its interaction with Keap1 through binding to the Kelch domain (Ma et al., 2012).
KPNA6 (also known as importin α7) is a nucleocytoplasmic transport adaptor involved in the
nuclear import of proteins. Keap1 has been shown to shuttle between the nucleus and cytoplasm
via KPNA6 which interacts with the Kelch domain of Keap1. Within the nucleus, Keap1 binds to
Nrf2 to facilitate its nuclear export and subsequent ubiquitination in the cytosol, thus allowing for
attenuation of Nrf2 activity during the postinduction phase (Sun et al., 2011). Knockdown of
KPNA6 impairs Keap1 nuclear shuttling and attenuates the Keap1-mediated ubiquitination of
Nrf2, whereas overexpression of KPNA6 facilitates Keap1 nuclear import and inhibits Nrf2
signalling (Sun et al., 2011).

1.2.7 Other Mechanisms of Nrf2 Regulation
The transcriptional activity of Nrf2 may also be inhibited by Bach1, a protein in the same CNCbZIP family as Nrf2 that functions as a transcriptional repressor. Bach1 competes with Nrf2 in the
nucleus for heterodimerization with the sMaf proteins which are required for Nrf2/ARE binding
(Dhakshinamoorthy et al., 2005). Other forms of Nrf2 regulation include phosphorylation of Nrf2
at Ser40 by protein kinase C (PKC), which impairs Keap1 binding (Huang et al., 2002), and
phosphorylation of Nrf2 by the MAPK/ERK pathway, which increases Nrf2 stability (Nguyen et
al., 2003).
Finally, phosphoglycerate mutase family member 5 (PGAM5) is a protein phosphatase with
various functions in mitochondrial homeostasis and mitophagy (Hammond et al., 2001).
Interestingly, PGAM5 can recruit both Keap1 and Nrf2 to the outer mitochondrial matrix by
binding to one molecule of a Keap1 dimer while simultaneously binding Nrf2 to form a ternary
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Keap1-PGAM5-Nrf2 complex (Lo & Hannink, 2006; Lo & Hannink, 2008). Interestingly, this
results in the stress-induced Keap1-mediated ubiquitination and degradation of not Nrf2, but of
mitochondrial Rho GTPase 2 (Miro2), a mitochondrial GTPase involved in mitochondrial motility
(Mealey et al., 2017). This demonstrates that Nrf2 function is not limited to stress-induced gene
transcription but highlights Nrf2’s involvement in other cellular processes.

1.3

Nrf2 in Cell Physiology

In addition to its primary role as the master transcriptional regulator of the antioxidant response,
Nrf2 is involved in numerous other cellular processes including, among others, mitochondrial
redox signalling, autophagy, inflammation, and endoplasmic reticulum stress. Each will be
discussed very briefly.

1.3.1 Mitochondrial Redox Signaling
Mitochondria are powerhouses for ATP synthesis and are a major source of ROS (Muller, 2000;
Turrens, 2003; Andreyev et al., 2005; Adam-Vizi & Chinopoulos, 2006). Mitochondria primarily
traffic along microtubules (Leopold et al., 1992; Drubin et al., 1993; Lazzarino et al., 1994) which
require adaptor proteins TRAK1/2 and Miro1/2 to link mitochondria to microtubules (Schwarz,
2013). Although the functional significance is not well understood, the retrograde microtubuledependent movement of mitochondria towards the centrosome has been observed in response to
various cell stress conditions including oxidative stress (Hallmann et al., 2004) and hypoxia (AlMehdi et al., 2012). As previously mentioned, binding of Nrf2 and Keap1 to PGAM5 results in a
ternary complex that is recruited to the outer mitochondrial membrane (Lo & Hannink, 2006; Lo
& Hannink, 2008). Importantly, retrograde microtubule-dependent mitochondrial movement
requires an intact Keap1-PGAM5-Nrf2 complex, and disruption of this complex results in Keap1Cul3 mediated degradation of mitochondrial Rho GTPase 2 (Miro2), a mitochondrial GTPase
involved in mitochondrial motility, thereby impairing the association between mitochondria and
microtubules (Mealey et al., 2017). This demonstrates the importance of Nrf2 in mitochondrial
redox signalling during oxidative stress. Additionally, Nrf2 protects mitochondria from oxidative
damage by regulating mitochondrial ROS levels through the Keap1-Nrf2 antioxidant pathway
(Kovac et al., 2015) and possibly through direct interaction with mitochondrial components (Strom
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et al., 2016). Cells lacking Nrf2 are more prone to mitochondrial damage and apoptosis (Piantadosi
Claude et al., 2008). Additionally, Nrf2 is involved in mitochondrial biogenesis, the process by
which cells increase their mitochondrial mass, through its ARE-driven activation Nrf1 which
stimulates mitochondrial biogenesis for increased stress resistance (Piantadosi Claude et al., 2008).

1.3.2 Autophagy
Autophagy is a controlled catabolic process that results in the degradation and recycling of old,
damaged, or excess cellular proteins and organelles and is vital to protein homeostasis and cellular
and organelle health. Autophagy can be induced by oxidative stress, ER stress, or nutrient
deprivation (Eskelinen & Saftig, 2009). The aforementioned p62 works as an autophagy adaptor
protein that binds to ubiquitinated proteins and delivers them to autophagosomes for degradation
(Komatsu et al., 2007; Pankiv et al., 2007; Ichimura et al., 2008). As previously discussed, the
autophagy and oxidative stress pathways are linked by p62 which can sequester Keap1 into
apoptotic inclusions to facilitate Nrf2 stabilization (Copple et al., 2010; Fan et al., 2010; Jain et
al., 2010; Komatsu et al., 2010; Lau et al., 2010), implying a noncanonical mechanism of Nrf2
activation by autophagy. p62 overexpression decreases Keap1 levels, suggesting that Keap1 is a
substrate for p62-mediated autophagy (Copple et al., 2010). Also recall that p62 is induced by
oxidative stress through activation of the ARE within its promotor by Nrf2, thereby creating a
positive feedback loop (Jain et al., 2010).

1.3.3 Inflammation
Inflammation is a biological defence mechanism that is triggered in response to harmful insults
such as pathogens, toxins, injury, and damaged cells. Through cytokine production and the
recruitment of inflammatory cells, inflammation aims to eliminate the insult, limit its spread, and
clear the area for healing and repair (Turner et al., 2014; Bennett et al., 2018). Nrf2 plays a role in
regulating the anti-inflammatory response through redox control and activation of ARE-mediated
anti-inflammatory genes, including the expression of the antioxidant genes NQO1, HO-1, and
PRX1, all of which exhibit anti-inflammatory effects (Braun et al., 2002; Itoh et al., 2004; Chen et
al., 2006b; Rushworth et al., 2008). The anti-inflammatory role of Nrf2 also includes Nrf2mediated inhibition of the pro-inflammatory NF-ΚB pathway and inhibition of pro-inflammatory
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cytokines (Ma et al., 2003; Li et al., 2008; Freigang et al., 2011). Of note, the expression of proinflammatory cytokine genes in M1 macrophages is inhibited by Nrf2-ARE binding (Kobayashi
et al., 2016); however, Nrf2 has also been found to block the transcriptional upregulation of proinflammatory cytokine genes including interleukin 6 (IL-6) and interleukin 1 beta (IL-1β) in an
ARE-independent manner through direct binding to the proximity of pro-inflammatory genes to
inhibit RNA polymerase II recruitment, suggesting that Nrf2’s role in inflammation is not limited
to just oxidative stress control (Kobayashi et al., 2016). Nrf2 plays numerous additional roles in
inflammation that are nicely summarized in the following review (Ahmed et al., 2017).

1.3.4 ER Stress and the UPR
Endoplasmic reticulum (ER) stress is caused by the accumulation of unfolded, misfolded, or excess
proteins in the ER lumen which triggers the unfolded protein response (UPR). The UPR is induced
by three key signalling pathways in humans: PERK, IRE1α, and ATF6 (Ron & Walter, 2007; Hetz,
2012; Hetz et al., 2020). Activation of protein kinase RNA-like endoplasmic reticulum kinase
(PERK) phosphorylates eukaryotic initiation factor 2 alpha (eIF2α) which leads to inhibition of
protein translation and cell cycle arrest in response to protein stress in the ER (Harding et al.,
1999). Notably, Nrf2 is a PERK substrate and PERK-dependent phosphorylation of Nrf2 results
in dissociation of the Keap1/Nrf2 complex and induction of Nrf2-mediated antioxidant genes that
promote increased glutathione levels and reduced ROS in the ER (Cullinan et al., 2003; Cullinan
& Diehl, 2004). Cells with an Nrf2 deletion experience significantly higher levels of apoptotic cell
death following exposure to ER stress compared to wild-type cells (Cullinan et al., 2003), thereby
illustrating the important role of Nrf2 in ER stress.
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1.4

Nrf2 in Human Disease

Due to its crucial role in oxidative stress regulation and additional roles in normal cell physiology,
oxidative stress and aberrant Nrf2 expression have been associated with numerous disease
pathologies. Three major human diseases, cardiovascular disease, neurodegenerative disease, and
cancer are briefly discussed.

1.4.1 Cardiovascular Disease
Cardiovascular disease is a multifaceted disease with a variety of risk factors including
hypercholesterolemia, hypertension, and atherosclerosis (Nabel, 2003). Oxidative stress may play
a role in the development of vascular complications that promote cardiovascular disease by
contributing to the pathogenesis of hypertension (Ceriello, 2008; Rodrigo et al., 2011) and
atherosclerosis (Ruotsalainen et al., 2013). The endothelial isoform of nitric oxide synthase
(eNOS) is responsible for the biosynthesis of NO in endothelial cells which mediates vascular
relaxation (Vallance et al., 1989). The uncoupling of eNOS under pathogenic conditions (e.g.,
hypertension, atherosclerosis, or diabetes) results in both impaired NO production and increased
superoxide production, which leads to hypertension and blood vessel damage, respectively
(Santhanam et al., 2012). Additionally, increased oxidative stress has been found to promote the
conversion of harmful low-density lipoprotein (LDL) cholesterol to the more atherogenic oxidized
LDL form (oxLDL) (Itabe, 2012; Lara-Guzmán et al., 2018). Nrf2 has been shown to protect
cardiomyocytes from ROS-induced damage through the expression of antioxidant enzymes (Cao
et al., 2006; Ichikawa et al., 2009) while lack of Nrf2 promotes aggravation of vessel lesions
towards atherosclerosis (Ruotsalainen et al., 2013). Nrf2 is thus a critical regulator of
cardiovascular homeostasis with implications in the development of cardiovascular disease.

1.4.2 Neurodegeneration
The link between oxidative stress and the pathogenesis of neurodegenerative diseases is well
established (Halliwell, 2001; Barnham et al., 2004). The brain consumes 20% of the body’s oxygen
relative to its small mass (2%) and is particularly susceptible to oxidative damage due to its high
rate of metabolic activity, high rate of oxygen metabolite production, relatively low levels of
antioxidants, low capacity for repair, and high composition of lipids which are prone to
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peroxidation and oxidative modification by ROS (Butterfield et al., 2002; Niedzielska et al., 2016).
Damaged mitochondria and activated microglia are major sources of ROS in the brain (Halliwell,
2001). Oxidative damage has been implicated in all major neurodegenerative diseases including
Alzheimer’s disease (AD) (Smith et al., 2000; Cioffi et al., 2019), Parkinson’s disease (PD) (Dias
et al., 2013; Blesa et al., 2015), Huntington’s disease (HD) (Browne et al., 1999; Kumar & Ratan,
2016), amyotrophic lateral sclerosis (ALS) (Barber et al., 2006), and multiple sclerosis (MS)
(Gilgun-Sherki et al., 2004). Except for MS, all are characterized by the loss and/or deterioration
of neurons in a specific brain region due to hallmark protein misfolding and inclusion formation
(Soto, 2003).
Oxidative damage has been observed in the post-mortem brain tissues of patients with
neurodegenerative diseases (Halliwell, 2001), suggesting that oxidative stress plays a role in the
formation and/or aggravation of these hallmark protein inclusions. Nrf2 is activated in response to
oxidative stress but may be impaired or insufficient in neurodegenerative diseases. Significantly
reduced levels of nuclear Nrf2 have been observed in the brain regions of AD patients (Ramsey et
al., 2007). Conversely, while Nrf2 nuclear localization is observed in PD patient samples, the
response may be insufficient to prevent neuronal cell death (Uttara et al., 2009). Additionally,
studies have reported the protective role of Nrf2 in neurodegenerative diseases (Calkins et al.,
2005; Dinkova-Kostova et al., 2018). For example, Nrf2 activation in astrocytes confers protection
against neurodegeneration in mouse models of ALS (Vargas et al., 2008), and Nrf2-deficiency
results in increased sensitivity to MPTP-induced PD-like lesions in mice which is improved by
Nrf2 overexpression in astrocytes (Chen et al., 2009a). Nrf2 inducers have been shown to have
protective effects in the development of neurogenerative disease-associated brain lesions (Calkins
et al., 2005).

1.4.3 Cancer
Most cancers show elevated levels of ROS which cause DNA damage, impair protein function,
and alter mechanisms of cellular proliferation to promote tumorigenesis (Liou & Storz, 2010).
Traditionally, Nrf2 has been considered a tumour suppressor that confers protection against ROS
and cancer progression. For instance, mice deficient in Nrf2 are prone to chemical-induced toxicity
and tumorigenesis (Aoki et al., 2001). However, despite its beneficial role in cellular protection
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and cancer prevention, Nrf2 also has a harmful “dark side” in cancer (Wang et al., 2008). Some
somatic mutations give rise to hyperactive Nrf2 activity which allows for an enhanced antioxidant
capacity and confers protection of cancer cells from ROS and cancer therapy, thereby leading to
cancer progression and cancer therapy resistance (e.g., chemoresistance) (Figure 1.9)
(Padmanabhan et al., 2006; Singh et al., 2006; Nioi & Nguyen, 2007; Shibata et al., 2008; Wang
et al., 2008; Shibata et al., 2011; Ooi et al., 2013; Kerins & Ooi, 2018).

Figure 1.9: The aberrant Keap1-Nrf2 pathway in cancer. Some mutations are associated with
Nrf2 hyperactivation, which protects cancer cells from ROS and chemotherapeutic agents by
increased antioxidant activity.
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Constitutive Nrf2 hyperactivation is common in cancer (Praslicka et al., 2016) and numerous
studies have revealed aberrant Nrf2 expression and poor prognosis in a wide range of cancers,
including, among others, lung, esophageal, breast, bladder, liver, prostate, and colorectal
carcinomas (Ikeda et al., 2004; Shibata et al., 2008; Takahashi et al., 2010; Li et al., 2011; Shibata
et al., 2011; Hartikainen et al., 2012; Liu et al., 2015), most of which have been attributed to lossof-function mutations in the KEAP1 gene and/or gain-of-function mutations in the NFE2L2 gene
encoding Nrf2 (Padmanabhan et al., 2006; Singh et al., 2006; Nioi & Nguyen, 2007; Shibata et al.,
2008; Ooi et al., 2013). Mutations in KEAP1 were first discovered in human lung adenocarcinoma
cell lines, wherein a glycine-to-cysteine substitution within the Nrf2-binding domain of Keap1
reduces Keap1’s affinity for Nrf2, resulting in loss of canonical Nrf2 regulation and constitutive
Nrf2 hyperactivation (Padmanabhan et al., 2006). Similarly, mutations within the Keap1-binding
domain of Nrf2 impairs Keap1 recognition, allowing Nrf2 to escape Keap1-mediated degradation
and accumulate at high levels in cancer cells (Shibata et al., 2008). Genomic characterization of
squamous cell lung cancers showed significant alterations in the Nrf2 pathway in 34% of all
tumour specimens examined (The Cancer Genome Atlas Research, 2012). Mutation frequencies
vary greatly across different cancer types, but interestingly, some cancers show high rates of Nrf2
pathway alterations but low rates of KEAP1 or NFE2L2 mutations. This suggests that aberrant
Nrf2 regulation in certain cancers may also be due to Keap1-independent Nrf2 regulatory
pathways, or impaired Keap1-Nrf2 interactions at the protein level.
Nrf2 hyperactivation creates an environment that protects normal but also malignant cells from
oxidative stress and cancer therapy. The resultant upregulation of Nrf2-mediated antioxidant
proteins renders cancer cells resistant to chemotherapeutic drugs (e.g., 5-fluorouracil, docetaxel,
and bortezomib) and radiotherapy (Ramos-Gomez et al., 2001; Lee et al., 2004; Wang et al., 2008;
Jiang et al., 2010; Rushworth et al., 2011; Shibata et al., 2011; Manandhar et al., 2012; Zhou et al.,
2013). Cancer cells appear to hijack the Nrf2 antioxidant pathway as a means of protection against
chemotherapeutics to promote chemoresistance and tumorigenesis (Figure 1.10).
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Figure 1.10: Nrf2 protects cancer cells from cancer therapy. Cancer cells hijack the Nrf2
pathway to confer protection against cancer therapies such as chemotherapy and radiation. Cancer
cells that survive therapy develop resistance and proliferate, leading to chemoresistance and cancer
progression.

1.4.4 Nrf2 as a Therapeutic Target
The importance of Nrf2 in the protection against human diseases is well established and much
research has looked into the use of Nrf2 activators in the treatment of disease (Dinkova-Kostova
& Talalay, 2008; Suzuki et al., 2013; Zhuang et al., 2017). Examples include dimethyl fumarate
which has been approved for the treatment of multiple sclerosis (Linker et al., 2011), among
numerous others currently in clinical trials (ClinicalTrials.gov; Robledinos-Antón et al., 2019).
While some Nrf2 activators have shown promise, high levels of Nrf2 can have negative effects, as
observed in chemotherapy-resistant cancer cells. Research has thus also looked into the use of Nrf2
inhibitors as adjuvants to cancer therapy (Zhu et al., 2016; Robledinos-Antón et al., 2019). For
example, brusatol has been shown to enhance the efficacy of chemotherapy by inhibiting Nrf2
(Ren et al., 2011; Olayanju et al., 2015). Taken together, targeting Nrf2 for the treatment of human
disease has shown promise, and increased understanding of the delicate balance between Nrf2’s
protective and deleterious effects will contribute to its value as a therapeutic target.
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1.4.5 Ageing
Ageing is not a disease per se, but a predominant risk factor for the development of disease.
Progressive and irreversible oxidative damage accumulates with age and diminishes critical
aspects of cell physiology (Sykiotis & Bohmann, 2010; Jacinto et al., 2018; Luceri et al., 2018).
For example, ageing is associated with impaired activity of the proteasome and mitochondrial Lon
proteases (Bota & Davies, 2002; Bota et al., 2002; Morimoto & Cuervo, 2014) and reduced
capacity for macromolecule repair (Jacinto et al., 2018; Luceri et al., 2018). The “oxidative damage
theory of ageing” (Lin & Flint Beal, 2003) thus postulates that: (1) age-related functional losses
are caused by the gradual accumulation of ROS and general oxidative damage to macromolecules,
and that (2) ROS reduction and oxidative damage repair attenuate the rate of ageing and increases
lifespan. In line with this hypothesis, Nrf2 signalling has been found to decrease with age (Zhang
et al., 2015b) in a variety of model organisms including flies (Rahman et al., 2013), mice
(Sachdeva et al., 2014), nonhuman primates (Ungvari et al., 2011a; Ungvari et al., 2011b), and
humans (Suh et al., 2004; Valcarcel-Ares et al., 2012; Zhang et al., 2015b; Zhou et al., 2018).
Notably, experimental amplification of Nrf2-regulated antioxidant genes has been found to
increase resistance to oxidative stress in some aged models but not others (Zhang et al., 2015b),
indicating that increased steady-state levels of ROS and oxidized macromolecules may not be the
only contributor to age-related functional losses. The alternative “redox stress hypothesis” (Sohal
& Orr, 2012) instead proposes that impairments in physiologic function are due to an age-related
“pro-oxidizing shift” in the redox state of cells that results in the over-oxidation of redox-sensitive
thiol groups within the cysteine residues of proteins, resulting in the impairment of cellular
signalling pathways. Much evidence suggests that oxidative damage to proteins is associated with
ageing and is linked to protein misfolding (Beal, 2002; Santra et al., 2019).
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1.5

Proteins and Oxidative Stress

Proteins must fold and maintain a specific three-dimensional conformation to carry out their
normal functions within the cell. Factors that impair this proper protein folding, such as cell stress,
genetic mutations, metabolic aberrations, or pathological stress can therefore have detrimental
effects. The cell has thus evolved quality control mechanisms to maintain protein homeostasis, or
“proteostasis”.

1.5.1 Protein Folding and Quality Control
The amino acid sequence of a protein contains the information required for a protein to adopt its
proper three-dimensional conformation. Proteins demonstrate a funnel-shaped energy landscape
with many high-energy unfolded or partially folded conformations and few low-energy folded
conformations (Onuchic et al., 1997; Dill & MacCallum, 2012). A newly synthesized unfolded
polypeptide chain contains a high level of energy that is gradually reduced as it undergoes folding
events and adopts intermediate states to ultimately achieve its thermodynamically stable, native
conformation (Figure 1.11). From there, the protein may assemble with other proteins to form
protein complexes or undergo further modifications that are crucial for protein function.
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Figure 1.11: Thermodynamics of protein folding. Proteins fold into their native conformations
by minimizing free energy. Adopted from Onuchic et al. (Onuchic et al., 1997).

Cells, however, are continually exposed to endogenous and exogenous sources of stress, and
proteins are constantly being unfolded and misfolded in the cell. There thus exists a dynamic
equilibrium between folded, partially unfolded, and misfolded proteins in the cell which favours
the thermodynamically stable native conformation (Ptitsyn, 1994) (Figure 1.12).
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Figure 1.12: Equilibrium between native and non-native protein folding conformations. The
continual unfolding and misfolding of proteins in the cell create a dynamic equilibrium that favours
the thermodynamically favourable, folded native state.

A misfolded protein is a protein that has acquired a non-native, aberrant conformation. Misfolded
proteins often lose their normal function (i.e., loss of protein function) and can aggregate and form
inclusions that can have deleterious effects on the cell (i.e., toxic gain of function) (Dobson, 2003).
The cellular accumulation of misfolded proteins is strongly associated with ageing (Morley et al.,
2002; Morley & Morimoto, 2003) and is implicated in many diseases such as cancer (Dai et al.,
2007) and neurodegenerative disease (Soto, 2003; Morimoto, 2008). Cancer cells typically have a
higher load of misfolded proteins that is attributed to higher cell division and mutation rates
(Whitesell & Lindquist, 2005), while the development of most neurodegenerative diseases arises
as a result of protein misfolding and/or mislocalization that leads to neurotoxicity (Soto, 2003).
To prevent and resolve protein misfolding, the cell has evolved intricate protein quality control
mechanisms, including the refolding of misfolded proteins by molecular chaperones, which is the
primary form of proteostasis (Hartl & Hayer-Hartl, 2002; Kim et al., 2013b; Saibil, 2013),
followed by the degradation of misfolded proteins by the ubiquitin-proteasome system (UPS)
(Glickman & Ciechanover, 2002; Lecker et al., 2006; Amm et al., 2014) and the sequestration of
misfolded proteins into specific quality control compartments (Johnston et al., 1998; García-Mata
et al., 1999; Kaganovich et al., 2008). Misfolded proteins that cannot be refolded or degraded are
eliminated by autophagy (Hyttinen et al., 2014; Ciechanover & Kwon, 2015). These systems
function in parallel and cooperate to maintain the protein folding equilibrium and overall cellular
proteostasis (Figure 1.13).
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Figure 1.13: Cellular mechanisms of protein quality control. Misfolded proteins are primarily
refolded by molecular chaperones. However, misfolded, or aggregated proteins that cannot be
refolded are degraded by the proteasome or sequestered into spatial compartments. Sequestered
proteins may be sent for refolding or targeted for degradation. If these mechanisms fail, clearance
by autophagy occurs.

1.5.2 Molecular Chaperones
Proteostasis is primarily dependent on molecular chaperones (Frydman, 2001; Bukau et al., 2006)
which assist in the folding and refolding of proteins. Chaperones bind to unfolded, partially folded,
or exposed hydrophobic regions within protein substrates (known as ‘clients’) to stabilize them,
prevent further misfolding, and provide a favourable environment for proper protein folding (Hartl
et al., 2011). This chaperone/protein interaction is typically driven by transient cycles of binding
and release in an ATP-dependent manner (Tapley et al., 2010). For that reason, molecular
chaperones either contain ATPases or form interaction networks with ATPase-containing
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chaperone counterparts (co-chaperones) to jointly facilitate protein folding (Tapley et al., 2010).
Co-chaperones are proteins that assist chaperones by helping them bind to client proteins and/or
providing ATPase activity (Mayer & Bukau, 2005). Besides their well-established roles in protein
folding, chaperones cooperate with proteases to facilitate the degradation of misfolded proteins
(Youker et al., 2004; Kundrat & Regan, 2010) and may function as disaggregases in certain species
such as yeast (Warrick et al., 1999; Douglas et al., 2009).
Eukaryotic cells have two distinct molecular chaperone networks: chaperones linked to protein
synthesis (CLIPS) which are localized to protein translation machinery and guide in the folding of
newly synthesized proteins (Albanèse et al., 2010); and heat shock proteins (Hsps) which refold
misfolded proteins into their native conformation, thereby restoring their function and reducing
toxicity (Feder & Hofmann, 1999). Hsps are a family of molecular chaperones that are
ubiquitously expressed and recruited under conditions of proteotoxic cell stress, first observed in
response to heat stress but also induced upon cold stress, chemical stress, and exposure to UV
radiation (Feder & Hofmann, 1999). Hsps are classified according to their molecular weight, which
ranges from 10 to 200 kDa. The six major families of human Hsps are Hsp100, Hsp90, Hsp70,
Hsp60, Hsp40, and small Hsp (sHsp) (Kampinga et al., 2009). Each class of Hsp has a distinct
structure and specific function in protein quality control. Hsp90 is of particular interest to this work
and will be discussed in further detail.

1.5.3 Heat shock protein 90 (Hsp90)
Heat shock protein 90 (Hsp90) is a highly abundant molecular chaperone that facilitates the folding
of over 200 client proteins under both basal and stressed conditions (Schopf et al., 2017). Hsp90
can adopt dynamic conformations to bind to its functionally and structurally diverse array of client
proteins which include kinases, transcription factors, steroid hormone receptors, and E3 ubiquitin
ligases, among many others (Schopf et al., 2017). Human Hsp90 contains three highly conserved
domains (Figure 1.14): an N-terminal domain responsible for ATP-binding (Prodromou et al.,
1997); a middle domain responsible for ATP hydrolysis and the binding of client proteins and cochaperones (Meyer et al., 2003); and a C-terminal domain that is essential for Hsp90 dimerization
(Harris et al., 2004). The N-terminal and middle domains are connected by a flexible charged
linker sequence that regulates Hsp90 function (Hainzl et al., 2009; Tsutsumi et al., 2012). In
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eukaryotes, a MEEVD polypeptide chain is attached to the end of the C-terminus and allows for
binding to co-chaperones containing tetratricopeptide repeat (TPR) motifs (Taipale et al., 2010).

Figure 1.14: Domain structure of human Hsp90. Hsp90 contains three functional domains, a
charged linker region between the N-terminal and middle domains, and a MEEVD polypeptide
chain attached to the C-terminus for recognition of co-chaperones with TPR motifs.

Hsp90 is predominately dimeric under physiological conditions, as C-terminal dimerization is
essential for Hsp90 function and contributes to the dynamic conformational changes that are
coupled to N-terminal dimerization and ATPase activity (Prodromou et al., 2000; Wayne & Bolon,
2007). As outlined in Figure 1.15, in the absence of ATP, the C-terminal-mediated Hsp90
homodimer maintains an “open” ‘V’-shaped conformation with no interaction between the Nterminal domains (‘N’). The binding of ATP to the N-terminal domains results in N-terminal
dimerization and Hsp90 acquires a “closed” conformation that allows for the binding of client
proteins via the middle domain (‘M’). ATP hydrolysis to ADP results in a return to the open
conformation and the release of a properly folded protein (Li et al., 2012). Although Hsp90 is
dependent on ATPase activity, the rate of ATP turnover is very slow and Hsp90 co-chaperones are
required for the regulation of Hsp90 activity. These co-chaperones assist in Hsp90 binding to client
proteins, support Hsp90-mediated folding, and can inhibit or activate ATPase activity, thereby
regulating the rate of Hsp90 chaperoning activity (Li et al., 2012). Examples of Hsp90 cochaperones in humans include Aha1, a potent activator of Hsp90 ATPase activity (Meyer et al.,
2004); Cdc37, which suppresses ATP turnover and allows for the loading of kinase client proteins
to Hsp90 (Siligardi et al., 2002); and Hop, which modulates the interaction between Hsp90 and
Hsp70 and stimulates protein refolding (Johnson et al., 1998).
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Figure 1.15: Hsp90 chaperone activity. In the absence of ATP, Hsp90 exhibits an “open”
configuration with no chaperone activity. ATP-binding to the N-terminal domains leads to
homodimer interaction and Hsp90 adopts a “closed” configuration that allows for the binding and
refolding of the client protein. Hydrolysis of ATP to ADP results in a return to the open
conformation and release of a newly folded protein.

Hsp90 is highly conserved across species (Chen et al., 2006a). In humans, there are five Hsp90
isoforms, including the cytosolic stress-induced Hsp90α (isoforms 1 and 2), the constitutively
expressed Hsp90β, as well as two isoforms specific to the ER and mitochondria (Chen et al.,
2006a) (Table 1.5). In the budding yeast Saccharomyces cerevisiae, there are two cytosolic
isoforms: stress-inducible Hsp82 and constitutively expressed Hsc82 (Table 1.5). Constitutively
expressed Hsp90 isoforms are expressed at high levels under basal conditions, whereas stressinducible Hsp90 isoforms are expressed at low levels and strongly induced in response to proteindenaturing stressors (Sreedhar et al., 2004).
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Table 1.5: Hsp90 isoforms in humans and yeast.

Human

Yeast

Subcellular
Localization

Gene

Protein

Cytosolic

HSP90AA1
HSP90AA2
HSP90AB1

Hsp90α1 *
Hsp90α2 *
Hsp90β **

ER

HSP90B1

Grp94

Mitochondria

TRAP1

Trap1

Cytosolic

HSP82
HSC82

Hsp82 *
Hsc82 **

Stress-inducible *; constitutive **

Hsps such as Hsp90 are regulated by heat shock factor 1 (Hsf1), the master transcription factor
responsible for the upregulation of hsp genes in response to proteotoxic stress (Anckar & Sistonen,
2011). In turn, Hsp90 regulates the transcriptional activation of Hsf1 (Ali et al., 1998) (Figure
1.16).
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Figure 1.16: Hsps are regulated by Hsf1. Under basal conditions, Hsf1 is bound to Hsp90 and
maintained in its inactive form. Upon proteotoxic stress, Hsf1 is released from Hsp90 and
undergoes post-translational modification(s) that result in Hsf1 homotrimerization and binding to
the heat shock element (HSE) in the promotor region of hsp genes to initiate the transcription of
Hsps such as Hsp90.

In addition to its key role in protein folding, Hsp90 has central roles in cell growth, differentiation,
and survival. Notably, during oncogenesis, these functions may be subverted to promote malignant
transformation (Whitesell & Lindquist, 2005). Hsp90 expression is significantly increased in
tumours, and high Hsp90 expression levels are associated with decreased survival in cancers
including breast cancer (Pick et al., 2007). Somatic mutations in HSP90 have not yet been
identified; however, hyperactivation of Hsf1 in cancer enhances the expression of Hsps and may
thus contribute to oncogenic Hsp90 overexpression. For example, loss of the tumour suppressor
gene neurofibromatosis type 1 (NF1) activates Hsf1 to promote tumorigenesis in mouse embryonic
fibroblasts (Dai et al., 2012). Many Hsp90 client proteins, including tumour suppressor p53, protooncogene Src, and hypoxia-inducible factor 1α (HIF1α) regulate processes that are critical to
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tumour progression (Irby & Yeatman, 2000; Zilfou & Lowe, 2009; Jun et al., 2017) (Figure 1.17).
Hsp90 inhibitors have thus been the focus of many anti-cancer regimens. Several well-known
inhibitors of Hsp90 that inhibit ATP-binding are geldanamycin and radicicol (Roe et al., 1999;
Soga et al., 2003). Although some clinical trials have shown promising results, others have been
halted due to suboptimal therapeutic effects for reasons that remain to be investigated (Schopf et
al., 2017). More work must be done to investigate the use of Hsp90 inhibitors in cancer therapy.

Figure 1.17: The role of Hsp90 in promoting tumourigenesis. In addition to its role as a
molecular chaperone, many Hsp90 client proteins are involved in critical processes that may
contribute to tumourigenesis when Hsp90 function is subverted in cancer.

1.5.4 Protein Degradation
Cytosolic misfolded proteins that cannot be refolded by molecular chaperones may be targeted for
degradation by the ubiquitin-proteasome system (UPS), the major proteolytic pathway in
eukaryotes (Ciechanover et al., 1980; Hershko et al., 1980). Proteasomal degradation occurs by
two successive steps: (1) the enzymatic cascade of E1, E2, and E3 ubiquitin-associated enzymes
which polyubiquitinate old, damaged, and misfolded proteins for degradation; and (2) degradation
of the polyubiquitin-tagged protein by the downstream 26S proteasome. Evidence suggests that
E3 ubiquitin ligases interact with molecular chaperones. For instance, the mammalian E3 ubiquitin
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ligase carboxy-terminal Hsp70 interacting protein (CHIP) has been shown to tag Hsp90- and
Hsp70-bound substrates for degradation (Zhang et al., 2015a; Quintana-Gallardo et al., 2019).
Misfolded proteins that cannot be degraded by the proteasome may be cleared by autophagy.
For misfolded proteins that are localized to the endoplasmic reticulum (ER), degradation occurs
through the ER-associated protein degradation (ERAD) pathway (McCracken & Brodsky, 1996;
Werner et al., 1996). The accumulation of misfolded proteins in the ER leads to activation of the
unfolded protein response, a cell stress response related to ER stress (Kohno et al., 1993; Cox &
Walter, 1996; Liu & Chang, 2008). This halts protein synthesis, initiates degradation, and activates
signalling pathways for the recruitment of molecular chaperones. Degradation by the ERAD
pathway consists of three major steps: (1) recognition of misfolded proteins through the detection
of protein substructures (e.g., exposed hydrophobic regions); (2) retrotranslocation to the cytosol;
and (3) degradation by the unfolded protein response (Meusser et al., 2005).

1.5.5 Protein Sequestration
In scenarios where protein quality control mechanisms are overloaded due to cell stress or
increased misfolded protein loads, or in cases of irreversible misfolding, aggregation/inclusion
formation, proteins may be sequestered into spatially distinct compartments. In humans, misfolded
proteins may be sequestered into a dynamic pericentriolar structure called the aggresome (Johnston
et al., 1998; García-Mata et al., 1999). Aggresome formation begins with the packaging of
misfolded proteins into larger aggresomal particles throughout the cytosol. Shortly after their
formation, aggresomal particles are transported in a microtubule-dependent manner along with
dynein/dynactin motor complexes to the microtubule-organizing centre (MTOC) where they are
sequestered into an aggresome. Aggresome formation is usually accompanied by a reorganization
of the intermediate filament cytoskeleton to form a “cage-like” structure around the aggresome
(Johnston et al., 1998; García-Mata et al., 1999). From here, cytosolic degradative machinery such
as chaperones, ubiquitination enzymes, and proteasome components are recruited to the aggresome
to facilitate the clearance of the misfolded proteins (Johnston et al., 1998; Wigley et al., 1999).
The aggresome is eventually disassembled with the help of proteasomes (Hao et al., 2013) or
targeted for autophagic clearance from the cell (Bjørkøy et al., 2005). Aggresome formation has
also been implicated in numerous disease states wherein mutant forms of inclusion/aggregation43

prone proteins that cannot be degraded within the aggresome form pathological inclusion bodies
that can contribute to cellular dysfunction and/or cell death (e.g., α‐synuclein in Parkinson’s
disease (Masliah et al., 2000), huntingtin in Huntingtin’s disease (Davies et al., 1997), and
superoxide dismutase in ALS (Durham et al., 1997; Bruijn et al., 1998)).
Alternatively, in yeast, two intracellular compartments, the juxtanuclear quality control (JUNQ)
and the insoluble protein deposit (IPOD), sort and sequester misfolded cytosolic proteins in a
tightly regulated manner (Kaganovich et al., 2008). Soluble ubiquitinated misfolded proteins are
sequestered into JUNQ compartments where they may be refolded by cytoplasmic molecular
chaperones such as Hsp104 or degraded by the 26S proteasomes that are colocalized to JUNQ. On
the other hand, non-ubiquitinated, insoluble aggregated proteins, including disease-associated
proteins, are sorted into IPOD components. Instead of colocalizing with proteasomes, IPOD
colocalizes with autophagy-related protein 8 (Atg8) for aggregate clearance through autophagic
pathways. Delivery to these compartments is dependent on molecular chaperones, co-chaperones,
and the actin cytoskeleton (Narayanaswamy et al., 2009). In both yeast and humans, misfolded
proteins that cannot be cleared within compartments are also cleared by autophagy.

1.5.6 Autophagy
Autophagy, or lysosomal degradation, is a highly regulated intracellular degradation system that
delivers degraded constituents from the cytosol, such as degraded misfolded proteins, to the
lysosome for clearance (Yorimitsu & Klionsky, 2005; Mizushima, 2007; Glick et al., 2010). There
are three types of autophagy in mammals: macroautophagy, microautophagy, and chaperonemediated autophagy (CMA). The mechanisms for CMA involve the sequential and targeted
delivery of misfolded proteins from the cytosol to the lysosomal lumen by molecular chaperones
(Dice, 2007; Cuervo, 2010; Kaushik et al., 2011). Degradation by CMA requires the pentapeptide
motif related to the sequence 5’-KFERQ-3’ that is recognized by the chaperone for transport to
the lysosome (Dice, 1990). Currently, Hsp70 is the only chaperone that can recognize this KFERQlike motif but may function with assistance from molecular chaperones (Chiang et al., 1989).
Unlike macro- and microautophagy which requires vesicle formation with the lysosome, CMA
involves the translocation of a substrate across the membrane of the lysosomal lumen (Mizushima,
2007). Notably, this translocation process requires that the protein substrate is in an unfolded state
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(Salvador et al., 2000), implying that some insoluble protein aggregates, such as those present in
neurodegenerative diseases, cannot be degraded by CMA.

1.5.7 Protein Oxidation
Misfolded proteins may accumulate due to protein oxidation. When the balance between ROS
production and elimination is tipped, proteins may become modified and damaged. Most protein
amino acids can be oxidized by ROS, but those containing sulfur (S) (i.e., cysteine and methionine)
and aromatic rings (i.e., tyrosine and tryptophan) are particularly susceptible (Stadtman, 1993).
Oxidation products of cysteines include disulfide (S−S) bonds and mixed disulfide bonds that are
reduced by the thioredoxin/thioredoxin reductase system. Thioredoxin reductase system catalyzes
the reduction of oxidized thioredoxin which then goes on to reduce protein disulfides (Laurent et
al., 1964; Moore et al., 1964; Nordberg & Arnér, 2001). Oxidized methionine is converted to
methionine sulfoxide which can be reverted to methionine by methionine sulfoxide reductase
(Msr) (Caldwell et al., 1978; Jiang & Moskovitz, 2018). Oxidation of most other amino acids
usually involves the irreversible addition of a hydroxyl or carbonyl group; the latter is a biomarker
for protein oxidation in cells (Dalle-Donne et al., 2003).
Protein oxidation leads to decreased thermodynamic stability and impaired activity due to partial
protein unfolding and disruption of the native state (Kim et al., 2001; Petrov et al., 2016). Protein
oxidation may also cause hydrophobic residues to become exposed at the protein surface (Friguet
et al., 1994) thereby targeting them for degradation by the proteasome which binds preferentially
to hydrophobic residues (Davies, 2001). However, upon conditions of severe oxidative stress,
oxidized and misfolded proteins may become severely cross-linked, misfold, and aggregate into
insoluble protein inclusions that cannot be degraded by the proteasome. These protein inclusions
may in fact bind to the 20S proteasome and irreversibly inhibit their function (Davies, 2001).
Cysteines are of particular interest due to their strong propensity for oxidation and cross-linking
through disulfide bond formation.
It is important to note, however, that not all forms of protein oxidation are harmful to the cell.
Some cellular processes require protein oxidation, such as the oxidation of specific cysteine
residues in Keap1 that is required for Nrf2 stabilization (Dinkova-Kostova et al., 2002; Zhang &
Hannink, 2003; Wakabayashi et al., 2004).
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1.5.8 Cysteine Thiol Oxidation
The susceptibility of cysteines to oxidation is due to the presence of a sulfur atom. The sulfur atom
is a strong nucleophile contained within the thiol functional group (also known as a sulfhydryl
group) of cysteine residues where it exists at the lowest oxidation state (Poole, 2015). A thiol
(RSH) that is deprotonated becomes a thiolate anion (RS–) (Figure 1.18).

Figure 1.18: Forms of cysteine. The protonated form of cysteine contains a thiol group (left),
while the deprotonated form contains a thiolate anion (right).

Oxidants can initiate a sulfur oxidation pathway of protein thiols through the step-wise oxidation
to sulfenic acid (RSOH) and sulfinic acid (RSO2H) and finally to sulfonic acid (RSO3H) (van
Bergen et al., 2014) (Figure 1.19A). This occurs in the following steps: (1) oxidation of a thiol
group produces sulfenic acid; (2) disulfide bonds are formed by a nucleophilic attack of a thiol on
a sulfenic acid; (3) further oxidation of sulfenic acid produces sulfinic acid; (4) even further
oxidation of sulfinic acid produces sulfonic acid which is a very strong acid that is comparable to
sulfuric acid (Bayse, 2011; van Bergen et al., 2014). The oxidation process towards sulfinic acid
is considered mostly irreversible and can only be reverted by the Nrf2-regulated enzyme
sulfiredoxin; however, no known enzymes can reverse the oxidation to sulfonic acid (van Bergen
et al., 2014). A charged thiolate anion can also go through the sulfur oxidation pathway (Figure
1.19B). Within the sulfur oxidation pathway, disulfide bonds are formed through the nucleophilic
attack of a thiol on sulfenic acid.
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Figure 1.19: The sulfur oxidation pathway with oxidation by hydrogen peroxide (H2O2).
Thiol oxidation produces sulfenic acid. A nucleophilic attack of a thiol on sulfenic acid and results
in disulfide bond formation. Further oxidation of sulfenic acid produces sulfinic acid which can be
further oxidized to sulfonic acid. (B) This same pathway is illustrated for the oxidation of a thiolate
anion. Adapted from van Bergen et al. (van Bergen et al., 2014).

In redox-sensitive proteins such as Keap1, reactive cysteine residues tend to be located adjacent to
basic amino acids which markedly lowers their pKa value, resulting in increased reactivity
(Wakabayashi et al., 2004). Additionally, reactive cysteine thiols tend to be situated in proximity
to other cysteine thiols (Sanchez et al., 2008), thereby allowing thiols to more readily attack other
thiols within the same protein or a different protein, leading to the formation of intramolecular or
intermolecular disulfide bonds between cysteines, respectively:
2RSH ⇌ RS−SR + 2H+ + 2e−
This susceptibility of thiols to oxidation makes cysteine thiols very versatile with important roles
in cell physiology (Poole, 2015); however, this high level of reactivity may also lead to negative
events that impair normal function, such as protein inclusion formation by cysteine thiol oxidation
and disulfide bond formation (Figure 1.20).
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Figure 1.20: Oxidative stress-induced cysteine oxidation. Exposure to ROS results in the
oxidation of cysteine thiol groups, leading to intra- and/or intermolecular disulfide bond formation
which can contribute to protein misfolding and inclusion formation.

It is important to note that aberrant cysteine oxidation in the cytoplasm (which can be uncontrolled
and harmful) differs from cysteine oxidation in the ER (which is controlled and intentional).
Within the ER, temporary, non-native disulfide bonds can form within a protein that helps to
stabilize proteins during the folding process, though the ultimate reduction of these non-native
disulfide bonds is necessary for proper folding (Jansens et al., 2002). Non-native disulfide bond
formation in the ER is therefore a normal part of the protein folding pathway, while non-native
disulfide bonds are prevalent within aberrantly misfolded cytosolic proteins (Ellgaard et al., 2018).
The delicate balance of cysteine oxidation is thus an important topic of study in protein redox
biology.
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1.6

Studying Protein Interactions

The study of proteins and their interactions is fundamental for understanding biochemical reactions
and cellular pathways at the molecular level. For example, nearly all aspects of Nrf2 activity are
regulated by its interactions with other proteins. Many techniques have been developed to decipher
the genetic and physical interactions of proteins.

1.6.1 Genetic Interactions and Physical Protein-Protein Interactions
A genetic interaction can be defined as the phenomenon by which the phenotypic effects of the
function of one gene modifies the phenotypic effects of another gene or group of genes (Mani et
al., 2008). Genetic interaction studies have been used to study the functional relationship between
genes and their protein products and have successfully been used to identify many protein partners,
complexes, and pathways (Mani et al., 2008). It is important to note that although all proteins
within a simple complex (e.g., the ribosomal complex) share a functional genetic interaction, not
all proteins within a complex physically interact. This distinguishes genetic interactions from
physical protein-protein interaction interactions.
A protein-protein interaction (PPI) is defined as the physical interaction between two proteins that
occur through specific physical contact and molecular docking (De Las Rivas & Fontanillo, 2010).
A protein interaction must meet two major criteria to be considered a PPI: (1) the contact must be
specific and exclude chance interactions with other proteins in the cell; and (2) the contact is not
generic and excludes any interactions experienced during protein synthesis, folding, and
degradation (De Las Rivas & Fontanillo, 2010). Most PPIs are neither static nor permanent, as
cells experience continuous turnover and PPIs will vary depending on the biological state of the
cell (De Las Rivas & Fontanillo, 2010). All things considered; it is important to differentiate
between physical PPIs with purely functional genetic interactions that do not involve direct
physical contact. These interactions can be studied using various methods and models and can
quite easily be studied using yeast models.
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1.6.2 Yeast as a Model Organism to Study Protein Interactions
Saccharomyces cerevisiae, also known as budding yeast or baker’s yeast, is a eukaryotic singlecelled organism that has been frequently used as a model organism to study protein mechanisms,
pathways, and interactions. Yeast is a powerful model organism because of its rapid growth, which
allows for high throughput studies, its single-celled nature, which allows for simple in vivo
analysis, and the fact that yeast and human cells share fundamental commonalities for many
conserved cellular processes (Smith & Snyder, 2006; Mohammadi et al., 2015). About one-third
of yeast genes have a human ortholog and over two-thirds share significant homology with human
genes (Laurent et al., 2016). Notably, yeast was the first eukaryotic organism to have its complete
genome sequenced (Goffeau et al., 1996) and subsequently, a wide range of yeast-associated
genetic tools have been developed, including large strain libraries for deletion mutants (Giaever et
al., 2002), overexpression mutants (Sopko et al., 2006), and strains with genes tagged by reporter
genes (Huh et al., 2003). In this work, we utilize the yeast model to (1) study genetic interactions
using yeast growth expression studies, and (2) study physical PPIs using the split-ubiquitin system
(Figure 1.21).

Figure 1.21: Using a yeast model to study protein interactions. Yeast growth expression studies
and the split-ubiquitin system can be used to study genetic and physical interactions, respectively,
for human proteins expressed in yeast.
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To study genetic interactions using yeast, growth assays can be performed wherein two human
proteins of interest are co-expressed together in yeast cells and their individual and combined
effects can be observed from the resulting growth phenotype to determine possible genetic
interactions. If their co-expression phenotype differs from the phenotype of either protein
expressed alone, a genetic interaction may exist. For example, Figure 1.22 demonstrates that the
expression of ‘protein A’ is toxic in yeast (i.e., impaired growth compared to the control); however,
the co-expression of protein A together with ‘protein B’ results in a partial rescue of protein A’s
toxicity. This indicates a genetic interaction between proteins A and B.

Figure 1.22: Yeast growth assay for detecting genetic interactions. The co-expression of
proteins A and B together partially rescues the toxic phenotype observed for the expression of
protein A alone, thereby indicating that a genetic interaction exists between them.

With regards to studying physical PPIs in yeast, several methods have been developed including
the yeast two-hybrid (Y2H) system (Fields & Song, 1989; Brückner et al., 2009) and the splitubiquitin system (Johnsson & Varshavsky, 1994; Müller & Johnsson, 2008). The Y2H system
functions under the premise that the binding of a transcription factor to an upstream activating
sequence (UAS) initiates the activation of a downstream reporter gene. The transcription factor is
split into two fragments: the DNA-binding domain (DBD) which binds to the UAS, and the
activating domain (AD) which activates transcription. Note that neither fragments alone can
initiate transcription. For Y2H screening, protein fusions are prepared for two proteins of interest,
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termed the ‘bait’ and the ‘prey’ (i.e., DBD-bait and AD-prey, or vice versa). If the bait protein
interacts with the prey protein, then the DBD and AD reconstitute and transcription of the reporter
gene occurs, resulting in a specific and detectable change in the yeast cell phenotype (Figure 1.23).

Figure 1.23: Yeast two-hybrid (Y2H) system for detecting PPIs. Two proteins of interest (the
‘bait’ and ‘prey’) are fused to the DNA-binding domain (DBD) and activating domain (AD),
respectively, within the promoter region of a downstream reporter gene. The DBD is bound to the
upstream activating sequence (UAS). (A) The bait and prey interact and the DBD and AD
reconstitute. Transcription of the reporter gene occurs and a detectable change in cell phenotype is
observed due to reporter gene activity. (B) The bait and prey do not interact. The reporter gene is
not transcribed and no change in phenotype is observed.

The split-ubiquitin system was developed based on similar underlying principles as the Y2H
system, but instead of utilizing two transcription factor fragments, the bait and prey are fused to
two fragments of a ubiquitin molecule, wherein reconstitution of two ubiquitin fragments results
in the cleavage of a reporter molecule, leading to a specific growth phenotype that can be detected
on growth media (Figure 1.24). Since the split-ubiquitin system does not rely on the utilization of
a transcription factor, it offers the great advantage of detecting interactions between non-nuclear,
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insoluble, and hydrophobic proteins, and is sensitive enough to detect transient interactions, such
as those with molecular chaperones (Stagljar et al., 1998).

Figure 1.24: The split-ubiquitin system for detecting PPIs. Two proteins of interest (the ‘bait’
and ‘prey’) are fused to the N-terminal (Nub) and C-terminal (Cub) halves of a ubiquitin molecule.
(A) The bait and prey interact and the two halves of ubiquitin re-associate to form a quasi-native
ubiquitin. This leads to cleavage and degradation of an R-URA3 reporter fused to the Cub by
ubiquitin-specific proteases. In this scenario, yeast cells are unable to produce uracil and cannot
grow on growth media that lacks uracil (uracil-) but do grow on media selecting for the absence
of URA3, i.e., media containing 5-fluoroorotic acid (5FOA). (B) The bait and prey do not interact.
The R-URA3 reporter remains intact and yeast cells retain their ability to synthesize uracil;
however, in the presence of 5FOA, uracil is converted to 5-fluorouracil, which is toxic to yeast.
This is detected by growth on uracil- media and no growth on media containing 5FOA.

Taken together, investigating protein interactions is very important for studying proteins such as
Nrf2, whose regulation and activity are heavily dependent on its interactions with other proteins.
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1.7

Hypothesis and Aims

Both the antioxidant response (mediated by Nrf2 and Keap1) and the heat shock response
(facilitated by molecular chaperones such as Hsp90) are crucial for the maintenance of cellular
homeostasis. We hypothesize that oxidative damage to Nrf2 and Keap1 and their interactions with
Hsp90 alter their function within the cellular antioxidant stress response. This is explored
throughout three chapters encompassing three aims that investigate important cellular and
molecular aspects of the Keap1-Nrf2 antioxidant pathway.
Aim 1: To establish and characterize a yeast model for studying human Nrf2. Using the
complementary experimental tools available for yeast, a previously unexplored interaction
between Nrf2 and the heat shock response is detected. From there, further exploration into the
nexus between the antioxidant and heat shock responses is studied with emphasis on protein
oxidation and cellular responses to cancer therapy.
Aim 2: To investigate protein oxidation and misfolding in Nrf2 regulation. Using yeast,
mammalian cells, and purified proteins, we describe and assess the oxidative stress-induced
inclusion formation of Nrf2 and Keap1 to determine if protein oxidation and misfolding affect
Nrf2 regulation.
Aim 3: To explore potential crosstalk between cell stress responses in cancer. By using a clinically
relevant model of HER2+ breast cancer, we investigate the interplay between the antioxidant and
heat shock responses and their dependence on Hsp90 chaperone activity in cancer therapy
resistance.
The results from these studies suggest previously unexplored mechanisms by which the cysteine
oxidation of Keap1 and Nrf2 alter their cellular function during oxidative stress, and that both
Keap1 and Nrf2 folding and activity are regulated by Hsp90, implicating crosstalk between these
two cell stress response pathways (Figure 1.25).

54

Figure 1.25: Investigating crosstalk between the antioxidant and heat shock responses. This
work investigates key cellular and molecular aspects of the Keap1-Nrf2 antioxidant pathway,
including its crosstalk with the heat shock response and its implications in protein folding and
quality control and cancer.
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Chapter 2
2

A novel yeast model detects Nrf2 and Keap1 interactions with
Hsp90

Nrf2 is the master transcriptional regulator of cellular responses against oxidative stress. It is
chiefly regulated by Keap1, a substrate adaptor protein that mediates Nrf2 degradation. Nrf2
activity is also influenced by many other protein interactions that provide Keap1-independent
regulation. To study Nrf2 regulation, we establish and characterize yeast models expressing human
Nrf2, Keap1, and other proteins that interact with and regulate Nrf2. Yeast models have been wellestablished as powerful tools to study protein function and genetic and physical protein-protein
interactions. In this work, we recapitulate previously described Nrf2 interactions in yeast and
discover that Nrf2 interacts with the molecular chaperone Hsp90. Our work establishes yeast as a
useful tool to study Nrf2 and provides novel insight into the crosstalk between the antioxidant
response and the heat shock response.

_____________________________
A version of this chapter has been submitted for publication.
Ngo, V., Brickenden, A., Liu, H., Yeung, C., Choy, W. Y., & Duennwald, M. L. (2020). A novel
yeast model detects Nrf2 and Keap1 interactions with Hsp90.
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2.1

Introduction

Nuclear factor erythroid 2-related factor 2 (Nrf2) is the master transcriptional regulator of cellular
responses against oxidative stress (Moi et al., 1994). Nrf2 is negatively regulated by Kelch-like
ECH-associated protein (Keap1), a substrate adaptor protein that binds to Nrf2 in the cytoplasm to
promote Nrf2 ubiquitination via the Cullin 3 (Cul3) E3 ubiquitin ligase for proteasomal
degradation under basal conditions (Itoh et al., 1999; Itoh et al., 2003; McMahon et al., 2003;
Nguyen et al., 2003; Kobayashi et al., 2004; Kobayashi et al., 2006). Under oxidative stress,
specific stress-sensing cysteine residues in Keap1 are modified (Dinkova-Kostova et al., 2002;
Zhang & Hannink, 2003; Wakabayashi et al., 2004), leading to a conformational change that
impairs the interaction between Keap1 and Nrf2, thereby preventing Nrf2 ubiquitination and
degradation and stabilizing Nrf2 for accumulation, nuclear translocation, and the induction of
cytoprotective antioxidant genes (Itoh et al., 1999; Itoh et al., 2003; McMahon et al., 2003;
Kobayashi et al., 2006).
Stability, and therefore the activity of Nrf2, is tightly regulated by two binding events to Keap1.
Keap1 first recruits Nrf2 by binding to the high-affinity ETGE motif within the Neh2 domain of
Nrf2. Subsequent binding at the low-affinity DLG motif within Neh2 locks Nrf2 in place by
orienting the lysine residues within Neh2 in the correct position for ubiquitination (Tong et al.,
2006; Tong et al., 2007). This two-site binding model has been widely accepted as the primary
mechanism of Keap1-mediated Nrf2 regulation. Mutations that disrupt the Keap1-Nrf2 interaction
alter Nrf2 regulation and contribute to the pathogenesis of many human diseases (Padmanabhan
et al., 2006; Shibata et al., 2008). For example, gain-of-function mutations within the Keap1binding domain of Nrf2, specifically within the DLG motif (e.g., L30F) and ETGE motif (e.g.,
T80R) impair its recognition by Keap1-Cul3, leading to the dysregulation and subsequent
hyperactivation of Nrf2 in lung cancer (Shibata et al., 2008). In addition to Keap1, Nrf2 regulation
is greatly dependent on its interactions with many other proteins.
An interesting alternate mechanism of Nrf2 regulation first proposed by Zhang et al. identified p21
(also known as p21WAF1/Cip1) as a regulator of Nrf2 transcriptional activity (Chen et al., 2009). p21
is a cyclin-dependent kinase inhibitor with well-established roles in p53-regulated tumour
suppression, including cell cycle control, DNA replication and repair, and apoptosis (Xiong et al.,
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1993; Gartel & Radhakrishnan, 2005; Abbas & Dutta, 2009). The authors found that ablation of
p21 results in increased cellular levels of reactive oxygen species (ROS). Reciprocal
immunoprecipitation assays and pull-down experiments for p21 and Nrf2 suggest that p21 directly
interacts with Nrf2 by competing with Keap1 for binding, indicating that p21 binding to Nrf2
prevents Keap1-directed Nrf2 degradation (Chen et al., 2009). Several studies have linked the
overexpression of cytoplasmic p21 to decreased responsiveness to chemotherapy and radiotherapy
(Liu et al., 2003) and poor prognosis in numerous cancers (Baretton et al., 1999; Bae et al., 2001;
Cheung et al., 2001). The cellular and molecular mechanisms of the interaction of p21 with Nrf2
remain unclear.
Other key proteins in the Nrf2 interactome that are investigated in this study include β-transducin
repeat-containing protein (βTrCP), which acts as a substrate receptor for the Skp1-Cul1Rbx1/Roc1 ubiquitin ligase complex involved in Keap1-independent Nrf2 degradation (Rada et
al., 2011; Chowdhry et al., 2013); the Cullin 3 (Cul3) ubiquitin E3 ligase, which binds Keap1 in
the cytosol and upon Keap1-Nrf2 binding, polyubiquitinates Nrf2 for degradation by the 26S
proteasome (Kobayashi et al., 2004; Zhang et al., 2004); and the underexplored prothymosin alpha
(ProTα/PTMA), which is thought to inhibit the Keap1-Nrf2 complex by competing with Nrf2 for
Keap1 binding (Karapetian et al., 2005; Khan et al., 2013).
In this work, we establish a novel approach to studying the interactions of human Nrf2 in the
budding yeast Saccharomyces cerevisiae. Yeast and human cells share fundamental
commonalities in many conserved cellular processes, making yeast a powerful model system for
studying the mechanisms of important cellular processes, including those that underlie protein
regulation and human disease (Hartwell, 2005; Smith & Snyder, 2006; Tenreiro & Outeiro, 2010;
Di Gregorio & Duennwald, 2018). Yeast is a formidable model to identify and characterize genetic
interactions, which can be defined as the phenomenon by which the phenotypic effects of the
function of one gene modifies the phenotypic effects of another gene or genes (Mani et al., 2008).
Yeast can also be used to study physical protein-protein interactions (PPIs) by employing the yeast
two-hybrid system (Fields & Song, 1989) or split-ubiquitin system (Johnsson & Varshavsky,
1994) to identify and characterize such physical interactions that occur through specific contact
and molecular docking (De Las Rivas & Fontanillo, 2010). Yeast does not express any close Nrf2
homologue, which allows us to minimize interference with endogenous Nrf2 regulation as it occurs
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in mammalian cells. This feature makes yeast an optimal living test tube for studying Nrf2
interactions. Our yeast model of human Nrf2 confirms previously established genetic and physical
Nrf2 interactions and allowed us to characterize a previously unexplored interaction between Nrf2
with the molecular chaperone Hsp90.

2.2

Results

2.2.1 Expression of human Nrf2 and associated proteins in yeast
Yeast growth assays were used to assess the relative growth and toxicity of select human proteins
within the Nrf2 interactome (Figure S2.1) expressed in yeast to determine genetic interactions
with Nrf2. Human Nrf2 expressed in yeast leads to toxicity, defined as an impaired growth
phenotype on growth media compared to the empty vector control (Figure 2.1A, left). Relative
growth on solid media was quantified to show statistical significance, performed as described
before (Petropavlovskiy et al., 2020) (Figure 2.1A, right). Means derived from five biological
replicates were used during analysis. These results were also confirmed quantitatively by assessing
the growth rate of yeast cells grown in liquid culture (Figure 2.1B). Nrf2 toxicity in yeast is likely
attributed to cellular quiescence but not cell death, as determined by a propidium iodide (PI) assay
which showed no cell death in yeast cells expressing Nrf2 compared to the boiled positive control
(Figure S2.2). Protein expression of Nrf2 in yeast is confirmed by western blot analysis (Figure
2.1C). Fluorescence microscopy also confirmed protein expression through the visualization of a
YFP (yellow fluorescent protein) or DsRed (Discosoma red fluorescent protein) tag fused to the
carboxy-terminus of Nrf2, which shows that Nrf2 is diffusely localized in the yeast cytoplasm and
nucleus (Figure S2.3A). In ensuing studies, we exploit Nrf2 toxicity as a tractable phenotype for
our genetic interaction studies, as done previously in well-established yeast models expressing
other human proteins (Hartwell, 2005; Tenreiro & Outeiro, 2010; Di Gregorio & Duennwald,
2018).
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Figure 2.1: Expression of human Nrf2 in yeast. (A) Growth assay of yeast cells expressing
human Nrf2 (left). Relative growth is quantified to the right of the image. Means derived from five
biological replicates were used during analysis. Means were analyzed using the student’s T-test.
Data are expressed as mean ± SD. p<0.05 was considered statistically significant; *p<0.05,
**p<0.01, ***p<0.001. (B) Growth curve of yeast cells expressing Nrf2 grown in liquid culture.
Means derived from three biological replicates were obtained. Data are expressed as mean ± SD.
(C) Nrf2 protein expression in yeast documented by western blot analysis, with β-tubulin serving
as the internal loading control.

To assess which regions in Nrf2 give rise to the protein’s toxic phenotype in yeast, three fragments
of Nrf2 were examined (Figure 2.2A): (1) the N-terminal (NH2) fragment, consisting of the Neh2,
Neh4, Neh5, and Neh7 domains; (2) the ∆Neh2/3 variant, with deletions of the Neh2 and Neh3
domains; and (3) the C-terminal (COOH) fragment, containing the Neh6, Neh1, and Neh3
domains. Like wild-type Nrf2, the NH2 and COOH fragments are toxic in yeast while the ∆Neh2/3
variant is not (Figure 2.2B). Fluorescence microscopy in shows the diffuse expression of Nrf2
∆Neh2/3-YFP but greater localization to fluorescent foci for Nrf2 NH2-YFP and Nrf2 COOHYFP, which might indicate protein inclusions, particularly for the NH2 fragment (Figure 2.2C).
(Note that YFP-tagged yeast cells were imaged with a green fluorescent protein (GFP) filter due
to the unavailability of a YFP filter at the time of imaging). The NH2 fragment contains the crucial
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Neh2 (Keap1-binding) domain of Nrf2 which has been characterized as intrinsically disordered
(Tong et al., 2006). Intrinsically disordered proteins or regions are more prone to misfolding under
certain conditions (Uversky, 2011); thus, the Neh2 domain is likely a plausible main driver of this
observed misfolding and toxicity in living cells. However, despite its intrinsically disordered
nature and increased propensity to misfold, the Neh2 domain remains a key functional domain
within Nrf2.
In addition, GFP-tagged protein constructs for mammalian expression in HeLa cells recapitulates
the fluorescence microscopy results observed in yeast, illustrating the formation of protein
inclusions for Nrf2 NH2-GFP (Figure 2.2D). Upon analyzing the cell viability of wild-type Nrf2
and its fragmented variants in HeLa cells, we find that overexpression of wild-type Nrf2 is not
toxic to HeLa cells, but instead promotes increased cell viability (determined by the quantification
of ATP levels which indicates the presence of metabolically active cells (Crouch et al., 1993))
compared to the untreated control; however, cell viability was impaired with the expression of
Nrf2 NH2 (Figure 2.2E). Experiments in the HEK293 cell line reproduced the results observed in
HeLa cells (Figure S2.4).
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Figure 2.2: Nrf2 fragments expressed in yeast. (A) Schematic representation of the domains
within full-length wild-type human Nrf2 and the fragmented variants of Nrf2: N-terminal fragment
(NH2), the Neh2/3 deletion variant (∆Neh2/3), and the C-terminal fragment (COOH). (B) Growth
assay of yeast cells expressing the three Nrf2 fragments. (C) Fluorescence microscopy of yeast
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cells expressing the YFP-tagged Nrf2 fragments. Scale bars correspond to 10 μm. (D)
Fluorescence microscopy of HeLa cells expressing the Nrf2 GFP-tagged fragments (top), merged
with DAPI nuclear staining (bottom). Scale bars correspond to 25 μm. (E) Relative cell viability
of HeLa cells transfected with wild-type Nrf2 and its fragments. (B, E) Means derived from a
minimum of three biological replicates were used during analysis. Means were analyzed using
one-way ANOVA followed by Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05
was considered statistically significant; *p<0.05, **p<0.01, ***p<0.001.

To assess genetic Nrf2 interactions, we co-transformed yeast with well-established Nrf2interacting proteins described in the literature, including Keap1 (Itoh et al., 1999), p21 (Chen et
al., 2009), and βTrCP (Rada et al., 2011; Chowdhry et al., 2013), as well as the Keap1-interacting
Cul3 (Kobayashi et al., 2004; Zhang et al., 2004) and ProTα (Karapetian et al., 2005) to serve as
negative controls. As previously observed, human Nrf2 is toxic in yeast, but human Keap1
expression alone is only mildly toxic. When Keap1 is co-expressed with Nrf2, improved growth
is observed relative to the expression of Nrf2 alone (Figure 2.3A), i.e., the expression of Keap1
results in a partial rescue of Nrf2 toxicity, suggesting a genetic interaction. This is also observed
in liquid growth assays (Figure S2.5). It is important to note that in yeast expression studies, coexpression of a mildly toxic protein with a toxic protein adds toxicity in an additive manner if there
is no interaction; however, if there is a rescue in toxicity, as observed for Keap1 co-expressed with
Nrf2, then it is indicative of a genetic interaction. Thus, our yeast model confirms the wellestablished genetic interaction between Keap1 and Nrf2 observed in mammalian cells.
When human p21 is co-expressed with Nrf2, there is no significant rescue of Nrf2 toxicity,
indicating no genetic p21-Nrf2 interaction in yeast (Figure 2.3B) although a physical proteinprotein interaction may still exist (to be discussed). Co-expression with human βTrCP exacerbates
Nrf2 toxicity, indicating a βTrCP-Nrf2 genetic interaction (Figure 2.3C) as suggested before
(Rada et al., 2011; Chowdhry et al., 2013). Of note, this may be a result of synthetic toxicity and
thus a limitation of the yeast model because GSK3 is not present in yeast to phosphorylate Nrf2
for modulation of βTrCP activity (Rada et al., 2011; Chowdhry et al., 2013). Co-expression of
Nrf2 with human Cul3 does not modify the Nrf2 phenotype (Figure 2.3D), nor does co-expression
with human ProTα (Figure 2.3E). This is consistent with literature describing both Cul3 and
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ProTα as binding partners of Keap1 (Karapetian et al., 2005; Khan et al., 2013). Protein expression
in yeast is confirmed by western blot analysis for all proteins of interest (Figure 2.3F) except for
ProTα where no yeast-compatible commercially available antibody could be found. Fluorescence
microscopy with YFP-tagged constructs also confirms protein expression in yeast for all proteins
of interest, both alone and co-expressed with Nrf2 (Figure S2.3B).
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Figure 2.3: Co-expression of Nrf2 with other Nrf2-associated proteins._Growth assays of yeast
cells co-expressing human Nrf2 along with the following human proteins: (A) Keap1, (B) p21, (C)
βTrCP, (D) Cul3, and (E) ProTα. All growth assays are quantified as shown on the right with
means derived from three biological replicates. Means were analyzed using one-way ANOVA
followed by Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was considered
statistically significant; *p<0.05, **p<0.01, ***p<0.001. (F) Keap1, p21, βTrCP, and Cul3
expression are shown by western blot analysis, with β-tubulin serving as the internal loading
control. ProTα could not be reliably detected (see text for details).
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In addition to wild-type Nrf2, we examined two variants of Nrf2 with mutations in the Neh2,
Keap1-binding domain of Nrf2: an L30F mutation in the DLG motif, and a T80R mutation in the
ETGE motif. Like wild-type Nrf2, Nrf2 L30F and T80R were toxic in yeast. (Figure 2.4A). Protein
expression was confirmed by western blot analysis (Figure 2.4B) and fluorescence microscopy
(Figure S2.3C), which showed no major differences between wild-type and L30F and T80R Nrf2
steady-state protein levels and subcellular localization in yeast. We then assessed genetic
interactions of the L30F and T80R variants. When Keap1 is co-expressed with Nrf2 L30F or T80R,
Keap1’s ability to rescue Nrf2 toxicity (observed in Figure 2.3A) is impaired (Figure 2.4C). As
observed for wild-type Nrf2, co-expression of p21 with the L30F and T80R variants did not affect
toxicity (Figure S2.6). Collectively, these experiments demonstrate how simple growth assays of
yeast cells expressing wild-type Nrf2, fragmented and mutated variants of Nrf2, and Nrf2associated proteins allow the assessment of genetic interactions, such as that with Keap1 and
βTrCP, that regulate Nrf2 in mammalian cells.
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Figure 2.4: Nrf2 mutant variants expressed in yeast. (A) Growth assays of yeast cells
expressing wild-type human Nrf2 and its mutant variants, L30F and T80R. (B) Expression of Nrf2
L30F and Nrf2 T80R in yeast documented by western blot analysis, with β-tubulin serving as the
internal loading control. (C) Growth assays of yeast cells expressing wild-type Nrf2 and its mutant
variants co-expressed with Keap1. (A, C) Means derived from three biological replicates were
used during analysis. Means were analyzed using one-way ANOVA followed by Tukey’s post hoc
test. Data are expressed as mean ± SD. p<0.05 was considered statistically significant; *p<0.05,
**p<0.01, ***p<0.001.

2.2.2 The split-ubiquitin system detects protein-protein interactions of Nrf2
We next employed the split-ubiquitin system (Johnsson & Varshavsky, 1994; Stagljar et al., 1998;
Müller & Johnsson, 2008), outlined schematically in Figure 2.5A, to assess the physical proteinprotein interactions of Nrf2 (i.e., interactions between a ‘bait’ protein with a ‘prey’ protein). We
engineered Nrf2, Keap1, and other proteins of interest fused to Nub, the amino-terminal half of a
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full-length 'pseudo-ubiquitin' molecule, and to Cub-R-URA3 (CRU), the carboxy-terminal (Cub)
half of pseudo-ubiquitin fused to a URA3 reporter containing a degron (R) for rapid degradation
by cellular ubiquitin specialized proteases (Ubps). These Nub and CRU fusions were co-expressed
in yeast. Nrf2 interactions can be detected by growth on the following selective growth media: (1)
media lacking uracil (uracil-), which selects for the presence of the URA3 reporter—an interaction
between the bait and prey results in degradation of the URA3 reporter and loss of uracil synthesis,
detected by impaired growth on uracil- media; (2) media containing 5-fluoroorotic (5FOA), which
selects for the absence of the URA3 reporter and associated loss of uracil synthesis (5FOA reacts
with uracil to produced a toxic metabolite, 5-fluorouracil, that impairs yeast growth)—if the bait
and prey interact, then the URA3 reporter is degraded and growth is observed on 5FOA media
(Figure 2.5A). Different mutant alleles of Nub—NuI, NuA, and NuG (in order from highest to
lowest affinity for Cub)—are used to differentiate strong interactions (e.g., in stable complexes)
from weaker ones (e.g., transient interactions), where NuI detects stable interactions and NuG only
detects transient interactions (Stagljar et al., 1998).
Figure 2.5B confirms that the CRU constructs expressed in yeast grow on agar plates lacking
uracil, which is a prerequisite for the split-ubiquitin assay to work. Testing the established Keap1Nrf2 interaction utilizing the Nrf2-CRU + Keap1 NuI/NuA/NuG in yeast demonstrated no growth
on uracil- plates but growth on 5FOA plates, which confirms the physical PPI between Keap1 and
Nrf2 (Figure 2.5C, 2nd row). This was also observed for Nrf2-CRU + p21-NuI/NuA/NuG,
indicating a physical interaction between p21 and Nrf2 (Figure 2.5C, 3rd row). Phosphoglycerate
kinase 1 (Pgk1), an enzyme involved in gluconeogenesis with no reported Nrf2 interactions, was
used as a negative specificity control and indeed did not interact with Nrf2 in the split-ubiquitin
assay (Figure 2.5C, 1st row). Note that the low expression of the Nrf2-split-ubiquitin fusion
proteins did not result in cellular toxicity compared to the high expression plasmids used in our
genetic interaction studies. We then assessed PPIs of all combinations of Nrf2, Keap1, p21, βTrCP,
Cul3, and ProTα (data not shown), summarized in Figure 2.5D, with ‘+’ indicating an interaction
and ‘-’ indicating no interaction, which confirms the physical interactions between Nrf2 with
Keap1, p21, and βTrCP.
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Figure 2.5: The yeast split-ubiquitin system for studying physical Nrf2 protein-protein
interactions. (A) Schematic representation of the split-ubiquitin system. If the bait and prey
proteins interact, then the following growth conditions are met: no growth on uracil- and growth
on 5FOA. (B) Confirmation of the CRU constructs showing that yeast cells expressing the CRU
fusions grow on uracil- plates. (C) Split-ubiquitin assays for the Nrf2-CRU + Keap1-Nub and
Nrf2-CRU + p21-Nub combinations. Pgk1 served as a negative specificity control. Three
biological replicates were performed. (D) Summary of tested protein-protein interactions within
the Nrf2-interactome as detected by the split-ubiquitin assay; ‘+’ indicates an interaction and ‘-’
indicates no interaction.
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2.2.3 Interaction between Nrf2 and Keap1 with Hsp90
Since Nrf2 contains disordered regions (Itoh et al., 2004) and certain fragmented variants of Nrf2
form inclusions in yeast (Figure 2.2C) and mammalian cells (Figure 2.2D), we used the splitubiquitin assay to probe for interactions with molecular chaperones which help to fold, stabilize,
and degrade disordered and misfolded proteins (Frydman, 2001; Bukau et al., 2006). Interestingly,
our split-ubiquitin data indicate that both Nrf2 and Keap1 physically interact with the molecular
chaperone heat shock protein 90 (Hsp90) (Figure 2.6A and Figure 2.6B, respectively).
Furthermore, we had previously shown that the co-expression of Keap1 with Nrf2 partially rescued
Nrf2 toxicity (Figure 2.3A); however, treatment with 2.5 µM radicicol, a small molecule inhibitor
of Hsp90, impaired the ability of Keap1 to rescue Nrf2 toxicity (Figure 2.6C), further suggesting
a genetic interaction between Keap1 and Nrf2 with Hsp90. Of note, the interaction between Keap1
and Hsp90 has previously been described (Taipale et al., 2012; Prince et al., 2015) but is not well
explored. The interaction between Nrf2 and Hsp90, to our knowledge, has not been previously
described.
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Figure 2.6: Interaction between Nrf2 and Keap1 with Hsp90. (A-B) Split-ubiquitin assays of
yeast cells co-expressing the indicated Nub and CRU fusion proteins for (A) Nrf2 and (B) Keap1,
in combination with Hsp90. (C) Growth assay of yeast cells co-expressing Nrf2 and Keap1 in the
absence of radicicol (DMSO solvent control) and presence of 2.5 µM radicicol. Means derived
from three biological replicates were used during analysis. Means were analyzed using one-way
ANOVA followed by Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was
considered statistically significant; *p<0.05, **p<0.01, ***p<0.001.

98

To further investigate this interesting link between Nrf2 and Keap1 with Hsp90, Nrf2 and Keap1
were expressed in deletions strains for yeast Hsp90 (∆hsp82 and ∆hsc82) and two yeast Hsp90 cochaperones (∆aha1 and ∆sti1). Deletion of HSP82, HSC82, or co-chaperone STI1 exacerbate Nrf2
toxicity compared to wild-type cells, whereas the AHA1 deletion had no effect (Figure 2.7A).
These deletion strains did not significantly alter Keap1 expression (Figure S2.7). Nrf2 toxicity
was not, however, altered in cells overexpressing Hsp90 and its co-chaperones (Figure 2.7B).
Western blot analysis confirms the expression of Hsp82 and Hsc82 in yeast cells for our
overexpression studies (Figure 2.7C).
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Figure 2.7: Expression of Nrf2 in yeast Hsp90 and co-chaperone deletion strains and
overexpression constructs. (A) Growth assays of yeast cells expressing Nrf2 in deletions strains
for yeast Hsp90 (∆hsp82 and ∆hsc82) and two yeast Hsp90 co-chaperones (∆aha1 and ∆sti1). (B)
Growth assays of yeast cells expressing Nrf2 and overexpressing (OE) Hsp90 or its co-chaperones.
(A-B) Means derived from three biological replicates were used during analysis. Means were
analyzed using one-way ANOVA followed by Tukey’s post hoc test. Data are expressed as mean
± SD. p<0.05 was considered statistically significant; *p<0.05, **p<0.01, ***p<0.001. (C) Hsp82
and Hsc82 protein expression in yeast is shown by western blot analysis, with β-tubulin serving as
the internal loading control.
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Finally, we begin to assess the interaction between Hsp90 and Nrf2 and Keap1 in mammalian
cells. Figure 2.8A shows both endogenous and transfected Nrf2-GFP together with endogenous
Hsp90 detected by immunofluorescence microscopy in HeLa cells. Similarly, Figure 2.8B shows
endogenous and transfected Keap1-GFP with endogenous Hsp90. Co-localization with Hsp90 is
observed for both Nrf2 and Keap1. We then assessed the effect of Hsp90 inhibition on cells
overexpressing Nrf2 and Keap1. GFP-tagged Nrf2- and Keap1-transfected HeLa cells were treated
with 15 μM of the Hsp90 inhibitor radicicol for 6 h, which induced the formation of Nrf2 and
Keap1 inclusions in the nucleus (Figure 2.8C). Radicicol treatment also increased the cell viability
(detected by increased ATP levels (Crouch et al., 1993)) of cells expressing Nrf2 and Keap1 when
compared to untreated control cells (Figure 2.8D).
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Figure 2.8: Nrf2 and Keap1 expressed in HeLa cells with Hsp90 detection. (A)
Immunofluorescence microscopy for endogenous Nrf2 and Hsp90 (top) and fluorescence
microscopy for transfected Nrf2-GFP and endogenous Hsp90 detected by immunofluorescence
(bottom). (B) Immunofluorescence microscopy for endogenous Keap1 and Hsp90 (top) and
fluorescence microscopy for transfected Keap1-GFP and endogenous Hsp90 detected by
immunofluorescence (bottom). (C) Fluorescence microscopy of HeLa cells transfected with Nrf2GFP and Keap1-GFP treated with 15 μM radicicol for 6 h. (A-C) All unlabeled scale bars
correspond to 25 μm. (D) Viability assays for HeLa cells expressing Nrf2-GFP or Keap1-GFP
treated with 15 μM radicicol. Means derived from three biological replicates were used during
analysis. Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test. Data
are expressed as mean ± SD. p<0.05 was considered statistically significant; *p<0.05, **p<0.01,
***p<0.001.

2.3

Discussion

We establish the yeast Saccharomyces cerevisiae as a living test tube to identify and characterize
genetic and physical Nrf2 interactions. Importantly for our studies, yeast does not express any
close Nrf2 homologue which allows for the advantage of minimizing interference with endogenous
Nrf2 regulation as it occurs in mammalian cells. Since yeast genes do not contain the antioxidant
response element (ARE) within their promotor which is required for Nrf2-mediated transcriptional
activation (Itoh et al., 1997), Nrf2 is likely non-functional in yeast, allowing for protein
interactions to be examined in isolation. We note that this is also a limitation in that endogenous
factors that may have otherwise influenced the interaction or mechanism are not present. Nrf2
contains long disordered regions (Tong et al., 2006) and thus may misfold easily in yeast, where
many of its interacting proteins are not expressed and it is not degraded. This misfolding may be
the cause of Nrf2 toxicity in yeast, as documented for other misfolded proteins before (Outeiro &
Lindquist, 2003; Duennwald, 2011; Fushimi et al., 2011). Also, yeast does not endogenously
express proteins that, under normal conditions, lead to the rapid degradation of Nrf2 in mammalian
cells, leading to high expression levels of Nrf2 in yeast, which can contribute to its misfolding and
the ensuing toxicity. Here, we exploit Nrf2 toxicity in yeast as a tractable phenotype to study
genetic Nrf2 interactions.
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We examined Nrf2 fragments to assess which region(s) of the protein contribute to its toxicity and
found that the N-terminal NH2 fragment was the most toxic in both yeast and mammalian cells.
The NH2 fragment also formed protein inclusions in both yeast and mammalian cells. The Neh2
domain within the N-terminus of Nrf2 has been structurally characterized and is highly
intrinsically disordered with little secondary structure (Tong et al., 2006) and thus, a plausible
main driver of this misfolding process and toxicity in living cells. Additionally, while
overexpression of wild-type Nrf2, the ΔNeh2/3 variant, and C-terminal fragment in HeLa cells
conferred increased cell viability—likely through increased antioxidant capacity—the NH2
fragment did not to the same degree. We speculate that this may be due to the absence of the Neh1
domain which is required for DNA/ARE-binding to activate the oxidative stress response.
Since this work focuses on characterizing a new model to study Nrf2 interactions, it is important
to confirm already known interactions to determine the validity of the model. Notably, we were
able to recapitulate key Nrf2 interactions with Keap1 and other documented proteins using yeast
growth assays and the split-ubiquitin system. Keap1 partially rescues wild-type Nrf2 toxicity in
yeast but does not rescue toxicity for the Neh2 domain mutants, L30F and T80R, indicating that
the impairments in the Keap1-Nrf2-interaction that are associated with mutations in this Keap1binding domain previously described by Shibata et al. (Shibata et al., 2008), is reflected in our
yeast model. We provide evidence for other previously documented Nrf2 interactions, notably the
physical interaction between Nrf2 and p21, which may have strong implications in cancer. Of note,
the yeast system does not detect a genetic interaction between p21 and Nrf2, possibly because
yeast cells lack other cellular factors or mechanisms that characterize this interaction in
mammalian cells. We furthermore document the genetic and physical interactions between both
Nrf2 and Keap1 with the molecular chaperone Hsp90. This interaction was also observed in
cultured mammalian cells, as treatment with Hsp90-inhibitor radicicol altered Nrf2 and Keap1
localization patterns in HeLa cells.
Taipale et al. found that ubiquitin E3 ligases with Kelch domains (e.g., Keap1) interact with Hsp90
in a high-throughput study (Taipale et al., 2012) and Prince et al. have since confirmed the
interaction between Keap1 and Hsp90 (Prince et al., 2015) which is further confirmed by our
model. To our knowledge, the Nrf2-Hsp90 interaction detected in our studies has not been
previously described. Heat shock proteins and molecular chaperones such as Hsp90 have
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protective roles in the refolding of proteins damaged or misfolded by cell stress and stabilizing
newly synthesized proteins to ensure their correct folding (Schopf et al., 2017). Hsp90 might bind
and stabilize the mostly intrinsically disordered protein Nrf2 to allow it to effectively function as
a transcription factor. Further work must be done to determine the mechanism and functional
outcome of the Nrf2-Hsp90 and Keap1-Hsp90 interactions.
Taken together, we show that genetic interaction assays and the split-ubiquitin system in yeast are
powerful tools to study known Nrf2 interactions and to identify previously unknown interactions.
Due to its intrinsically disordered structure and numerous binding partners, Nrf2 can in some cases
be challenging to study in mammalian systems. Our yeast model presents a useful and effective
complementary tool to explore Nrf2 regulation and function and may serve as a platform to screen
for small molecules that modulate Nrf2 interactions and activity, which has potential therapeutic
value. Our work also provides evidence for the interaction of Nrf2 and Keap1 with the molecular
chaperone Hsp90 and may thus indicate an important nexus between two cellular stress response
pathways, i.e., the antioxidant response and the heat shock response, with possible implications in
normal cellular stress regulation and cancer.

2.4

Materials and Methods

2.4.1 Plasmids
All plasmids for yeast growth assays, fluorescence microscopy, western blots, and mammalian cell
expression were created using the Gateway cloning technology developed by Invitrogen (Katzen,
2007) according to the manufacturer’s protocol. The yeast and mammalian plasmids used in this
study are listed in Table 2.1 and Table 2.2 respectively. All plasmids for split-ubiquitin assays
were created using traditional restriction digest and ligation-based cloning and are listed in Table
2.3. Note that the p21-CRU construct was not viable in E. coli during the plasmid generation
process and was excluded from the study.
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Table 2.1: Yeast expression plasmids created using Gateway cloning.
Template

Destination Vector(s)

Nrf2 wild-type

pAG423Gal-ccdB
pAG425Gal-ccdB

Nrf2 NH2

pAG423Gal-ccdB

Nrf2 ΔNeh2/3

pAG423Gal-ccdB

Nrf2 COOH

pAG423Gal-ccdB

Nrf2 L30F

pAG425Gal-ccdB

Nrf2 T80R

pAG425Gal-ccdB

Keap1

pAG423Gal-ccdB

p21

pAG423Gal-ccdB

βTrCP

pAG423Gal-ccdB

Cul3

pAG423Gal-ccdB

ProTα

pAG423Gal-ccdB

Hsp82

pAG423Gal-ccdB

Hsc82

pAG423Gal-ccdB

Hsp82 overexpression

pAG423Gal-ccdB

Hsc82 overexpression

pAG423Gal-ccdB

Aha1 overexpression

pAG423Gal-ccdB

Sti1 overexpression

pAG423Gal-ccdB

Table 2.2: Mammalian expression plasmids created using Gateway cloning.
Template

Destination Vector

Nrf2 wild-type

pcDNA3.1-ccdB

Nrf2 NH2

pcDNA3.1-ccdB

Nrf2 ΔNeh2/3

pcDNA3.1-ccdB

Nrf2 COOH

pcDNA3.1-ccdB

Nrf2 L30F

pcDNA3.1-ccdB

Nrf2 T80R

pcDNA3.1-ccdB

Keap1

pcDNA3.1-ccdB
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Table 2.3: Yeast split-ubiquitin plasmids created using restriction digest and ligation-based
cloning.
Template

Destination Vectors

Nrf2

p415-Cub-R-URA3 CUP

p414-NuI CUP

p414-NuA CUP

p414-NuG CUP

Keap1

p415-Cub-R-URA3 CUP

p414-NuI CUP

p414-NuA CUP

p414-NuG CUP

p21

N/A (see text)

p414-NuI CUP

p414-NuA CUP

p414-NuG CUP

βTrCP

p415-Cub-R-URA3 CUP

p414-NuI CUP

p414-NuA CUP

p414-NuG CUP

Cul3

p415-Cub-R-URA3 CUP

p414-NuI CUP

p414-NuA CUP

p414-NuG CUP

ProTα

p415-Cub-R-URA3 CUP

p414-NuI CUP

p414-NuA CUP

p414-NuG CUP

Hsp90

p415-Cub-R-URA3 CUP

p414-NuI CUP

p414-NuA CUP

p414-NuG CUP

Pgk1

p415-Cub-R-URA3 CUP

p414-NuI CUP

p414-NuA CUP

p414-NuG CUP

2.4.2 Yeast strains, culture conditions, and growth assays
For assessment of relative yeast growth and protein toxicity, yeast strains derived from W303
(MAT a leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15) (Thomas & Rothstein, 1989) were
used. Yeast deletion strains were obtained from the Saccharomyces Genome Deletion Project
(Thomas & Rothstein, 1989). Yeast cells were transformed using the standard lithium
acetate/salmon sperm carrier DNA/PEG method for the incorporation of yeast plasmids (Gietz &
Schiestl, 2007). Transformed yeast cells were grown overnight in synthetic selective media to
maintain these plasmid(s). Growth assays and split-ubiquitin assays were performed by spotting
5X serial dilutions of OD600 = 0.2 on selective agar plates. To induce protein expression for liquid
growth assays, fluorescence microscopy, and western blots, overnight cultures were washed twice
with water and resuspended in media containing 2% galactose and incubated overnight. Liquid
growth assays were performed using the Bioscreen C Pro Automated Microbiology Growth Curve
Analysis System (Growth Curves USA).

2.4.3 Spotting assay growth quantification
Quantification was carried out as described before (Petropavlovskiy et al., 2020). In brief, yeast
agar plates were imaged in black and white using the Gel Doc XR+ System (Bio-Rad). Images
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were pre-processed using Image Lab Software (Bio-Rad) to remove colour and background data.
Images were then imported into ImageJ (NIH) and white pixel count was measured and summed
for dilutions 1-3 for each condition. Data was quantified relative to the empty vector control on
the same respective plate and imported into Prism 8 (GraphPad Software) where scatter dot plots
with bars were generated. Statistical analysis was performed as outlined in Section 2.4.9.

2.4.4 Yeast fluorescence microscopy
For assessment of fluorescently-tagged protein expression and localization, yeast strains derived
from BY 4741 (MAT α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0) (Brachmann et al., 1998) were used. Yeast
expression plasmids were tagged with either YFP or DsRed. Cells were transferred to a glass
microscope slide and coverslip and imaged using either the Olympus BX-51 Bright
Field/Fluorescence Microscope at 60X and captured using an equipped CCD camera (Spot Pursuit)
or the Cytation 5 Cell Imaging Multi-Mode Reader (BioTek) at 20X and captured using Gen5
Software (BioTek).

2.4.5 Electrophoresis and western blot analysis
Proteins were extracted from yeast cells using the alkaline lysis method (Kushnirov, 2000). 30 µl
of lysate was resolved on an SDS-PAGE gel. The membrane was blocked with 5% BSA in PBST
and incubated with primary antibody overnight (refer to Table 2.4). The membrane was incubated
with an HRP-conjugated secondary antibody for 1 h at room temperature, either anti-rabbit
(Abcam, ab6721), anti-mouse (Abcam, ab6728) or anti-rat (Abcam, ab97057) as required. Western
blots were visualized using the Clarity Western ECL Substrate kit (Bio-Rad, 1705061) and images
were taken using the ChemiDoc Imaging System (Bio-Rad).
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Table 2.4: Antibodies for western blot analyses.
Antigen

Supplier

Product Code

Species

Concentration

Nrf2

Abcam

ab62352

Rabbit

1:1000

Proteintech

10503-2-AP

Rabbit

1:1000

Cell Signaling

2947S

Rabbit

1:1000

βTrCP

Santa Cruz

sc-390629

Mouse

1:50

Cul3

Bethyl Laboratories A301-109A

Rabbit

1:2000

ProTα/PTMA

(1) Invitrogen

PA5-75828

Rabbit

1:500

LS-C162288

Rabbit

1:1000

Hsp90

(2) LifeSpan
BioSciences
Abcam

ab13492

Mouse

1:1000

β-Tubulin

Abcam

ab6160

Rat

1:5000

Keap1
p21/p21

CiP/Waf

2.4.6 Mammalian cell culture conditions and transfections
The HeLa and HEK293 cell lines were maintained in Dulbecco's Modified Eagle Medium
(DMEM; Gibco, 41966-029), supplemented with 10% FBS (Wisent, 080-150) and 1X penicillinstreptomycin (Corning, 30-001-CI). Cells were cultured at 37°C with 5% CO2. For transfections,
cells were seeded in a 6-well plate at 1.0x106 cells per well and grown to approximately 80%
confluency. Cells were transfected using Lipofectamine LTX with PLUS Reagent (Thermo Fisher
Scientific, A12621) according to the manufacturer’s protocol in Opti-MEM I Reduced Serum
Medium (Gibco, 31985-062). The transfected cells were incubated at 37°C for 6 h followed by
incubation in DMEM for 18 h at 37°C. Cells were then split into the appropriate plates for
subsequent experiments.

2.4.7 Immunofluorescence microscopy
Transfected HeLa cells were seeded onto 15 mm circular glass coverslips (Matsunami, C015001)
in a 12-well plate at 1x105 cells per well to ensure approximately 80% confluency the following
day. Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS,
blocked with 20% goat head serum in PBB (0.5% BSA in PBS), and incubated with one of the
following primary antibodies overnight at 4°C at a concentration of 1:100: mouse anti-Nrf2
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(Abcam, ab62352), mouse anti-Keap1 (Proteintech, 10503-2-AP), or rabbit anti-Hsp90
(Proteintech, 13171-1-AP). The coverslips were incubated with the following Alexa Fluorconjugated secondary antibody for 1 h at room temperature at a concentration of 1:1500: goat antimouse (Thermo Fisher Scientific, A-11094)., or goat anti-rabbit (Thermo Fisher Scientific,
A11036). Coverslips were then mounted onto glass microscope slides with SlowFade Gold
Antifade Mountant with DAPI (Thermo Fisher Scientific, S36938) and cured at room temperature
for 24 h. Cells were imaged using the Cytation 5 Cell Imaging Multi-Mode Reader (BioTek) using
a 20X objective lens.

2.4.8 Cell viability assays
Transfected HeLa or HEK293 cells were seeded into 96-well solid white microplates (Greiner,
M0187-32EA) at 4x104 cells per well and incubated for 16 h. Following treatment, cell viability
was assessed using the CellTiter-Glo 2.0 Cell Viability Assay (Promega, G9242) according to the
manufacturer’s protocol. Luminescence was measured using the Cytation 5 Cell Imaging MultiMode Reader (BioTek).

2.4.9 Statistical analysis
Statistical analyses were conducted using Prism 8 (GraphPad Software). Statistical significance
was obtained by performing a one-way ANOVA with Tukey post hoc for comparison between
groups, or the Student’s t-test for comparison between two groups (with a minimum of 3 biological
replicates). Error bars represent standard deviation. P-values less than 0.05 were considered
statistically significant. Significance levels are indicated using asterisks, where * is p<0.05, ** is
p<0.01, and *** is p<0.001. Shapiro-Wilk tests were performed for all data sets to ensure
normality.
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2.5

Supplemental Figures

Figure S2.1: Nrf2 protein interactions. Select proteins in the Nrf2 interactome were observed in
this study.
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Figure S2.2: Propidium iodide assay for Nrf2 and Keap1 expressed in yeast. Induced
expression of Nrf2 and Keap1 in yeast was monitored by propidium iodide (PI) assays. Boiled
cells served as a positive control for cell death. Means derived from three biological replicates
were used during analysis. Means were analyzed using one-way ANOVA followed by Tukey’s
post hoc test. Data are expressed as mean ± SD. p<0.05 was considered statistically significant;
*p<0.05, **p<0.01, ***p<0.001.
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Figure S2.3: Fluorescence microscopy for all proteins of interest expressed in yeast.
(A) Fluorescence microscopy of yeast cells expressing YFP- and DsRed-tagged wild-type Nrf2.
(B) Fluorescence microscopy of yeast cells expressing YFP-tagged Keap1, p21, βTrCP, Cul3, and
ProTα alone and co-expressed with Nrf2-DsRed. (C) Fluorescence microscopy of yeast cells
expressing YFP- and DsRed-tagged Nrf2 mutant variants, L30F and T80R. (D) Fluorescence
microscopy of yeast cells expressing Keap1-YFP co-expressed with DsRed-tagged wild-type or
mutant Nrf2. (E) Fluorescence microscopy of yeast cells expressing p21-YFP co-expressed with
DsRed-tagged wild-type or mutant Nrf2. All scale bars correspond to 10 μm.
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Figure S2.4: Cell viability assay for wild-type Nrf2 and its fragmented variants expressed in
HEK293 cells. Results recapitulate those observed in HeLa cells. Means derived from five
biological replicates were used during analysis. Means were analyzed using one-way ANOVA
followed by Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was considered
statistically significant; *p<0.05, **p<0.01, ***p<0.001.
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Figure S2.5: Liquid growth curve for the co-expression of Nrf2 and Keap1 in yeast. Results
recapitulate those observed on solid growth media. Means derived from three biological replicates
were used during analysis. Data are expressed as mean (shown in black) ± SD (shown in colour).
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Figure S2.6: p21 co-expressed with Nrf2 mutant variants in yeast. Growth assays were
performed for yeast cells co-expressing wild-type Nrf2 or its mutant variants L30F and T80R with
p21. Means derived from three biological replicates were used during analysis. Means were
analyzed using one-way ANOVA followed by Tukey’s post hoc test. Data are expressed as mean
± SD. p<0.05 was considered statistically significant; *p<0.05, **p<0.01, ***p<0.001.
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Figure S2.7: Keap1 expressed in yeast Hsp90 deletion strains. Growth assays of yeast cells
expressing Keap1 in deletions strains for yeast Hsp90 (∆hsp82 and ∆hsc82) and its co-chaperones
(∆aha1 and ∆sti1). Means derived from three biological replicates were used during analysis.
Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test. Data are
expressed as mean ± SD. p<0.05 was considered statistically significant; *p<0.05, **p<0.01,
***p<0.001.
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Figure S2.8: (A-E) Control plates for growth assay interaction studies. Yeast peptone dextrose
(YPD) and selective dextrose (SD) control plates are shown.
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Figure S2.9: (A-E) Control plates for split-ubiquitin interaction studies. Yeast peptone
dextrose (YPD) and selective dextrose (SD) plates are shown.
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Figure S2.10: (A-B) Control plates for Hsp90 deletion and overexpression studies. Yeast
peptone dextrose (YPD) and selective dextrose (SD) plates are shown.
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Chapter 3
3

Oxidative stress-induced misfolding and inclusion formation of
Nrf2 and Keap1

Cells that experience high levels of oxidative stress respond with the induction of antioxidant
proteins through the activation of the transcription factor Nrf2. Nrf2 is negatively regulated by
Keap1 which binds to Nrf2 to facilitate its ubiquitination and ensuing proteasomal degradation
under basal conditions. Upon oxidative stress, stress-sensing cysteines in Keap1 are modified,
leading to a conformational change in Keap1 that stabilizes Nrf2 for accumulation, nuclear
translocation, and activation of the oxidative stress response. Here, we study Nrf2 and Keap1 in
yeast, mammalian cells, and purified proteins and find that both Nrf2 and Keap1 are susceptible
to protein misfolding and inclusion formation upon oxidative stress. We argue that the disordered
regions in Nrf2 and the high cysteine content of Keap1 contribute to their misfolding. Our work
reveals previously unexplored aspects of Nrf2 and Keap1 regulation by oxidation-induced protein
misfolding.

_____________________________
A version of this chapter has been submitted for publication.
Ngo, V., Karunatilleke, N., Song, Z., Brickenden, A., Choy, W. Y., & Duennwald, M. L. (2020).
Oxidative stress-induced misfolding and inclusion formation of Nrf2 and Keap1.
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3.1

Introduction

Oxidative stress is regulated by the transcription factor nuclear factor erythroid 2-related factor 2
(Nrf2) (Moi et al., 1994). Nrf2 regulates the expression of a multitude of antioxidant genes and is
negatively regulated by Kelch-like ECH-associated protein 1 (Keap1) (Itoh et al., 1999), a
substrate adaptor protein that binds to Nrf2 in the cytoplasm to promote its ubiquitination and
ensuing degradation by the proteasome (Itoh et al., 1999; Itoh et al., 2003; McMahon et al., 2003;
Nguyen et al., 2003; Kobayashi et al., 2006). During oxidative stress, specific stress-sensing
cysteine residues in Keap1 become oxidized (Dinkova-Kostova et al., 2002; Zhang & Hannink,
2003; Wakabayashi et al., 2004), resulting in a conformational change in Keap1 that leads to
dissociation of the Keap1-Nrf2 complex. This in turn leads to Nrf2 stabilization, nuclear
translocation, and ultimately, activation of cytoprotective antioxidant genes (Yamamoto et al.,
2018; Baird & Yamamoto, 2020). Induction of the Keap1-Nrf2 antioxidant pathway is
fundamental to protecting cells against oxidative stress and mutations that disrupt Keap1-Nrf2
binding compromise Nrf2 regulation and contribute to disease pathogenesis (Padmanabhan et al.,
2006; Shibata et al., 2008). Thus, the transcriptional activity of Nrf2 is tightly regulated by its
interaction with Keap1 (Tong et al., 2006; Tong et al., 2007).
Nrf2 contains seven conserved regions that are referred to as the Nrf2-ECH homology (Neh)
domains. Notably, the Neh2 domain that mediates Nrf2’s binding with Keap1 is shown to be
intrinsically disordered (Tong et al., 2006). Intrinsically disordered proteins (IDPs) or proteins that
contain long intrinsically disordered regions (IDRs) lack a fixed three-dimensional structure and
are susceptible to protein misfolding and inclusion formation in cells due to their structural
heterogeneity and flexible nature; however, this also allows for enhanced binding capacity and
multifunctionality (Dunker et al., 2001; Dyson & Wright, 2005; Uversky, 2019). This may explain
Nrf2’s ability to bind to a vast array of different proteins. We use the term ‘protein misfolding’
here to indicate proteins that have acquired a non-native, aberrant conformation, often in the form
of inclusions or aggregates. Misfolded proteins often lose their normal function (i.e., loss of protein
function) and tend to aggregate and form inclusions that can have deleterious effects on the cell
(i.e., toxic gain of function) (Dobson, 2003). Examples of disease-associated IDPs include αSynuclein in Parkinson’s disease (Wise-Scira et al., 2013), while in cancer, many key tumour
suppressors contain long IDRs, such as p53 (Xue et al., 2013). Interestingly, oxidative stress can
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affect the structural flexibility of IDPs/IDRs (Wise-Scira et al., 2013) and may thus, also modulate
the folding or contribute to the misfolding of intrinsically disordered Nrf2, which may impair its
interactions with other proteins as well as its transcriptional activity.
Protein misfolding may also expose hydrophobic or oxidation-prone cysteine residues to the
surface of the protein, rendering them targets for oxidation by reactive oxygen species (ROS) and
other oxidants (Stadtman, 1993). Oxidation products of cysteines include disulfide bonds and
mixed disulfide bonds. Oxidation can also lead to alteration of non-covalent interactions within
proteins, fragmentation of peptide chains, cross-linking of proteins, and/or oxidation of specific
side chains, ultimately leading to protein destabilization and misfolding (Dean et al., 1985; Davies,
1987; Davies et al., 1987). Cysteine residues are particularly susceptible to aberrant oxidation by
ROS due to the presence of their nucleophilic thiol groups (Di Simplicio et al., 2003). Keap1,
which contains a very high percentage of cysteine residues, may thus be particularly susceptible
to oxidation and inclusion formation.
In this study, we examine two aspects of protein oxidation: the misfolding of the intrinsically
disordered Nrf2, and the misfolding of the cysteine-rich Keap1, under oxidative stress conditions.
Using yeast, cultured mammalian cells, and purified proteins, we find that both Nrf2 and Keap1
misfold and form aberrant cytoplasmic and possibly nuclear protein inclusions upon exposure to
high levels of oxidative stress. Our results suggest a previously unexplored mechanism by which
the Keap1-Nrf2 interaction may be altered by oxidative stress as it pertains to protein misfolding
and inclusion formation.

3.2

Results

3.2.1 Nrf2 is intrinsically disordered and Keap1’s high cysteine content is
evolutionarily conserved
Figure 3.1A schematically illustrates the functional domains of human Nrf2 and Keap1. Nrf2
contains seven conserved Neh domains and six cysteine residues, whereas Keap1 contains three
functional domains and an abundant 27 cysteine residues. The key oxidative stress-sensing sensor
cysteines in Keap1 are indicated with an asterisk (*) (Dinkova-Kostova et al., 2002; Zhang &
Hannink, 2003; Wakabayashi et al., 2004; McMahon et al., 2010).
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Disordered profile plots for Nrf2 and Keap1 predict the location of intrinsically disordered regions
as predicted by three independent algorithms (PrDOS, IUPred2A, and PONDR) (Ishida &
Kinoshita, 2007; Xue et al., 2010; Mészáros et al., 2018) (Figure 3.1B). (See Figure S3.1 for the
individual algorithm predictions). Intrinsically disordered regions are highlighted in yellow. In our
analyses, an amino acid residue is denoted as ‘disordered’ if it is predicted as ‘disordered’ by all
three individual algorithms, i.e., a prediction value of >0.5 = +1 (disorder) and prediction value of
<0.5 = -1 (order); thus, a combined valued of +3 was denoted as ‘disordered’. From these results,
Nrf2 is predicted to contain 11 intrinsically disordered regions with an overall combined percent
disordered score of 39.34%. In comparison, Keap1 is mostly ordered with a single predicted
disordered region and an overall combined percent disordered score of 0.48%, which is also
corroborated by structural studies of the folded Kelch domain of Keap1 (Li et al., 2004).
Next, we looked at the amino acid composition of Nrf2 and Keap1 and calculated the percentage
of cysteine content across 15 metazoan species (Figure S3.2) from humans to zebrafish (Figure
3.1C). The total cysteine content in human Nrf2 is 0.99%, which is below the average for the
human proteome of 2.3% (Miseta & Csutora, 2000), while the average for Nrf2 across all 15
species is 1.11%. Intriguingly, human Keap1 contains an abundant 4.33% cysteine content, which
is highly above average; the average for Keap1 across all species is 4.07%. To determine if cysteine
residues are evolutionarily conserved across these 15 species, we performed a protein sequence
alignment using MEGA X (Kumar et al., 2018) and found that all six cysteine residues in Nrf2
(highlighted in yellow) are either completely or highly conserved across species (i.e., perfectly
aligned in 13-15 species) (Figure 3.1D, top). For Keap1, 24 of the 27 cysteine residues in human
Keap1 are either completely or highly conserved (i.e., perfectly aligned in 12-15 species) (Figure
3.1D, bottom). Interestingly, all sensor cysteines within Keap1 (indicated with an asterisk (*)) are
either completely or almost completely conserved (i.e., perfectly aligned in 14-15 species).
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Figure 3.1: Protein disorder analyses and cysteine analyses for Nrf2 and Keap1. (A) Domain
maps for Nrf2 and Keap1 showing the location of all cysteine residues. Key oxidative stresssensing cysteines in Keap1 are marked with an asterisk (*). (B) Disordered profile plots for Nrf2
and Keap1 predicting the location of intrinsically disordered regions within each protein as
predicted by three independent algorithms (PrDOS, IUPred2A, and PONDR). The intrinsically
disordered regions predicted by all three algorithms are highlighted in yellow. (C) The percentage
of cysteine content is calculated for 15 species from human to zebrafish. (D) Protein sequence
alignment for cysteine residues in Nrf2 and Keap1 across 15 species. All cysteines are highlighted
in yellow. Sensor cysteines within Keap1 are marked with an asterisk (*).

3.2.2 Oxidative stress and Nrf2 and Keap1 expression in yeast
We previously established yeast as a useful tool to study Nrf2 interactions (Ngo et al., 2020,
submitted). Here, we use growth assays to assess if Nrf2 expression in yeast is affected by the
absence of certain oxidative stress genes. Human Nrf2 expressed in yeast causes ‘toxicity’, defined
as an impaired growth phenotype on growth media compared to the empty vector control. Nrf2
was expressed in wild-type yeast and yeast strains deleted for an array of oxidative stress genes.
Only significant data is shown; for the complete list of deletion strains, refer to Figure S3.3. Yeast
AP-1 (Yap1) (Moye-Rowley et al., 1989) is a bZIP transcription factor and essential regulator of
the H2O2 adaptive response in yeast (Schnell et al., 1992; Kuge & Jones, 1994). Yeast Yap1
oxidant-sensing and the mammalian Keap1-Nrf2 pathway share parallels, including shared target
genes (e.g., GPX2), although the biochemical details differ (Simaan et al., 2019). The deletion of
YAP1 decreases Nrf2 toxicity (Figure 3.2A). Growth is quantified to the right as done previously
(Petropavlovskiy et al., 2020). Moreover, Keap1 expression in wild-type yeast is not toxic, but
Keap1 toxicity is induced by deletion of the antioxidant genes BTN1, SOD1, and TSA2 (Figure
3.2B). For the full panel of growth assays, refer to Figure S3.4 and Figure S3.5. For growth assay
control plates, refer to Figure S3.6.
Yeast cells expressing YFP-tagged wild-type Nrf2 or mutants of Nrf2, L30F and T80R, which
have a reduced or impaired capacity to interact with Keap1 (Shibata et al., 2008), were treated with
300 µM hydrogen peroxide (H2O2) for 3 h to elicit oxidative stress. A change in Nrf2 localization
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patterns was observed, as Nrf2-YFP was no longer diffusely spread throughout the yeast cytoplasm
and nucleus but formed fluorescent foci (Figure 3.2C). Moreover, when yeast cells expressing
Keap1-YFP were treated with 300 µM H2O2, Keap1-YFP formed protein inclusions (Figure
3.2D). The optimal treatment dose and duration were determined by measuring cell viability in
non-transfected HeLa cells to achieve a moderate, dose-dependent response to hydrogen peroxide
treatment (Figure S3.7).

Figure 3.2: Oxidative stress and Nrf2 and Keap1 in yeast. (A) Human Nrf2 and (B) human
Keap1 transformed into yeast deletion strains for various oxidative stress genes grown on agar
plates. Growth is quantified relative to the empty vector control. Means derived from three
biological replicates were used during analysis. Means were analyzed using one-way ANOVA
followed by Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was considered
statistically significant; *p<0.05, **p<0.01, ***p<0.001. (C) Yeast expressing YFP-tagged Nrf2
and two Nrf2 mutants treated with 300 µM H2O2. (D) Yeast expressing Keap1-YFP treated with
300 µM H2O2.

132

3.2.3 Nrf2 forms protein inclusions under oxidative stress conditions in HeLa
cells
Figure 3.3A documents the intramolecular localization of wild-type Nrf2 and two Nrf2 mutants,
L30F and T80R, in HeLa cells. HeLa cells were transfected with wild-type or mutant GFP-tagged
Nrf2 and treated with 100 or 300 µM H2O2 for 3 h. The dose and duration were optimized in nontransfected HeLa cells as shown in Figure S3.7. Fluorescence microscopy revealed the formation
of cytosolic and possibly nuclear protein inclusions of wild-type and mutant Nrf2 in both untreated
and treated cells, at endogenous expression levels and even more so when Nrf2 was overexpressed
by transient transfection. The percentage of cells with inclusions increased in a hydrogen peroxide
dose-dependent manner (Figure 3.3B). Nrf2 T80R shows a significantly higher percentage of cells
with inclusions compared to wild-type (Figure 3.3C). In comparison, no stress-induced protein
inclusions were observed for control HeLa cells transfected with GFP alone (Figure S3.8).
Untreated cells expressing wild-type Nrf2 and Nrf2 L30F demonstrated increased cell viability
(determined by the quantification of ATP levels which indicates the presence of metabolically
active cells (Crouch et al., 1993)) relative to the untreated control; however, cell viability decreased
in all Nrf2-expressing cells upon treatment with 300 µM H2O2. These results are recapitulated in
the HEK293 cell line (Figure S3.9).
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Figure 3.3: Nrf2 forms inclusions upon exposure to oxidative stress in vitro. (A) HeLa cells
transfected with GFP-tagged Nrf2 and two Nrf2 mutants and treated with 100 or 300 µM H2O2 for
3 h, visualized by fluorescence microscopy. (B) Quantification of Nrf2-expressing cells with
inclusions following hydrogen peroxide treatment observed in (A). (C) Cell viability assays for
Nrf2-expressing cells treated with 300 µM H2O2 for 3 h. (B, C) Means derived from a minimum
of three biological replicates were used during analysis. Means were analyzed using one-way
ANOVA followed by Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was
considered statistically significant; *p<0.05, **p<0.01, ***p<0.001.
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3.2.4 Nrf2 inclusion formation is oxidative stress-specific and prevented by
certain antioxidants
To determine whether oxidative-stress induced Nrf2 inclusion formation is an artifact of
overexpression by transient transfection, un-transfected HeLa cells were treated with 300 µM
H2O2 for 3 h and observed by immunofluorescence for endogenous Nrf2. The localization patterns
for endogenous Nrf2 are similar to that of transfected Nrf2 with hydrogen peroxide treatment
(Figure 3.4A), confirming that this observed effect is likely, not due to Nrf2 overexpression. To
determine if Nrf2 inclusion formation is oxidative stress-specific, HeLa cells expressing Nrf2-GFP
were treated with 50 µM MG132, a proteasome inhibitor that elicits general protein misfolding
stress. Compared to cells treated with 300 µM H2O2 which formed some Nrf2 inclusions, treatment
with MG132 did not result in the formation of cytosolic Nrf2 inclusions (Figure 3.4B).
Furthermore, we explored if treatment with antioxidants, such as N-acetylcysteine (NAC) and
vitamin C (ascorbic acid), prevents Nrf2 inclusion formation. Transfected cells were pre-treated
with 3 µM NAC or 100 µM vitamin C for 24 h and subsequently treated with 300 µM H2O2 for 3
h. A reduction in Nrf2 inclusion formation was observed for pre-treatment with NAC but not
vitamin C (Figure 3.4C).

135

Figure 3.4: Further analyses of the oxidative stress-induced protein misfolding of Nrf2.
(A) Endogenous Nrf2 in un-transfected HeLa cells treated with 300 µM H2O2 for 3 h, visualized
by immunofluorescence microscopy. (B) Transfected Nrf2-GFP in HeLa cells treated with 50 μM
MG132 for 6 h, visualized by fluorescence microscopy. (C) Transfected Keap1-GFP in HeLa cells
pretreated with 3 μM NAC and or 100 μM vitamin C for 24 h followed by treatment with 300 µM
H2O2 for 3 h, visualized by fluorescence microscopy.
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3.2.5 Keap1 forms protein inclusions under oxidative stress conditions in HeLa
cells
HeLa cells were transfected with GFP-tagged Keap1 and treated with 100 or 300 µM H2O2 for 3
h. Fluorescence microscopy revealed the formation of cytosolic and possibly nuclear protein
inclusions in both untreated and treated cells (Figure 3.5A). Confocal microscopy was used to
visualize these inclusions at a higher resolution (Figure 3.5B) and 3-dimensional stacking reveals
that Keap1 inclusions are situated around the nucleus rather than within it (Figure 3.5C), thus,
confirming these inclusions are cytosolic. Quantification of the percentage of cells containing
inclusions reveals that the oxidative stress-induced Keap1 inclusions form in a hydrogen peroxide
dose-dependent manner (Figure 3.5D). Cells expressing Keap1 demonstrated increased cell
viability with hydrogen peroxide treatment (determined by the quantification of ATP levels
(Crouch et al., 1993)) (Figure 3.5E). Results are recapitulated in the HEK293 cell line (Figure
S3.9).
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Figure 3.5: Keap1 forms inclusions upon exposure to oxidative stress in vitro. (A) HeLa cells
transfected with Keap1-GFP and treated with 100 or 300 µM H2O2 for 3 h, visualized by
fluorescence microscopy. (B) Confocal microscopy for Keap1-expressing cells treated with 300
µM H2O2 for 3 h, visualized by immunofluorescence. (C) Confocal microscopy with 3-D stacking
for Keap1-expressing cells treated with hydrogen peroxide, visualized by immunofluorescence
and demonstrating that Keap1 inclusions are cytosolic. (D) Quantification of Keap1-expressing
cells with inclusions following hydrogen peroxide treatment in (A). (E) Cell viability assay for
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Keap1-expressing cells treated with 300 µM H2O2 for 3 h. (D, E) Means derived from three
biological replicates were used during analysis. Means were analyzed using one-way ANOVA
followed by Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was considered
statistically significant; *p<0.05, **p<0.01, ***p<0.001.

3.2.6 Keap1 inclusion formation is oxidative stress-specific and cannot be
prevented by tested antioxidants
Again, to determine whether oxidative stress-induced Keap1 inclusion formation is an artifact of
overexpression by transient transfection, un-transfected HeLa cells were treated with 300 µM
H2O2 for 3 h and observed using immunofluorescence microscopy for endogenous Keap1.
Endogenous Keap1 also formed inclusions upon treatment with hydrogen peroxide (Figure 3.6A),
confirming that this observed effect is not due to Keap1 overexpression. To determine if Keap1
inclusion formation is oxidative stress-specific, HeLa cells expressing Keap1-GFP were treated
with 50 µM MG132 to elicit general protein misfolding stress. Compared to cells treated with 300
µM H2O2 which formed Keap1 inclusions, treatment with MG132 did not result in the formation
of inclusions (Figure 3.6B).
Finally, we determined if NAC and vitamin C could prevent Keap1 inclusion formation upon
oxidative stress. Transfected cells were pre-treated with 3 µM NAC or 100 µM vitamin C for 24
h and subsequently treated with 300 µM H2O2 for 3 h; however, no significant reduction in Keap1
inclusions was observed (Figure 3.6C).

139

Figure 3.6: Further analyses of Keap1 oxidative stress-induced protein misfolding.
(A) Endogenous Keap1 in un-transfected HeLa cells treated with 300 µM H2O2 for 3 h, visualized
by immunofluorescence microscopy. (B) Transfected Keap1-GFP in HeLa cells treated with 50
μM MG132 for 6 h, visualized by fluorescence microscopy. (C) Transfected Keap1-GFP in HeLa
cells pretreated with 3 μM NAC or 100 μM vitamin C for 24 h followed by treatment with 300
µM H2O2 for 3 h, visualized by fluorescence microscopy.
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3.2.7 Oxidative stress-induced Keap1 inclusion formation in breast cancer cell
lines
To ensure that Keap1 stress-induced inclusion formation is not a HeLa cell-specific phenomenon,
we treated two human breast cancer cell lines, 21MT-1 and SKBR3, with 300 µM H2O2 for 3 h
and performed immunofluorescence microscopy for endogenous Keap1. Upon oxidative stress,
both cell lines showed Keap1 inclusions (Figure 3.7A and Figure 3.7B), quantified to be
statistically significant from the untreated control (Figure 3.7C).

Figure 3.7: Keap1 forms oxidative stress-induced inclusions in breast cancer cell lines.
(A-B) Endogenous Keap1 expression in two breast cancer cell lines, 21MT-1 and SKBR3, treated
with 300 µM H2O2 for 3 h, visualized by immunofluorescence microscopy. (C) Quantification of
Keap1 inclusions following hydrogen peroxide treatment. Means derived from three biological
replicates were used during analysis. Means were analyzed using one-way ANOVA followed by
Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was considered statistically
significant; *p<0.05, **p<0.01, ***p<0.001.
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3.2.8 Purified proteins for Nrf2 and Keap1 form inclusions upon exposure to
oxidative stress
Purified proteins were used to biochemically assess Nrf2 and Keap1 misfolding and inclusion
formation (or aggregation) using two methods: (1) traditional SDS-PAGE with Coomassie blue
gel staining, and (2) semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) with
western bot analysis. As shown in Figure 3.8A, purified Nrf2 was incubated with 600 μM H2O2
in the absence and presence of reducing agent β-mercaptoethanol (βME). Upon treatment with
hydrogen peroxide, Nrf2 forms a dense high molecular weight smear, indicating the formation of
aggregated, higher molecular weight species. With the addition of 5% βME, this structure
collapses, indicating that this high molecular weight protein species is, to some degree, dependent
upon disulfide bonds. Furthermore, analysis of purified Neh5 domain of Nrf2, which harbours one
of the six cysteines in the protein, revealed the formation of an aggregated higher molecular weight
species with hydrogen peroxide treatment that also collapses with the addition of βME (Figure
3.8B).
Similarly, purified Keap1 protein was treated with 600 μM H2O2 in the presence and absence of
βME. Upon treatment with hydrogen peroxide, Keap1 forms a dense high molecular weight smear,
indicating the formation of an aggregated higher molecular weight species. With the addition of
5% βME, this structure collapses (Figure 3.8C), indicating that this high molecular weight protein
species is also, at least in part, dependent on the formation of disulfide bonds. Purified protein for
Keap1’s Kelch domain was then used to determine if this domain alone, which contains eight
cysteine residues, would misfold under oxidative stress conditions. Unlike full-length Keap1,
treatment of the Kelch domain alone with 600 µM H2O2 did not produce a high molecular weight
species (Figure 3.8D).
Finally, fractionation assays were used to determine the soluble and aggregated fractions for
purified Nrf2 and Keap1 (Figure 3.8E). The ‘total’ purified protein sample was centrifuged and
divided into the soluble ‘supernatant’ fraction and the aggregated ‘pellet’ fraction and resolved
using traditional SDS-PAGE with Coomassie blue gel staining. Both Nrf2 and Keap1 contain
soluble and aggregated protein fractions in the supernatant and pellet, respectively.
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Figure 3.8: Nrf2 and Keap1 purified proteins aggregate upon exposure to oxidative stress in
vitro. Purified protein treated with 600 μM H2O2 ± βME for (A) Nrf2, (B) Nrf2’s Neh5 domain,
(C) Keap1, and (D) Keap1’s Kelch domain. (E) Fractionation assay for purified Nrf2 and Keap1
protein. All purified proteins are resolved using SDS-PAGE with Coomassie Blue gel staining
and/or SDD-AGE, as indicated.
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3.3

Discussion

In this work, we demonstrate that two key proteins of the antioxidant pathway, Nrf2 and Keap1,
form intracellular inclusions upon exposure to high levels of oxidative stress. We find that at least
in part, the aberrant formation of disulfide bonds causes the misfolding and inclusion formation of
both proteins. Nrf2’s intrinsically disordered nature may also contribute to its propensity to
misfold.
We observe that in both yeast and mammalian cells, treatment of cells expressing Nrf2 with
hydrogen peroxide results in the formation of protein inclusions in a dose-dependent manner.
Interestingly, protein inclusion formation was exacerbated for the Nrf2 mutants, L30F and T80R,
wherein Keap1-binding to the Neh2 domain in Nrf2 at the low- and high-affinity motifs,
respectively, is impaired, resulting in loss of Keap1-mediated degradation (Tong et al., 2006;
Shibata et al., 2008). Oxidatively damaged Nrf2 accumulates in the cell as inclusions, most notably
for the Nrf2 T80R mutant which escapes all Keap1-mediated degradation. This could explain the
significantly high levels of Nrf2 T08R inclusions. On the other hand, Nrf2 L30F demonstrates
impaired binding at the low-affinity motif but may still retain some Nrf2-binding via the highaffinity motif. Nonetheless, ubiquitination is unlikely without the intact low-affinity binding site
(Tong et al., 2007). Future work will further investigate the consequence of these mutants and how
impaired Keap1-dependent Nrf2 regulation affects stress-induced inclusion formation.
The Neh2 domain of Nrf2 has previously been characterized as intrinsically disordered (Tong et
al., 2006) and our data suggest that other regions within Nrf2 are also highly intrinsically
disordered. While this structural flexibility could allow Nrf2 to bind to a large number of different
proteins (Nam & Keum, 2019), it may also render Nrf2 susceptible to aberrant protein misfolding.
Intrinsically disordered proteins tend to misfold under certain conditions (Uversky, 2011) which
appears to also be the case for Nrf2 during high levels of oxidative stress. This misfolding and
inclusion formation of Nrf2 could be an adaptive mechanism of Nrf2 regulation (i.e., the
‘functional misfolding’ of IDPs (Uversky, 2011)) which allows Nrf2 to escape Keap1 degradation,
resulting in ARE activation) or a maladaptive one (i.e., misfolded Nrf2 cannot activate AREcontaining genes in response to oxidative stress). To determine this, future work will assess the
functional outcome of this stress-induced Nrf2 misfolding and its consequences on Nrf2 regulation
and activity.
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Moreover, wildtype Nrf2 contains only six cysteine residues but our in vitro experiments document
that at least some of the cysteines in Nrf2 are oxidized and are central to the formation of high
molecular weight protein species. It is plausible that oxidation-induced inclusion formation
impairs the transcriptional activity of Nrf2, as He et al. have found that some cysteine residues of
Nrf2 play important roles in oxidant sensing, Keap1-dependent ubiquitination and degradation of
Nrf2, and in the transcriptional activation of ARE-containing Nrf2 target genes (He & Ma, 2009).
In contrast, Keap1 is not an IDP and its misfolding may be mostly dependent on the presence of
reactive cysteine residues. Keap1 contains 27 cysteines, 24 of which were found to be highly or
completely conserved. Interestingly, except for the chicken and zebrafish, all key sensor cysteines
within Keap1 (Dinkova-Kostova et al., 2002; Zhang & Hannink, 2003; Wakabayashi et al., 2004;
McMahon et al., 2010) were completely or almost completely conserved, which demonstrates their
importance for Keap1 function. Cystines are one of the least abundant amino acids in mammals,
comprising an average of 2.3% for the human proteome (Miseta & Csutora, 2000). Yet we find
that human Keap1 contains 4.33% cysteine content, almost double the average for the human
proteome (Miseta & Csutora, 2000). This high content of cysteine residues in Keap1 may render
it more susceptible to oxidation, for example by aberrant disulfide bond formation. Indeed, we find
that Keap1 forms inclusions and high molecular weight protein species upon treatment with
hydrogen peroxide in yeast, mammalian cells, and purified proteins. Of note, our in vitro data argue
that the cysteines within the stably folded Kelch domain of Keap1 are not susceptible to oxidation
and misfolding for the Kelch domain alone, which is consistent with the notion that not all cysteine
residues within Keap1 are equally reactive. Future work must determine which cysteines in Keap1
are most susceptible to oxidation and inclusion formation (e.g., by cysteine mutation analyses),
and if the full-length protein is required for this misfolding to occur.
Under normal conditions, Keap1 is constantly shuttling between the cytosol and the nucleus via
importin α7 (also known as karyopherin α6, KPNA6), and the nuclear import of Keap1 represses
the Nrf2 antioxidant response (Sun et al., 2011); however, our results show that misfolded Keap1
inclusions are cytosolic and cannot enter the nucleus. Misfolded Keap1 may render the protein
inactive, impairing Keap1-mediated degradation of both cytosolic and nuclear Nrf2. We speculate
that Keap1, upon forming aberrant intra- and/or inter-molecular disulfide bonds, cannot bind to
Nrf2 to target it for degradation, thus allowing free Nrf2 to activate the antioxidant response. It is
plausible that this Keap1 inactivation is irreversible and that even newly synthesized Keap1 cannot
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escape this oxidation-based inactivation under high levels of oxidative stress, thus causing a longlasting constitutive activation of Nrf2. This mechanism may be predominant in cancer, where ROS
levels are high due to high metabolic activity and genetic instability (Kumari et al., 2018).
However, whether misfolded Nrf2 is still functional remains to be explored and will be
subsequently investigated.
It is important to mention the work by Taguchi et al. which proposes that oxidative stress causes
Keap1 misfolding and its sequestration into inclusion bodies that are removed by p62/SQSTM1
(Taguchi et al., 2012). This is a mechanism that is not mutually exclusive to the one proposed in
this study; however, it is also important to note that the inclusion bodies observed by Taguchi et
al. seem to differ in morphology compared to the inclusions observed in this study and that the end
product of the p62-Keap1 interaction is Keap1 degradation by autophagy, which is not observed
here. In addition, purified Keap1 protein misfolds and forms inclusions upon oxidative stress
treatment in a test tube scenario where p62 is absent. Importantly, future work must still be done
to further establish this mechanism and how it differs from p62-mediated autophagy.
Taken together, we employed yeast models, cultured mammalian cells, and purified proteins to
assess the oxidative stress-induced inclusion formation of Nrf2 and Keap1. We argue that the
intrinsically disordered nature of Nrf2 exposes its cysteine residues to ROS and thus makes it more
prone to misfolding, while the more structured Keap1’s unusually high content of cysteine residues
makes the protein more susceptible to misfolding by aberrant disulfide bond formation. Our work
provides new insight into previously unexplored aspects of Nrf2 regulation by oxidationdependent protein inclusion formation, and future work will seek to explore the functional outcome
of this oxidation event in normal cells and cancer.

3.4

Materials and Methods

3.4.1 Prediction of intrinsically disordered regions
Three independent algorithms, PrDOS, IUPred2A, and PONDR (Ishida & Kinoshita, 2007; Xue
et al., 2010; Mészáros et al., 2018) were used to predict intrinsically disordered regions using
protein sequences obtained from UniProt ("The Universal Protein Resource (UniProt)," 2008).
Using the scores obtained from each algorithm, each amino acid residue within the protein was
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assigned a numerical value of ‘+1’ or ‘-1’, where >0.5 = +1 (disordered) and values <0.5 = -1
(ordered). The scores were summed for each residue. Residues with a combined score of +3 across
all three algorithms were considered ‘disordered’.

3.4.2 Protein sequence alignment
MEGA X (Kumar et al., 2018) was used to perform protein sequence alignments using protein
sequences obtained from UniProt ("The Universal Protein Resource (UniProt)," 2008).

3.4.3 Yeast growth assays and microscopy
For assessment of relative growth, wild-type yeast and deletion strains obtained from the
Saccharomyces Genome Deletion Project (Thomas & Rothstein, 1989) were used. Yeast cells were
transformed using the standard lithium acetate/salmon sperm carrier DNA/PEG method for the
incorporation of yeast plasmids (Gietz & Schiestl, 2007). Transformed yeast cells were grown
overnight in synthetic selective media to maintain these plasmids. Growth assays were performed
by spotting 5X serial dilutions of OD600 = 0.2 on agar plates and incubated at 30°C. Plates were
imaged using the Bio-Rad ChemiDoc (Bio-Rad). Growth was quantified as previously described
(Petropavlovskiy et al., 2020). For assessment of protein expression using fluorescence
microscopy, yeast was transformed with YFP-tagged plasmids. Cells were transferred to a glass
microscope slide and coverslip and imaged using the Olympus BX-51 Bright Field/Fluorescence
Microscope at 60X and captured using an equipped CCD camera (Spot Pursuit).

3.4.4 Cell lines and culture conditions
The HeLa and HEK293 cell lines were maintained in Dulbecco's Modified Eagle Medium
(DMEM; Gibco, 41966-029), supplemented with 10% FBS (Wisent, 080-150) and 1X penicillinstreptomycin (Corning, 30-001-CI). Cells were cultured at 37°C with 5% CO2. For transfections,
cells were seeded in a 6-well plate at 1.0x106 cells per well and grown to approximately 80%
confluency. Cells were transfected with Lipofectamine LTX with PLUS Reagent (Thermo Fisher
Scientific, A12621) according to the manufacturer’s protocol in Opti-MEM I Reduced Serum
Medium (Gibco, 31985-062). Transfected cells were incubated at 37°C for 6 h, followed by a wash
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in 1X PBS, and incubated in DMEM for 18 h at 37°C. Cells were then split into the appropriate
plates for subsequent experiments.

3.4.5 Fluorescence and immunofluorescence microscopy
Transfected HeLa cells were seeded on a 15 mm circular glass coverslip (Matsunami, C015001)
in a 12-well plate at 1x105 to ensure approximately 80% confluency the following day. Cells were
fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS, blocked with
20% goat head serum in PBB (0.5% BSA in PBS), and incubated with one of the following primary
antibodies overnight at 4°C at a concentration of 1:100: mouse anti-Nrf2 (Abcam, ab62352) or
mouse anti-Keap1 (Proteintech, 10503-2-AP). The coverslips were incubated with the following
Alexa Fluor 488-conjugated secondary antibody for 1 h at room temperature at a concentration of
1:1500: goat anti-mouse (Thermo Fisher Scientific, A-11094). Coverslips were mounted onto glass
microscope slides with SlowFade Gold Antifade Reagent with DAPI (Thermo Fisher Scientific,
S36938) and cured at room temperature for 24 h. Cells were imaged using the Cytation 5 Cell
Imaging Multi-Mode Reader (BioTek) using a 20X objective lens.

3.4.6 Cell viability assays
Transfected HeLa cells were seeded into 96-well solid white microplates (Greiner, M0187-32EA)
at 4x104 cells per well and incubated for 16 h. Following treatment, cell viability was assessed
using the CellTiter-Glo 2.0 Cell Viability Assay (Promega, G9242) according to the
manufacturer’s protocol. Luminescence was measured using the Cytation 5 Cell Imaging MultiMode Reader (BioTek).

3.4.7 SDS-PAGE and Coomassie blue gel staining
Purified protein (10 µg) was resolved on a 10% SDS-PAGE gel. The gel was stained with
Coomassie Brilliant Blue (0.1% Coomassie Brilliant Blue R-250, 50% methanol [v/v], 10% glacial
acetic acid [v/v], 40% H2O) for 30 minutes and de-stained overnight using a destining solution
(50% methanol [v/v], 10% glacial acetic acid [v/v], 40% H2O) with gentle agitation. Blots were
imaged using the ChemiDoc Imaging System (Bio-Rad).
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3.4.8 SDD-AGE (semi-denaturing detergent agarose gel electrophoresis)
Purified protein (10 µg) was resolved on a 1.8% agaraose-2% SDS gel and run at 80 V for
approximately 1.5 h at room temperature in 1X TAE-0.1% SDS running buffer. The gel was
transferred at room temperature to PVDF by an overnight wet transfer by gravity according to the
manufacturer’s protocol (Whatman TurboBlotter Transfer System). The membrane was blocked
with 5% skim milk in PBST (phosphate-buffered saline, 1% Tween-20) and incubated with one of
the following primary antibodies overnight at 4°C at a concentration of 1:1000: mouse anti-Nrf2
(Abcam, ab62352) or mouse anti-Keap1 (Proteintech, 10503-2-AP). The membrane was incubated
with the following Alexa Fluor 680-conjugated antibody for 1 h at room temperature at a
concentration of 1:1500: goat anti-mouse (Thermo Fisher Scientific, A-21057). Blots were imaged
using the ChemiDoc Imaging System (Bio-Rad).

3.4.9 Combined SDD-AGE and fractionation assay
For partitioning into soluble and insoluble fractions, purified protein was first aliquoted into a
chilled microcentrifuge tube which represents the ‘total’ fraction. A second aliquot was centrifuged
at 10 000xg for 10 min at 4°C. The supernatant was transferred into a chilled microcentrifuge tube
which represented the soluble ‘supernatant’ fraction. The pellet was resuspended in dialysis buffer
(from the preceding protein purification process) and represents the insoluble ‘pellet’ fraction.
Equal volumes of each fraction equivalent to 10 µg of the total fraction were resolved by SDDAGE (see Section 3.4.8.).

3.4.10 Statistical analysis
Statistical analyses were conducted using Prism 8 (GraphPad Software). Statistical significance
was obtained by performing a one-way ANOVA with Tukey post hoc for comparison between
groups. Error bars represent standard deviation. P-values less than 0.05 were considered
statistically significant. Significance levels are indicated using asterisks, where * is p<0.05, ** is
p<0.01, and *** is p<0.001. Shapiro-Wilk tests were performed for all data sets to ensure
normality.
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3.5

Supplementary Figures

Figure S3.1: Individual disordered profile plots for PrDOS, IUPred2U, and PONDR.
Disorder probability prediction graphs for Nrf2 and Keap1 are shown for all three prediction
algorithms. A score of >0.5 predicts ‘disorder’ and a score of <0.5 predicts ‘order’.
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Species

Specific Name

UniProt Code

Nrf2

Human
Chimpanzee
Orangutan
Rhesus macaque
Marmoset
Galago
Mouse
Rat
Golden hamster
Rabbit
Cow
Bat
Elephant
Chicken
Zebrafish

Homo sapiens
Pan troglodytes
Pongo abelii
Macaca mulatta
Callithrix jacchus
Otolemur garnettii
Mus musculus
Rattus norvegicus
Mesocricetus auratus
Oryctolagus cuniculus
Bos taurus
Myotis lucifugus
Loxodonta africana
Gallus gallus
Danio rerio

Q16236
H2RAX5
H2P7Y6
F7GPD8
F7CLI8
H0Y129
Q60795
O54968
A0A1U7QFW3
G1SEJ1
Q5NUA6
G1P184
G3TGN3
F1P315
Q7ZVI2

Keap1

Human
Chimpanzee
Orangutan
Rhesus macaque
Marmoset
Galago
Mouse
Golden hamster
Rat
Rabbit
Cow
Bat
Elephant
Chicken
Zebrafish

Homo sapiens
Pan troglodytes
Pongo abelii
Macaca mulatta
Callithrix jacchus
Otolemur garnettii
Mus musculus
Mesocricetus auratus
Rattus norvegicus
Oryctolagus cuniculus
Bos taurus
Myotis lucifugus
Loxodonta africana
Gallus gallus
Danio rerio

Q14145
H2QFB9
Q5R774
G7NL03
F7HDW0
H0X799
Q9Z2X8
A0A1U7R3C2
P57790
G1SFF4
A7MBG4
G1PRL8
G3TJS6
Q5ZL67
E7FB56

Figure S3.2: The 15 species observed in cysteine analysis studies. The species name, specific
name, and UniProt code are shown.
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Gene

Protein

Function (UniProt Consortium)

UniProt
Code

BTN2

Protein BTN2

V-SNARE binding protein that facilitates specific protein retrieval
from a late endosome to the Golgi. Modulates the rate of arginine
uptake. Involved in pH homeostasis.

P53286

CTA1

Peroxisomal
catalase A

Occurs in almost all aerobically respiring organisms and serves to
protect cells from the toxic effects of hydrogen peroxide.

P15202

GLR1

Glutathione
reductase

Maintains high levels of reduced glutathione in the cytosol.

P41921

SOD1

Superoxide
dismutase [CuZn]

Destroys radicals which are normally produced within the cells and
which are toxic to biological systems.

P00445

SOD2

Superoxide
dismutase

Destroys radicals which are normally produced within the cells and
which are toxic to biological systems.

S4VPL7

UBI4

Polyubiquitin

Becomes conjugated to proteins, marking them for selective
degradation via the ubiquitin-26S proteasome system.

P0CG63

YAP1

AP-1-like
transcription
factor YAP1

Transcription activator involved in oxidative stress response and
redox homeostasis. Regulates the transcription of genes encoding
antioxidant enzymes and components of thiol-reducing pathways.

P19880

SNO4

Probable
glutathioneindependent
glyoxalase SNO4

Catalyzes the conversion of methylglyoxal (MG) to D-lactate in a Q04902
single glutathione (GSH)-independent step. May play a role in
detoxifying endogenously produced glyoxals. Involved in
protection against reactive oxygen species (ROS).

SRX1

Sulfiredoxin

Contributes to oxidative stress resistance by reducing cysteine- P36077
sulfinic acid formed under exposure to oxidants in the peroxiredoxin
TSA1. May catalyze the reduction in a multi-step process by acting
both as a specific phosphotransferase and as thioltransferase.

TSA1

Peroxiredoxin
TSA1

Thiol-specific peroxidase catalyzing the reduction of hydrogen P34760
peroxide and organic hydroperoxides to water and alcohols,
respectively.

TSA2

Peroxiredoxin
TSA2

Thiol-specific peroxidase catalyzing the reduction of hydrogen Q04120
peroxide and organic hydroperoxides to water and alcohols,
respectively.

TRX1

Thioredoxin-1

Participates as a hydrogen donor in redox reactions through the P22217
reversible oxidation of its active center dithiol to a disulfide,
accompanied by the transfer of 2 electrons and 2 protons.

TRX2

Thioredoxin-2

Participates as a hydrogen donor in redox reactions through the P22803
reversible oxidation of its active center dithiol to a disulfide,
accompanied by the transfer of 2 electrons and 2 protons.

Figure S3.3: Yeast oxidative stress gene deletion strains used in this study. The gene name,
protein name, function (obtained from UniProt), and UniProt Code are shown.
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Figure S3.4: Full panel of growth assays for Nrf2 expression in yeast oxidative stress deletion
strains. Growth was quantified relative to control. Means derived from three biological replicates
were used during analysis. Means were analyzed using one-way ANOVA followed by Tukey’s
post hoc test. Data are expressed as mean ± SD. p<0.05 was considered statistically significant;
*p<0.05, **p<0.01, ***p<0.001.
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Figure S3.5: Full panel of growth assays for Keap1 expression in yeast oxidative stress
deletion strains. Growth was quantified relative to control. Means derived from three biological
replicates were used during analysis. Means were analyzed using one-way ANOVA followed by
Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was considered statistically
significant; *p<0.05, **p<0.01, ***p<0.001.
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Figure S3.6: Growth assay control plates for all yeast oxidative stress deletion studies. Yeast
peptone dextrose (YPD) and selective dextrose (SD) control plates are shown for (A) Nrf2 and (B)
Keap1 experiments. Note that some deletions strains harbour an inherent toxic growth phenotype
observed even on control media.
155

Fluorescence Units (FU)

Cell Viability

H2O2 (M)

120000

0

100000

100

80000

300

60000

500

40000

750
1000

20000

1500

0
0

1

2

3

4

5

6

7

8

9

10

2000

Time (h)

Figure S3.7: Optimization of hydrogen peroxide treatment concentration and duration. Nontransfected HeLa cells were treated with various concentrations of hydrogen peroxide for 1, 3, 5,
and 10 h and cell viability was assessed (measured by ATP levels).
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Figure S3.8: GFP controls for protein oxidation studies in HeLa cells. Cells were transfected
with a pcDNA3.1-GFP empty vector for mammalian expression.
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Figure S3.9: Cell viability following hydrogen peroxide treatment in HEK293 cells.
Transfected HEK293 cells were treated with 300 µM H2O2 for 3 h and cell viability was assessed
(measured by ATP levels). Results recapitulate those observed in HeLa cells. Means derived from
five biological replicates were used during analysis. Means were analyzed using one-way ANOVA
followed by Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was considered
statistically significant; *p<0.05, **p<0.01, ***p<0.001.
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Chapter 4
4

Hyperactive stress response pathways in HER2+ breast
cancers

Drug resistance represents one of the greatest challenges in cancer therapy. This is especially true
for patients with HER2-enriched (HER2+) breast cancers, who undergo higher rates of recurrence
and metastasis compared to other molecular breast cancer subtypes. While molecular chaperones
such as Hsp90 guide the normal folding and proteolytic turnover of key regulators of cell growth
and survival, their overexpression during oncogenesis promotes the process of tumorigenesis.
Hsp90 regulates the activity of heat shock factor 1 (Hsf1) which initiates a transcriptional response
to proteotoxic stress, but also facilitates a transcriptional program to sustain highly malignant
cancers. Our previous studies have also identified a link between Hsp90 and Nrf2, the
transcriptional master regulator of oxidative stress known to promote tumorigenesis and resistance
to chemotherapeutic agents. We show here that the inducible isoform of Hsp90, HSP90AA1, is
upregulated in HER2+ (but not HER2-) breast cancers, and this is associated with the Hsf1 and
Nrf2 signalling pathways. Additionally, inhibition of Hsp90 in HER2+ breast cancer cells leads to
increased mRNA expression levels for glutathione peroxidase (GPx) 2 and 3 , which may confer
increased antioxidant abilities. Accordingly, combined inhibition of HER2, Hsp90, and GPx
activity may increase response rates to targeted HER2+ breast cancer therapy.

_____________________________
A version of this chapter is in preparation for publication.
Ngo, V., Krstic, M., Goodale, D., Allan, A. L., & Duennwald, M. L. (2021). Hyperactive stress
response pathways in HER2+ breast cancers.
163

4.1

Introduction

The human epidermal growth factor 2 (HER2) proto-oncogene is a membrane-bound receptor
tyrosine kinase that promotes cancer growth, differentiation, and cell survival (Yarden &
Sliwkowski, 2001; Gschwind et al., 2004). The ERBB2/neu gene, which encodes HER2, is
amplified in approximately 15-30% of breast cancers and characterizes the HER2-enriched
(HER2+) molecular subtype (Burstein, 2005; Mitri et al., 2012). Existing therapy for patients with
HER2+ breast cancers often involves the use of a monoclonal antibody against HER2 (e.g.,
Trastuzumab), which provides benefit both when administered alone (Vogel et al., 2002; Baselga
et al., 2005) or in combination with chemotherapy (Slamon et al., 2001; Marty et al., 2005). Despite
these targeted treatment strategies, HER2+ breast cancers are still associated with low survival
rates (Carey et al., 2006).
An adaptive mechanism to cellular stress is enhanced expression of antioxidant proteins and
molecular chaperones and heat shock protein (Hsps) induced by the antioxidant and heat shock
responses, respectively. By promoting these cytoprotective signalling pathways, cancer cells can
adapt to the quickly-changing tumour microenvironment, ultimately resulting in enhanced cancer
cell survival (Ciocca et al., 2013; Taguchi & Yamamoto, 2017; Rojo de la Vega et al., 2018; Yun
et al., 2019; Robertson et al., 2020). Increased expression of Hsps is observed in a wide range of
human cancers (Ciocca et al., 1993; Kimura et al., 1993; Kaur & Ralhan, 1995; Yano et al., 1996;
Cornford et al., 2000; Whitesell & Lindquist, 2005; Hwang et al., 2009). Currently, Hsp90 is the
Hsp with the most clinically relevant small-molecule inhibitors in clinical trials
(ClinicalTrials.gov; Zagouri et al., 2013; Li et al., 2021). Hsp90 activity is required for the growth
of several cancer types due to its capacity to chaperone the normal folding and function of a
multitude of oncogenic proteins (Whitesell & Lindquist, 2005; Pick et al., 2007). Through
stabilization of oncogenic client proteins, Hsp90 overexpression promotes cell survival, malignant
transformation, tumour growth, and invasion (Whitesell et al., 1994; Lewis et al., 2000; Sato et al.,
2000; Basso et al., 2002a; Chen et al., 2002; Teng et al., 2012; Azoitei et al., 2014), particularly
through its stabilization of HER2 (Xu et al., 2002). Hsp90 inhibitors such as radicicol, display a
strong, nanomolar affinity for Hsp90 (Zagouri et al., 2013; Li et al., 2021) and can suppress
oncogenic transformation driven by several oncogenes, including Ras and Src (Sharma et al.,
1998).
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The Hsp90α1 isoform of Hsp90, encoded by the HSP90AA1 gene, is up-regulated in response to
cellular stress (Sreedhar et al., 2004). Hsp90 interacts with and regulates heat shock factor 1 (Hsf1)
(Nair et al., 1996; Ali et al., 1998; Hu & Mivechi, 2003), which can mediate a transcriptional stress
program that promotes resistance of cancer cells to chemotherapy and radiation (Dai et al., 2007;
Mendillo et al., 2012), particularly in HER2+ breast cancers (Meng et al., 2010; Santagata et al.,
2011). Similarly, cancer cells exhibit persistently high levels of reactive oxygen species (ROS)
due to genetic and metabolic instability (Vander Heiden et al., 2009; Finkel, 2011) which is
counteracted by Nrf2, the master transcriptional regulator of the oxidative stress response (Taguchi
& Yamamoto, 2017; Rojo de la Vega et al., 2018). We have previously identified a genetic and
physical interaction between Hsp90 and Nrf2 (Ngo et al., 2020, submitted).
Interestingly, Hsp90 regulates HER2 function by limiting HER2 heterodimerization which is
required for HER2 signalling (Brennan et al., 2000; Olayioye et al., 2000). Inhibition of Hsp90 has
been shown to result in the rapid degradation of the HER2 receptor (Tikhomirov & Carpenter,
2000; Solit et al., 2002) and accordingly, Hsp90 inhibitors have been used in the treatment of
HER2+ breast cancer in conjunction with HER2 monoclonal antibodies (Raja et al., 2008;
Canonici et al., 2018). However, HER2+ breast cancers are still associated with induced resistance
(Rimawi et al., 2015; Vernieri et al., 2019) and low survival rates (Carey et al., 2006). Therefore,
more work must be done to explore off-target effects and mechanisms of induced resistance.
In this study, we examined the interplay between Nrf2 and Hsf1 in breast cancer, along with the
involvement of Hsp90. We explored the crosstalk between the Nrf2 and Hsf1 signalling pathways,
together with their dependency on Hsp90 chaperone activity. Hsp90 inhibition was required to
induce expression of stress response genes in HER2+ breast cancers, notably through increased
mRNA expression of glutathione peroxidase (GPx) antioxidant genes which has been shown to
reduce responsiveness to cancer therapy. This project is not yet complete, but ensuing experiments
(see Section 5.8) will investigate the small molecule inhibition of Hsp90 (by radicicol), combined
with inhibition of glutamate-cysteine ligase (GCL) (by buthionine sulfoximine, BSO (Griffith &
Meister, 1979)) which diminishes the intracellular levels of the GSH cofactor required for GPx
enzymatic activity. We postulate that these small-molecule inhibitors, in combination with the
standard Trastuzumab and chemotherapy treatment regimen for HER2+ breast cancer, will
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enhance treatment outcomes. Our work provides novel insights into the crosstalk between the heat
shock and antioxidant stress responses in a translationally relevant model of breast cancer.

4.2

Results

4.2.1 HSP90AA1 is up-regulated in HER2-enriched breast cancers
A link between Hsp90 upregulation and reduced breast cancer survival has previously been
documented (Yano et al., 1996; Pick et al., 2007). Three distinct genes express cytosolic Hsp90s:
HSP90AA1 and HSP90AA2, encoding the two stress-inducible protein isoforms of Hsp90,
Hsp90α1 and Hsp90α2, respectively, and HSP90AB1, encoding the constitutively-expressed
Hsp90β (Sreedhar et al., 2004). Hsp90 transcript levels were examined across cancer types in the
International Cancer Genome Consortium (ICGC) dataset. The stress-inducible HSP90AA1 was
most highly expressed in breast cancer relative to all other cancer subtypes (Figure 4.1A).
Investigation of the TCGA breast cancer dataset revealed an association between elevated
HSP90AA1 transcript levels and reduced survival (Figure 4.1B). Alternatively, while HSP90AB1
was also relatively highly expressed in breast cancers, elevated expression of HSP90AB1 was not
associated with patient survival (data not shown). We therefore focused our downstream analysis
on mechanisms by which Hsp90α1 may promote tumorigenesis in breast cancer.
To define tumour characteristics associated with HSP90AA1 up-regulation, we further interrogated
the TCGA breast cancer dataset and report elevated HSP90AA1 expression in the HER2-enriched
molecular subtype (Figure 4.1C), along with HER2+ breast cancers (Figure 4.1D). This has
previously been suggested, as Hsp90 has been shown to associate with the intracellular domain of
receptor tyrosine kinases, including HER2 (Xu et al., 2002). We then assessed both protein levels
(Figure 4.1E) and mRNA levels (Figure 4.1F) of Hsp90α, Hsp90α1, and HER2 across a panel of
HER2+ (21PT, 21NT, 21MT-1, SKBR3) and HER2- (T47D, MCF7) breast cancer cell lines. We
have included an isogenic cell line series representing distinct stages of cancer progression isolated
from a single patient (21PT, 21NT, 21MT-1), which show concomitant amplification and
increased expression of HER2 (Band et al., 1990).
Since the client proteins of Hsp90 have important roles in tumorigenesis and tumour survival
(Lewis et al., 2000; Sato et al., 2000; Basso et al., 2002a; Chen et al., 2002), we examined which
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signalling pathways are enriched in HER2+ breast cancers. Co-expression analysis was conducted
for transcripts whose expression levels were positively correlated with that of HSP90AA1 in the
TCGA breast cancer cohort. The resulting list consists of 66 and 249 genes in HER2+ and HER2breast cancers, respectively. To examine signalling pathways associated with HSP90AA1
transcript levels in HER2+ breast cancers, we focused on 28 transcripts that positively correlate
with HSP90AA1 expression exclusively in HER2+ breast cancers (Figure 4.1G and Figure
S4.1A). Pathway analysis of the input gene list revealed that the transcription factor whose target
genes and transcriptional profiles match the input list most closely is Hsf1 (Figure S4.1B).
Additionally, comparison of our gene list to transcriptional profiles with transcription factor lossof-function datasets from the Gene Expression Omnibus (GEO) highlighted both Hsf1 and Nrf2
(Figure S4.1C), and there is significant overlap between the Nrf2 and Hsf1 signalling pathways,
i.e., their responses as transcription factors are correlated, yet they may not be linked (Dayalan
Naidu et al., 2015).
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Figure 4.1: HSP90AA1 is up-regulated in HER2-enriched breast cancers. (A) Assessment of
ICGC data (US Donor-centric) data shows HSP90AA1 mRNA levels across tumour subtypes.
HSP90AA1 mRNA expression in breast cancer is indicated by an arrow. (B) Kaplan-Meier survival
curve for breast cancer patients from the TCGA BRCA cohort, separated into high (upper quartile)
versus low (lower quartile) HSP90AA1 expression. (C, D) HSP90AA1 mRNA expression was
assessed across tumour characteristics in the TCGA BRCA cohort, including molecular subtype
(C) and HER2 status (D). (E) Relative protein steady-state levels of HER2, Hsp90α, and Hsp90β
across a panel of breast cancer cell lines, with β-tubulin serving as the internal loading control. (F)
Relative mRNA expression of HER2, HSP90AA1, and HSP90AB1 across a panel of breast cancer
cell lines, normalized to RPLP0 expression. (G) Overlap of transcripts positively associated with
HSP90AA1 mRNA levels in the TCGA breast cancer cohort by HER2 status. The 28 transcripts
positively correlated with HSP90AA1 in HER2+ breast cancers. (A, C, D, F) Means derived from
three biological replicates were used during analysis. Means were analyzed using one-way
ANOVA followed by Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was
considered statistically significant; *p<0.05, **p<0.01, ***p<0.001.

4.2.2 Increased glutathione peroxidase mRNA expression levels following
oxidative stress and Hsp90 inhibition in HER2+ breast cancer cells
We assessed the induction of both Nrf2 (ABCC2, HMOX1, NQO1, GPX2) and Hsf1 (HSPA1A,
DNAJA4) target genes (Figure S4.2) across a panel of HER2+ and HER2- breast cancer cell lines,
with or without the addition of an oxidative stress-inducing agent hydrogen peroxide (H2O2), the
Hsp90 inhibitor radicicol, and combined hydrogen peroxide and radicicol by RT-qPCR (Figure
4.2A). Of note, the Hsp90 inhibitor geldanamycin and its derivatives have been widely used in
clinical trials for the treatment of cancer (Miyata, 2005); however, recent evidence has shown that
geldanamycin-derived Hsp90 inhibitors are synthetic lethal combined with Nrf2 deletion, such that
activation of Nrf2 target genes by Hsp90 inhibition results in metabolism of the quinone moiety in
geldanamycin that could be responsible for its synthetic lethality (Baird et al., 2020). Radicicol is
an Hsp90 inhibitor that is not a geldanamycin derivative and thus lacks this toxic quinone moiety;
therefore, radicicol was used in this study. Additionally, we profile mRNA expression of NFE2L2,
HSF1, HSP90AA1, and HSP90AB1, as internal controls, along with several other Nrf2169

independent antioxidant genes including GPX1, GPX3, and GPX4. Some Nrf2 and Hsf1 target
genes are not induced with the addition of even 2 mM H2O2 for 3 h (Figure 4.2B). As an internal
control, we assessed the induction of the Hsf1 and Nrf2 target genes with the addition of radicicol
(Figure 4.2C). Several of the cell lines tested showed induced expression of both HSP90AA1 and
HSP90AB1 mRNA. With the addition of combined hydrogen peroxide and radicicol, we observed
that several genes within our panel are induced by this combined treatment (Figure 4.2D). Of
particular interest, mRNA expression levels for GPX2 and GPX3, two members of the GPx family,
showed large differences between combined treatment relative to treatment with hydrogen
peroxide alone. Of note, this induction of GPX2 and GPX3 by combined treatment is most explicit
in HER2+ cell lines. For mRNA expression of NFE2L2 and HSF1, refer to Figure S4.3.
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Figure 4.2: Relative mRNA expression levels for GPX2 and GPX3 are significantly
upregulated following oxidative stress with Hsp90 inhibition. (A) Relative mRNA levels of
Nrf2 and Hsf1 target genes were evaluated by RT-qPCR, normalized to RPLP0 transcript levels,
and depicted as fold change relative to the media control. Means derived from three biological
replicates were used during analysis. (B-D) Heat maps summarizing the fold changes in Nrf2 and
Hsf1 target gene expression for each treatment group relative to their respective controls.

4.2.3 Increased glutathione levels following oxidative stress and Hsp90
inhibition in HER2+ breast cancer cells
GPx2 and GPx3 are enzymes within the GPx family of enzymes responsible for catalyzing the
detoxification of hydroperoxides (e.g., H2O2) through the oxidation of reduced glutathione (GSH)
to oxidized glutathione (GSSG) (Brigelius-Flohé & Maiorino, 2013) (Figure 4.3A, top). GSH
plays a critical role in protecting cells from oxidative damage either through direct antioxidant
activity or coupled to GPx enzymatic activity (Pompella et al., 2003; Forman et al., 2009).
Accordingly, decreased GSH levels, increased GSSG levels, or a decreased GSH:GSSG ratio is
indicative of oxidative stress (Chai et al., 1994; Asensi et al., 1999) and implies GPx antioxidant
activity through the oxidation and consumption of GSH to GSSG (Figure 4.3A, bottom). We
sought to investigate GSH levels in the panel of HER2+ and HER2- cell lines treated with or
without oxidative stress, Hsp90 inhibition, and the combined treatment of both. A luminescencebased system was used to measure total glutathione (i.e., GSH+GSSG) and oxidized GSSG, and
the ratios of GSH:GSSG were calculated based on those values as a measure of oxidative stress
(Asensi et al., 1999). Except for 21PT cells, all HER2+ cell lines (21NT, 21MT-1, and SKBR3,
i.e., the high HER2-expressing cell lines) showed increased total glutathione levels with combined
treatment compared to hydrogen peroxide-induced oxidative stress treatment alone (Figure 4.3B).
For the same three HER2+ cell lines, oxidized GSSG levels increased significantly with oxidative
stress alone (~10-fold increase relative to control), with modest increases in the remaining three
cell lines (T47D, MCF7, 21PT) (~1.5-fold increase) (Figure 4.3C). However, when Hsp90 was
inhibited in the combined treatment condition, GSSG levels dropped back to baseline even in the
presence of oxidative stress (Figure 4.3C). Note that radicicol treatment alone does not alter total
or oxidized glutathione levels. When the ratios of reduced GSH to oxidized GSSG were compared,
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all cell lines show a decreased GSH:GSSG ratio upon oxidative stress alone (Figure 4.3D),
indicative of antioxidant activity. This ratio is markedly low for the 21NT, 21MT-1, and SKBR3
cell lines (~0.1:1). Intriguingly, added Hsp90 inhibition in the combined treatment condition
resulted in an increased GSH:GSSG ratio with significant differences between hydrogen peroxide
treatment alone and the combined treatment condition in the 21NT, 21MT-1, and SKBR3 HER2+
cell lines that are not observed for T47D, MCF7, and 21PT cell lines (Figure 4.3D).
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Figure 4.3: Glutathione levels and ratios in response to oxidative stress, Hsp90 inhibition,
and combined treatment. (A) The GPx-mediated breakdown of hydrogen peroxide to water
through the oxidation of GSH to GSSG in relation to levels of oxidative stress. (B) Total
glutathione (GSH + GSSG) levels across a panel of breast cancer cell lines. (B) Oxidized
glutathione (GSSG) levels across those same cell lines. (D) The ratio of reduced glutathione to
oxidized glutathione (GSH:GSSG) relative to control. Means derived from three biological
replicates were used during analysis. Means were analyzed using one-way ANOVA followed by
Tukey’s post hoc test. Data are expressed as mean ± SD. p<0.05 was considered statistically
significant; *p<0.05, **p<0.01, ***p<0.001.

4.2.4 Increased response to taxane-treatment and increased ROS levels in
HER2+ cells lines
Along with monoclonal antibody treatment (Trastuzumab), docetaxel and paclitaxel are two
taxane-based chemotherapy drugs that have been widely used in the neoadjuvant treatment of
HER2+ breast cancer (Merlin et al., 2002; Desai et al., 2008). To assess the effects of oxidative
stress and Hsp90 inhibition alone and combined with chemotherapy treatment, the panel of HER2+
and HER2- cell lines were treated with hydrogen peroxide, radicicol, or combined treatment
following pre-treatment with 50 nM of docetaxel or paclitaxel for a total of 24 h. Luminescencebased assays were performed to assess relative cell viability (determined by the quantification of
ATP levels which indicates the presence of metabolically active cells (Crouch et al., 1993)). Pretreatment with docetaxel or paclitaxel decreased relative cell viability compared to the untreated
controls across all six cell lines for all internal treatment conditions, with pronounced efficacy in
the four HER2+ cell lines compared to the HER2- cells (Figure 4.4A). However, the relative ratios
of viability between untreated and docetaxel/paclitaxel-treated cells remained the same for each
cell line. Furthermore, treatment with 600 μM H2O2 significantly reduced cell viability for the
T47D, MCF7, and 21PT cell lines but not for the high HER2-expressing cell lines (21NT, 21MT1, and SKBR3), which overall seem more oxidative stress-resistant than the non-/low HER2 cell
lines. Although all cell lines were sensitive to very high hydrogen peroxide levels (2 mM), the high
HER2-expressing cell lines still showed better overall viability (Figure 4.4A). Finally, except for
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21NT cells and to a lesser extent for 21MT-1 cells, all other cell lines demonstrated reduced cell
viability for the combined treatment conditions.
Cancer cells often show increased reactive oxygen species (ROS) levels that are generally
associated with increased rates of cell proliferation and metabolism (Vander Heiden et al., 2009;
Finkel, 2011). Here, ROS levels were measured at baseline and following treatment with hydrogen
peroxide, radicicol, and combined treatment. As expected, all cell lines demonstrated increased
ROS levels following hydrogen peroxide treatment both alone and in combination with radicicol
compared to the untreated controls (Figure 4.4B). Interestingly, HER2+ cell lines showed
significantly higher overall ROS levels upon treatment compared to HER- cell lines, whereas
baseline (untreated) ROS levels were comparable across all cell lines.
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Figure 4.4: Relative cell viability and ROS levels in response to oxidative stress, Hsp90
inhibition, or combined treatment. (A) Cell viability across a panel of breast cancer cell lines
with or without pre-treatment with chemotherapy agents, docetaxel or paclitaxel prior to treatment
with hydrogen peroxide, radicicol, or both. (B) Relative ROS levels following treatment with
hydrogen peroxide, radicicol, or both. Means derived from three biological replicates were used
during analysis. Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test.
Data are expressed as mean ± SD. p<0.05 was considered statistically significant; *p<0.05,
**p<0.01, ***p<0.001.

4.2.5 HER2, Hsp90α, and Hsp90β protein expression levels in response to
oxidative stress and Hsp90 inhibition
(Pending Completion)
To assess the expression of HER2, Hsp90α, and Hsp90β protein expression levels following
oxidative stress and/or Hsp90 inhibition, western blots were performed with β-Tubulin as an
internal control. Initial blots were performed for three of the six breast cancer cell lines (T47D,
MCF7, and 21PT) (Figure 4.5). However, the results cannot be interpreted due to changes in
expression levels for the internal control in response to radicicol treatment. Western blots will be
repeated using total protein as an internal control.
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Figure 4.5: Protein expression levels in response to oxidative stress, Hsp90 inhibition, and
combined treatment. Protein expression for HER2, Hsp90α, and Hsp90β across a panel of breast
cancer cell lines, with β-tubulin serving as the internal loading control, for 3 of 6 cell lines.

4.2.6 Co-inhibition of Hsp90 and GPx in HER2+ breast cancer therapy
(Pending Completion)
We found that Hsp90 inhibition in HER2+ breast cancer cell lines induced increased expression
of GPX2 and GPX3 which may confer enhanced cell survival through increased antioxidant
capacity. To mitigate this, we propose that targeting Hsp90 and GPx in combination to enhance
the efficacy of HER2+ breast cancer treatment response. HER2+ and HER2- cell lines will be
treated with the standard combined HER2-targeted therapy (a Trastuzumab analogue) with
chemotherapy (docetaxel or paclitaxel), in addition to the small-molecule inhibition of the Hsp90
protein (by radicicol) and GPx activity indirectly through inhibition of GSH synthesis (by
buthionine sulfoximine, BSO). Cell viability and cell death will be determined. BSO is a potent
inhibitor of GSH synthesis which depletes GSH levels in the cell (Griffith & Meister, 1979),
resulting in reduced levels of GSH required for GPx antioxidant activity. Thus, combined radicicol
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and BSO treatment are expected to render cancer cells more susceptible to cancer therapy
compared to radicicol treatment alone.

4.3

Discussion

Targeting Hsp90 in cancer treatment has been a growing area of research within the past two
decades (Whitesell & Lindquist, 2005; Trepel et al., 2010), although more research is required to
understand which patients may receive the greatest benefit from this therapeutic intervention. The
unique N-terminal ATP-binding pocket of Hsp90 is the target of several natural as well as semisynthetic pharmacological inhibitors. The binding of this active site by pharmacological inhibitors
can alter normal Hsp90 cellular functions (Roe et al., 1999; Pearl & Prodromou, 2006), leading to
events such as the recruitment of E3 ubiquitin ligases and subsequent proteasome-mediated
degradation of client proteins (Kobayashi et al., 2004). Hsp90 inhibitors have shown great clinical
promise in the treatment of cancer due to their ability to simultaneously suppress multiple Hsp90regulated pathways that are essential for tumour cell growth and resistance. HER2 is a direct client
protein of Hsp90, and Hsp90 inhibition has been shown to result in the rapid degradation of the
HER2 receptor (Basso et al., 2002b; Solit et al., 2002; Zsebik et al., 2006). Hsp90 inhibitors have
therefore been used in conjunction with the HER2 monoclonal antibody treatment standard,
Trastuzumab, for the treatment of HER2+ breast cancer and have shown promising results (Raja
et al., 2008; Canonici et al., 2018). However, off-target effects and induced therapy resistance
remain challenging in breast cancer treatment (Rimawi et al., 2015; Vernieri et al., 2019). In this
work, we show that the stress-inducible isoform of Hsp90, HSP90AA1, is upregulated in HER2enriched breast cancers, and Hsp90 inhibition is associated with activation of the Nrf2 and Hsf1
signalling pathways, with notable induction of Nrf2-regulated GPX2, and Nrf2-independent
GPX3, both of which are genes for potent antioxidant enzymes that may contribute to cancer
therapy resistance.
Previous studies have shown that HER2 receptor overexpression activates Hsf1 (Schulz et al.,
2014), the master transcriptional regulator of the heat shock response against proteotoxic stress
and that Hsf1 activity is negatively regulated by Hsp90 (Ali et al., 1998; Zou et al., 1998). In line
with these findings, we found HSP90AA1 transcript levels to be increased in the HER2-enriched
molecular subtype, specifically in HER2+ breast cancers, and that this correlated with signalling
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pathways for Hsf1 and Nrf2. The role of Nrf2 in promoting carcinogenesis and cancer therapy
resistance is well established. Nrf2 hyperactivation in cancer confers protection against oxidative
stress and promotes the detoxification and export of chemotherapeutic agents through the
upregulation of cytoprotective antioxidant enzymes (Taguchi & Yamamoto, 2017; Rojo de la Vega
et al., 2018). We therefore speculate that the observed HER2-associated increases in GPX2 and
GPX3 upon oxidative stress with Hsp90 inhibition are protective. Recent studies have
demonstrated the involvement of ROS in the development and progression of breast cancer (Zhu
et al., 2016a; Ma et al., 2018; Zhong et al., 2019) and GPx plays a major role in the protection of
cancer cells against ROS (Brigelius-Flohé & Kipp, 2009). We show that HER2+ cells under
oxidative stress conditions exhibit higher overall ROS levels and may therefore be especially
reliant on antioxidant enzymes, such as GPx. Additionally, while GPx3 is abundantly expressed
in the plasma, GPx2 is preferentially expressed in the gastrointestinal tract (Brigelius-Flohé &
Maiorino, 2013) but can be upregulated in malignant epithelial cells of other organs, such as the
breast (Naiki-Ito et al., 2007). Increased mRNA levels for GPx2 was observed in our HER2+ breast
cancer cell lines.
GPx enzymes are powerful antioxidant enzymes, and through the oxidation of reduced GSH into
its oxidized GSSG, these enzymes serve to detoxify hydroperoxides, including hydrogen peroxide
(Brigelius-Flohé & Maiorino, 2013). Indeed, the 21NT, 21MT-1, and SKBR3 HER2+ cell lines,
all of which show the highest HER2 expression levels (confirmed by western blot analyses),
showed the largest increases in GSSG levels in response to oxidative stress. This suggests that
HER2+ cell lines may have increased antioxidant activity. However, upon Hsp90 inhibition by
radicicol, GSSG levels dropped back to baseline which is peculiar as the HER2+ cell lines were
expected to have increased GPx activity and thus, increased levels of GSSG.
As previously mentioned, a decreased GSH:GSSG ratio is indicative of oxidative stress (Chai et
al., 1994; Asensi et al., 1999), and this was, as expected, observed for all hydrogen peroxidetreated cell lines. However, when combined with additional Hsp90 inhibition, this observed
decrease in GSH:GSSG ratio was abolished for the HER2+ cell lines and the ratio was comparable
to control. This is peculiar, as the expected enhancement in GPx expression should be associated
with a reduced GSH:GSSG ratio. HER2+ breast cancer cells may have increased expression of
glutathione reductase (GSR) for the conversion of GSSG back into GSH. This, however, seems
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unlikely, as mRNA expression for GSR upon combined treatment shows no significant changes
(Figure S4.4). This remains to be further explored.
Many studies have looked into the use of Nrf2 inhibitors (Robledinos-Antón et al., 2019) as
adjuvants to cancer therapy to inhibit the antioxidant response (Zhu et al., 2016b). However, while
GPx2 is regulated by Nrf2 (Singh et al., 2006), GPx3 is not. Thus, in this scenario, a more targeted
approach is needed to mitigate the increased GPx-associated antioxidant capacity of HER2+ breast
cancer cells upon Hsp90 inhibition. We thus proposed the more specific small-molecule inhibition
of GPx by BSO. BSO is a potent inhibitor of the rate-limiting enzyme required for GSH synthesis,
GCL (Griffith & Meister, 1979). BSO has been tested in preclinical models of cancers and has
shown promise in enhancing the efficacy of anti-cancer therapeutics, including in breast cancer
(Lewis-Wambi et al., 2008). We predict that inhibition of GSH biosynthesis in HER2+ breast
cancer cells by BSO should reduce their GPx-associated antioxidant capacity and render cancer
therapy more effective when combined with Hsp90 inhibition. This will be determined in our
ensuing studies.
Hsp90 inhibition has been widely studied in the context of breast cancer treatment; however,
mechanisms of induced resistance and off-target effects remained underexplored. This work
begins to decipher the functional interplay between HER2 and Hsp90 and identifies the specific
role of GPx enzymes in HER2+ breast cancer. By assessing the efficacy of HER2+ breast cancer
therapies, such as Trastuzumab, in conjunction with small-molecule inhibitors of Hsp90 and GPx
activity, we provide new insight into the combined use of these inhibitors in the improvement of
treatment outcomes for HER2+ breast cancer and open new avenues for breast cancer treatment in
general.

4.4

Materials and Methods

4.4.1 Cell lines and culture conditions
T47D cells were maintained in Roswell Park Memorial Institute (RPMI)1640 media supplemented
with 10% FBS. MCF7 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% FBS. The 21PT, 21NT, and 21MT-1 cell lines were maintained in α
Minimum Essential Medium (αMEM) supplemented with 2 mM L-glutamine, 1 µg/mL insulin,
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12.5 ng/mL EGF, 2.8 µM hydrocortisone, 10 mM HEPES, 1mM sodium pyruvate, 0.1 mM nonessential amino acids, 50 µg/mL gentamycin sulfate, and 10% FBS. SKBR3 cells were maintained
in McCoy's 5A media supplemented with 10% FBS. All reagents for the culture of breast cancer
cell lines were obtained from Gibco Inc. (Manassas, VA, USA).

4.4.2 Inhibitor treatment
Cells (T47D, MCF7, 21PT, 21NT, 21MT-1, and SKBR3) were seeded in a 6-well plate at 0.5x106
cells per well. The following day, cells were treated (in triplicate) with one of the following six
treatments: 600 µM H2O2 (3 h), 2 mM H2O2 (3 h), 30 µM radicicol (Cayman Chemical, 12772-575; 6h), 100 µM radicicol (6 h), and combined treatments with 100 µM radicicol (6 h) with 600 µM
H2O2 (3 h) and 100 µM radicicol (6 h) with 2 mM H2O2 (3 h). Controls included media only and
DMSO treatment (final concentration of 0.1% DMSO for 6 h for all DMSO and radicicol-treated
samples).

4.4.3 RNA isolation and quantitative reverse transcription PCR (RT-qPCR)
RNA was isolated using the RNA Extraction Kit (Pure Reagents, KIT-RNA-ISO-MAM-75), and
500 ng of RNA was converted into cDNA using the RevertAid H Minus First Strand cDNA
Synthesis Kit (Thermo Fisher Scientific, K1632). The PowerUp SYBR Green Master Mix
(Applied Biosystems, A25742) was utilized for quantitative PCR with the primer sequences listed
in Table 4.1. The output values were normalized to RPLP0 expression.
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Table 4.1: Primer sequences utilized for RT-qPCR in mRNA studies.
mRNA Probe
ABCC2

Primer Sequences
(Forward and Reverse, 5’ to 3’)
F: AGTCTTAGCAGGTGTTGGGG
R: GACTAAAGGCCAGCAGGTTCT

DNAJA4

F: AGGTGATAAAGCACGGGGAC
R: GCCAGTTCTGCTCATTGGGA

GPX1

F: GGAGAACGCCAAGAACGAAG
R: AGCATGAAGTTGGGCTCGAA

GPX2

F: GGATACCAGCCCACCTTCAC
R: GGTAGGCGAAGACAGGATGC

GPX3

F: GAGCTTGCACCATTCGGTCT
R: TTAGGGACAAAGCCTCCACC

GPX4

F: GCCTTCCCGTGTAACCAGT
R: GCGAACTCTTTGATCTCTTCGT

HMOX1

F: CCCCAACGAAAAGCACATCC
R: AGACAGCTGCCACATTAGGG

HSF1

F: CAGCTTCCACGTGTTCGAC
R: GGCCATGTTGTTGTGCTTGA

HSPA1A

F: TAACCCCATCATCAGCGGAC
R: AGCTCCAAAACAAAAACAGCAA

HSP90AA1

F: GCTGGACAGCAAACATGGAG
R: AGACAGGAGCGCAGTTTCAT

HSP90AB1

F: ATTGTGACCAGCACCTACGG
R: CATGGTGGAGTTGTCCCGAA

NQO1

F: TGGAAGAAACGCCTGGAGAAT
R: CTGGTTGTCAGTTGGGATGG

RPLP0

F: CCTCATATCCGGGGGAATGTG
R: GCAGCAGCTGGCACCTTATTG
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4.4.4 Preparation of protein lysates
Cells (T47D, MCF7, 21PT, 21NT, 21MT-1, and SKBR3) were seeded in a 6-well plate at 1x106
cells per well. The following day, 500 µl of RIPA buffer (150 mM NaCl, 1% Triton-X, 0.5%
deoxycholic acid, 0.1% SDS, 50 mM Tris-base; pH 8.0) with Pierce Protease Inhibitor Tablets
(Thermo Fisher Scientific, A32965) was added to confluent 6-well dishes. Cells were scraped,
collected in a microcentrifuge tube, incubated on ice for 10 min, and centrifuged at 13,000 rpm for
10 min at 4°C. The supernatant was collected, and the protein concentration per sample was
determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, 23225) by
comparison to BSA standards.

4.4.5 Electrophoresis and western blot analysis
Protein (20 µg) was resolved on a 10% SDS-PAGE gel. The membrane was blocked with 5% milk
in PBST and incubated with one of the following primary antibodies overnight at 4°C: rabbit antiHER2 (Invitrogen, MA5-15050), mouse anti-Hsp90α (Abcam, ab79849), mouse anti-Hsp90β
(Abcam, ab53497), or rat anti-β-Tubulin (Abcam, ab6160). The membrane was incubated with an
HRP-conjugated secondary antibody, either anti-rabbit (Abcam, ab6721), anti-mouse (Abcam,
ab6728), or anti-rat (Abcam, ab97057) as required, for 1 h at room temperature. Western blots
were visualized using the Clarity Western ECL Substrate kit (Bio-Rad, 1705061) and images were
taken using the ChemiDoc Imaging System (Bio-Rad). In ensuing experiments, densitometric
quantification will be performed using ImageLab (Bio-Rad) and quantities will be normalized to
total protein expression.

4.4.6 Cell viability, ROS, and glutathione assays
Cells (T47D, MCF7, 21PT, 21NT, 21MT-1, and SKBR3) were seeded in a white 96-well plate at
20 000 cells per well. The following day, cells were treated (in triplicate) with hydrogen peroxide,
radicicol, and combined treatments as outlined in Section 4.4.2. Cell viability was measured using
the CellTiter-Glo 2.0 Cell Viability Assay (Promega, G9242) and ROS levels were measured using
the ROS-Glo H2O2 Assay (Promega, G8820). Glutathione levels were measured using the
GSH/GSSG-Glo Assay (Promega, V6611). All assays were performed according to the
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manufacturer’s protocol. Fluorescence and luminescence were measured using the Cytation 5 Cell
Imaging Multi-Mode Reader (BioTek).

4.4.7 Bioinformatics analyses
The International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas breast
cancer (TCGA BRCA) datasets were interrogated, and data were exported using XenaBrowser
(Goldman et al., 2020). HSP90AA1 expression was compared across cancer type (ICGC), breast
cancer molecular subtype (TCGA BRCA), and HER2 status (TCGA BRCA). The aforementioned
datasets are listed in Table 4.2.
To examine transcripts that were co-expressed with HSP90AA1 in HER2- and HER2+ breast
cancers within the TCGA dataset, gene lists were constructed using Venny 2.1 (Oliveros, 2007).
Enrichr pathway analysis (Chen et al., 2013) was conducted with the input list consisting of 28
genes positively correlated with HSP90AA1 only in HER2+ breast cancers. Results assessing
Transcription Factor (TF) Interactions and TF-loss of function (LOF) (GEO) expression data are
reported. The combined score takes into account the p-value and z-score, with the calculation
CombinedScore = ln(p)*z, with p representing the p-value and z representing the z-score
(Kuleshov et al., 2016). Pharmacological inhibitor data was obtained from CancerRxGene (Yang
et al., 2013) and searching for Hsp90 inhibitors. Cell line characterization with respect to HER2
status was obtained from previously published studies (Suzuki et al., 2009; Valabrega et al., 2011;
Wang et al., 2011; Kalous et al., 2012; Di et al., 2014; Dai et al., 2017).

Table 4.2: Publicly available datasets utilized for analysis.
Dataset

Reference (or Link)

International Cancer Genome
Consortium (ICGC)

https://dcc.icgc.org

TCGA Breast Cancer (BRCA)

https://portal.gdc.cancer.gov/projects/TCGA-BRCA

CancerRxGene

https://www.cancerrxgene.org

186

4.4.8 Statistical analysis
Statistical analyses were conducted using Prism 8 (GraphPad Software). Statistical significance
was obtained by performing a one-way ANOVA with Tukey post hoc for comparison between
groups, or the Student’s t-test for comparison between two groups (with a minimum of 3 biological
replicates). Error bars represent standard deviation. P-values less than 0.05 were considered
statistically significant. Significance levels are indicated using asterisks, where * is p<0.05, ** is
p<0.01, and *** is p<0.001. Shapiro-Wilk tests were performed for all data sets to ensure
normality.
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4.5

Supplementary Figures

Figure S4.1: HSP90AA1 expression is associated with Nrf2 and Hsf1 signalling pathways in
HER2+ breast cancers. Overlap of transcripts positively associated with HSP90AA1 mRNA
levels in the TCGA breast cancer cohort by HER2 status. The 28 transcripts positively correlated
with HSP90AA1 in HER2 positive breast cancers. Pathway analysis was conducted on this gene
set, with results from (B) Transcription Factor (TF) Interactions and (C) TF loss of function (LOF)
(GEO) expression data reported.
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Nrf2

Hsf1

Gene

Protein Encoded

Function

NFE2L2

Nuclear factor erythroid 2related factor 2 (Nrf2)

Transcription factor regulates the
oxidative stress response

ABCC1

Multidrug resistanceassociated protein 2 (Mrp2)

ATPase activity coupled to
transmembrane movement for
detoxification

NQO1

NAD(P)H
dehydrogenase:quinone 1
(NQO1)

Reduces quinone to hydroquinone

HMOX1

Heme oxygenase 1 (HO-1)

Degrades heme to biliverdin

GPX2

Glutathione peroxidase 2
(GPx2)

Reduces H2O2 and hydroperoxides

GSS

Glutathione synthetase (GSS) Condensation of γglutamylcysteine and glycine to
glutathione (GSH) for glutathione
biosynthesis

GSR

Glutathione-disulfide
reductase (GSR)

Reduces GSSG to GSH for GSH
regeneration

Gene

Protein Encoded

Function

HSF1

Heat shock factor 1 (Hsf1)

Transcription factor that regulates
the heat shock response

HSP90AA1

Heat shock protein 90kDa
alpha (Hsp90α)

Stress inducible isoform of the
molecular chaperone Hsp90

HSP90AB1

Heat shock protein 90kDa
beta (Hsp90β)

Constitutively active isoform of
the molecular chaperone Hsp90

HSPA1A

Heat shock 70 kDa protein 1
(Hsp70)

Molecular chaperone

DNAJA1

DnaJ homolog subfamily A
member 1 (Hsp40)

Co-chaperone for HspA8/Hsc70

Figure S4.2: List of Nrf2 and Hsf1 target genes evaluated by RT-qPCR. Target genes and their
associated protein and protein function are listed.
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Figure S4.3: Relative mRNA levels for NFE2L2 and HSF1. Genes were evaluated by RTqPCR, normalized to RPLP0 transcript levels, and depicted as fold change relative to the media
control. Means derived from three biological replicates were used during analysis. Data are
expressed as mean ± SD.
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Figure S4.4: Relative mRNA levels for GSS and GSR. Genes were evaluated by RT-qPCR,
normalized to RPLP0 transcript levels, and depicted as fold change relative to the media control.
Means derived from three biological replicates were used during analysis. Data are expressed as
mean ± SD.
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Figure S4.5: STRING interaction of Nrf2 and Hsf1 target genes. Nrf2 target genes are shown
in blue and Hsf1 target genes are shown in green. Glutathione peroxidase (GPx)-associated genes
are illustrated in red. Network statistics and functional enrichments are shown. Data are derived
from the STRING Consortium.
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Chapter 5
5

Discussion

5.1

Summary of Chapters

The chapters in this work investigate key cellular and molecular aspects of the Keap1-Nrf2
antioxidant pathway, including genetic and physical protein-protein interactions of Nrf2, and the
folding and misfolding of Nrf2 and Keap1 under conditions of oxidative stress. From there, a
convergence between the antioxidant and heat shock response pathways was observed and
subsequent work examined this crosstalk in a clinically relevant model of breast cancer.

5.1.1 A novel yeast model for Nrf2 and Keap1 detects their interaction with
Hsp90
In Chapter 2, we established and characterized a yeast model of human Nrf2, Keap1, and other
proteins that interact with and regulate Nrf2. This chapter introduces yeast as a novel tool to study
Nrf2 in a living test tube scenario, as yeast do not express Nrf2 or any close homolog; thus, existing
and new interactions can be studied independently of external regulatory mechanisms. Our Nrf2
yeast model recapitulates previously described Nrf2 interactions in mammalian cells, including
the key interaction between Nrf2 and Keap1 that regulates Nrf2 activity in the cell. Using the
complementary experimental tools available for yeast, a previously unexplored interaction
between Nrf2 and the molecular chaperone Hsp90 was detected, in addition to that of Keap1 and
Hsp90. Through this Nrf2-Hsp90 interaction, this work starts to establish an important nexus
between the antioxidant and heat shock responses.
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Figure 5.1: Summary of the observed Nrf2 interactions in yeast. Using yeast growth assays
and the split-ubiquitin system to study genetic interactions and protein-protein interactions,
respectively, known and previously unexplored (*) interactions within the Nrf2 protein network
were detected.

5.1.2 Oxidative stress-induced inclusion formation of Nrf2 and Keap1
Chapter 3 examined aspects of protein oxidative damage, misfolding, and inclusion formation for
Nrf2 and Keap1 using various experimental models. We found that both in yeast and mammalian
cells, Nrf2 and Keap1 form intracellular protein inclusions upon exposure to oxidative stress,
which is mediated, at least in part, by aberrant disulfide bond formation, shown through
biochemical analyses using purified proteins. The intrinsically disordered nature of Nrf2 facilitates
its tendency for misfolding (which can also expose oxidation-prone cysteine residues), while the
high cysteine content of Keap1 promotes intra- and intermolecular disulfide bond formation by
thiol oxidation, leading to protein misfolding under oxidative stress conditions. This protein
inclusion formation was found to be oxidative stress-specific and dose-dependent. Although the
exact functional consequences of this phenomenon remain to be explored, these findings propose
a possible role of protein misfolding as a regulatory mechanism during oxidative stress conditions
and indicate the importance of protein folding—mediated by heat shock proteins and molecular
chaperones such as Hsp90—in regulating protein function.
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Figure 5.2: Nrf2 and Keap1 misfold and form protein inclusions upon oxidative stress.
Treatment with hydrogen peroxide to elicit oxidative stress resulted in the formation of Nrf2 and
Keap1 inclusions in yeast, cultured mammalian cells, and purified proteins.

5.1.3 Hyperactive stress response pathways in HER2+ breast cancers
Chapter 4 investigated the interplay between the antioxidant and heat shock responses and their
dependence on Hsp90 chaperone activity in cancer cells. Nrf2 is highly overexpressed in cancer,
which contributes to cancer cell growth, proliferation, and resistance to therapy (Takahashi et al.,
2010; Li et al., 2011; Hartikainen et al., 2012). The Nrf2 and Hsf1 signalling pathways were
examined in the context of breast cancer to explore the clinically relevant problem of cancer
therapy resistance. Initial bioinformatic analyses revealed that HER-enriched breast cancers are
among the highest expressers of HSP90AA1. We therefore investigated HER2+ and HER2- breast
cancer cells under conditions of stress using Hsp90 inhibitors, which have been commonly used
in the treatment of breast cancer (Zhong et al., 2019). Intriguingly, inhibition of Hsp90 leads to the
off-target upregulation of two glutathione peroxidase antioxidant genes specifically in HER2enriched cell lines during oxidative stress conditions. In alignment with the findings in Chapter 2,
this suggests that there is crosstalk between the heat shock and antioxidant responses within these
highly malignant cell lines. Ensuing experiments will explore a treatment regimen that addresses
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this off-target effect by introducing an indirect inhibitor of GPx enzymatic activity to eliminate the
antioxidant advantage that HER2-enriched breast cancer cells acquire upon Hsp90 inhibition.

Figure 5.3: Hsp90 inhibition in HER2+ breast cancer leads to GPx overexpression during
oxidative stress. (A) Inhibition of Hsp90 by radicicol under oxidative stress leads to the
upregulation of GPX2 and GPX3 in HER2-enriched breast cancer cells. (B) Indirect impairment
of GPx enzymatic activity by BSO is predicted to hinder this antioxidant advantage and render
cancer cells more susceptible to cancer therapy.

5.2

Exploring Nrf2 Interactions

Nrf2 activity is strictly regulated by its interactions with other proteins, namely its key interaction
with Keap1 through the binding of its DLG and ETGE motifs to the Kelch domain of Keap1 (Tong
et al., 2006; Tong et al., 2007). Indeed, mutations within either motif impair the Keap1-Nrf2
interaction, as observed for our yeast DLG and ETGE mutant variants, L30F and T80R (Shibata
et al., 2008). These mutations impair the ability of Keap1 to rescue the toxicity of Nrf2 expressed
in yeast, implying these mutations abolish the genetic Keap1-Nrf2 interaction. Numerous human
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cancers have demonstrated gain-of-function mutations in NFE2L2 and loss-of-function mutations
in KEAP1 (Padmanabhan et al., 2006; Singh et al., 2006; Nioi & Nguyen, 2007; Shibata et al.,
2008; Ooi et al., 2013). While it is unlikely that Nrf2 mutations cause cancer, Nrf2 mutations may
enhance the growth and development of existing cancer cells by conferring enhanced antioxidant
abilities to mitigate the stress of a hostile tumour environment (Taguchi & Yamamoto, 2017; Rojo
de la Vega et al., 2018).
When Keap1-dependent Nrf2 regulation fails, the question remains whether other mechanisms of
Keap1-independent regulation can adequately compensate. As previously discussed, there are
many forms of non-canonical Nrf2 regulation via the direct interaction and competitive inhibition
of proteins that bind to either Nrf2 or Keap1. Some major ones include Nrf2-binding βTrCP, p21,
RXRα, and BRCA1 (Chen et al., 2009; Rada et al., 2011; Chowdhry et al., 2013; Gorrini et al.,
2013; Wang et al., 2013; Xu et al., 2018), and Keap1-binding p62 and ProTα (Karapetian et al.,
2005; Copple et al., 2010; Fan et al., 2010; Jain et al., 2010; Komatsu et al., 2010; Lau et al., 2010).
Some of these proteins (βTrCP, p21, and ProTα) were included in our yeast studies and their
respective interactions were confirmed using yeast growth assays and the split-ubiquitin system.
Unfortunately, our studies did not include the many other interacting proteins, nor were these select
interactions that were chosen investigated in detail. Future work may investigate Nrf2-associated
genetic and physical protein-protein interactions in greater detail by taking advantage of the many
tools available for yeast studies. Of note, to establish the Nrf2 yeast model, the split-ubiquitin
system was used to detect known interactions; however, the high throughput capacity of the splitubiquitin system was not exploited, e.g., it can be used to screen whole human cDNA fusion
libraries to identify previously undiscovered interactions. Seeing as Nrf2 is highly intrinsically
disordered and can thus bind to a wide range of targets, exploiting this system will likely result in
the discovery of numerous unexplored Nrf2-binding partners. This system may also be used for
the detection of novel small molecule enhancers and inhibitors that modulate these interactions in
high throughput screens. Nevertheless, our yeast model of Nrf2 allowed us to discover the
interaction between heat shock protein Hsp90 and Nrf2, the two key players in the heat shock and
antioxidant responses, which inspired subsequent studies that sought to explore this intriguing
nexus.
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5.3

Oxidative Damage and Nrf2 Regulation

Although Nrf2 is primarily regulated through its protein interactions, other factors may influence
Nrf2 activity, such as competitive binding to the ARE by transcriptional repressors (e.g., Bach1
(Dhakshinamoorthy et al., 2005)), phosphorylation of Nrf2 (e.g., GSK3, PKC (Huang et al., 2002;
Rada et al., 2011; Chowdhry et al., 2013)), and the intracellular re-localization of Nrf2 (e.g.,
PGAM5 (Lo & Hannink, 2008)), among others. Given that Nrf2 is the key regulator of oxidative
stress, the extent of oxidation within the Nrf2 protein itself may also influence its activity in the
cell. Nrf2 contains six cysteine residues and Keap1 contains 27; cysteines are unique in that they
contain highly reactive sulfur-based thiol groups that are prone to oxidation by ROS and disulfide
bond formation with other cysteines (Stadtman, 1993). Indeed, we found that in yeast and cultured
mammalian cells, Nrf2 and Keap1 are oxidized and form protein inclusions upon oxidative stress.
Results using purified proteins showed that this was, at least in part, disulfide bond-dependent.
However, the presence of cysteine residues alone is not sufficient for misfolding, as the Kelch
domain of Keap1, which contains eight of the 27 cysteine residues in Keap1, did not misfold or
form inclusions upon oxidative stress. Keap1 misfolding could be a highly regulated event, or the
outcome of protein damage, but this remains to be explored. We speculate that perhaps under
conditions of high oxidative stress, Keap1 and/or Nrf2 may misfold and form aberrant protein
inclusions that impair the Keap1-Nrf2 interaction. Since Keap1 activity is dependent on its
interaction with Nrf2, its activity may be completely inactivated when Keap1 misfolds, which
allows for Nrf2 hyperactivation. On the other hand, Nrf2’s transcription factor activity is not
dependent on the Keap1-Nrf2 interaction and it may therefore still be functional, but this must also
be further explored.

5.4

Reversibility of Cysteine Oxidation Inclusions

Apart from the ER, where temporary disulfide bonds help to stabilize proteins during the folding
process (Jansens et al., 2002), most cysteines in the cell are kept reduced. Thioredoxin is a
ubiquitous antioxidant enzyme chiefly responsible for thiol-redox control to reduce disulfide bonds
and protect proteins from oxidative inclusion formation and inactivation (Collet & Messens, 2010).
The question remains then, if oxidized Nrf2 and Keap1 inclusions are reversible by mechanisms
such as disulfide bond reduction by thioredoxin and possible refolding by molecular chaperones,
206

and to what extent is this oxidative damage tolerated before it becomes irreversible and toxic. This
question is particularly important in the context of neurodegenerative diseases where oxidative
damage and protein misfolding and aggregation/inclusion formation are common hallmarks across
many different neurodegenerative diseases (Soto, 2003). Pre-treatment of HeLa cells with the
antioxidant NAC (but not vitamin C) reduced the formation of Nrf2 inclusions upon oxidative
stress, suggesting that ROS scavenging may alleviate or prevent, to a certain extent, oxidative
cysteine modifications; however, more evidence is required to confirm this. The use of live-cell
imaging would be very informative and allow us to observe, using time-lapse microscopy, the
formation of these stress-induced inclusions, and to determine if these inclusions can be reversed
over time either by endogenous cellular mechanisms or through exogenous chemical treatments.
The other arising question is whether molecular chaperones, which assist in the refolding of
misfolded proteins can refold cytosolic, disulfide bond-mediated, misfolded protein inclusions
such as those observed for Nrf2 and Keap1. Within yeast, Hsp104 cooperates with Hsp70 and
Hsp40 to function as a disaggregase that mediates the dissolution of protein aggregates and
inclusions to restore their function or facilitate their clearance from the cell (Glover & Lindquist,
1998; Goloubinoff et al., 1999). However, metazoans, including humans, do not possess a known
Hsp104 homologue so it remains unclear how some protein aggregates and inclusions are handled
in these cells and which molecular chaperones are important for this (Shorter, 2008). It is also
unlikely that molecular chaperones alone are capable of reducing disulfide bonds without the help
of thioredoxins as they do not possess the mechanisms for disulfide bond reduction.

5.5

Cysteine Oxidation in Protein Regulation

Cysteines are one of the most highly conserved amino acid residues (Marino & Gladyshev, 2010),
as observed in our cysteine alignments studies for Nrf2 and Keap1 in Chapter 3. Accordingly,
cysteines are crucial to many cellular processes and often occur in the functional site of proteins
(regulatory, catalytic, cofactor-binding, etc.) (Marino & Gladyshev, 2010). Within the Keap1-Nrf2
antioxidant pathway, specific cysteines within Keap1 are required for sensing oxidative stress and
are thus critical for regulation of the antioxidant response (Dinkova-Kostova et al., 2002; Zhang
& Hannink, 2003; Wakabayashi et al., 2004; McMahon et al., 2010). Similarly, the Nrf2interacting and Parkinson’s disease-associated protein, DJ-1, relies on the oxidation of Cys106 to
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perform its cytoprotective function (Kim et al., 2009), while the E3 ubiquitin ligase activity of
another Parkinson’s-associated protein, parkin, requires the S-nitrosylation (addition of a nitric
oxide group) to critical cysteine residues (Chung et al., 2004). Evidently, oxidative modifications
such as cysteine oxidation are important for protein function. Aberrant cystine oxidation of Keap1
and Nrf2 and inclusion formation may thus function as an “on/off switch” for Nrf2 regulation
under higher oxidative stress conditions.
Future studies must investigate the functional consequences of stress-induced inclusion formation
of Nrf2 and Keap1. Perhaps under high levels of oxidative stress, Keap1, upon forming aberrant
intra- and inter-molecular disulfide bonds, misfolds, is inactivated, and cannot bind to Nrf2 to
target it for degradation, thus permanently allowing free Nrf2 to activate the antioxidant response.
Conversely, oxidized Nrf2 may be unable to bind Keap1, therefore escaping Keap1-mediated
degradation. This could be an adaptive or maladaptive mechanism of Nrf2 regulation under high
oxidative stress conditions. In this regard, determining the reversibility of this cysteine oxidation
and misfolding event is important, as irreversible oxidative damage and inactivation may lead to
constitutive Nrf2 activation, as observed in many human cancers (Praslicka et al., 2016).
Accordingly, in rapidly dividing cancer cells where ROS production is high (Reuter et al., 2010),
or in the process of ageing where there are marked decreases in antioxidant capacity (Liguori et
al., 2018), Nrf2, Keap1, and other proteins may be over-oxidized, resulting in the loss or
dysregulation of their activity. This is in line with the “redox stress hypothesis” (Sohal & Orr,
2012) which proposes an age-associated, pro-oxidizing shift in the redox state of cells that results
in the over-oxidation of protein thiols, thereby impairing signalling pathways. This may also be
applicable for human diseases beyond ageing, such as cancer progression and cancer therapy
resistance.

5.6

Off-Target Effects and Crosstalk Between Cell Stress Pathways

Hsp90 inhibitors have been the focus of many anti-cancer treatment regimens, particularly for
HER2+ breast cancer since inhibition of Hsp90 results in degradation of the HER2 receptor
(Tikhomirov & Carpenter, 2000; Solit et al., 2002). Although some clinical trials have shown
promising results, others have been halted due to adverse side effects or cancer recurrence
following treatment (Schopf et al., 2017). Off-target effects may explain the latter and must be
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investigated to optimize treatment outcomes. In Chapter 4, we observe the off-target up-regulation
of the antioxidant pathways through GPX2 and GPX3 during oxidative stress by Hsp90 inhibition.
Thus, in highly malignant and advanced cancer cell lines such as HER2+ cells, inhibition of one
stress response pathway seems to call upon a different stress pathway to alleviate the insult
encountered by the cancer cell. Indeed, the Nrf2-regulated antioxidant enzyme GPx2, which is
normally exclusively expressed in the intestinal epithelium (Brigelius-Flohé & Maiorino, 2013),
was recruited in response to oxidative stress and Hsp90 inhibition, thereby suggesting crosstalk
between the two stress response pathways. The heat shock response and antioxidant response
pathways tend to be studied as separate cell stress response pathways and therapeutics targeting
chaperones and antioxidant enzymes are often used independently without considering the possible
influence of one pathway on the other. This may hinder the efficacy of the therapeutic, thus, more
research should be conducted to investigate these types of off-target effects and the connection
between different cellular stress responses before entering the clinical trial stage.

5.7

Limitations

5.7.1 Chapter 2
Yeast is a powerful model organism to study protein interactions and the basic mechanisms of
cellular pathways. Yeast and human cells share fundamental commonalities for many conserved
cellular processes, including those regulating protein quality control (Mohammadi et al., 2015),
making the results directly relevant to humans. However, the yeast model also has limitations.
Yeast are single-cell organisms that are much simpler than humans and some conserved pathways
are more simplified in yeast (e.g., the unfolded protein response in yeast contains one pathway
while humans have three (Wu et al., 2014)); therefore, results are not always directly translatable.
Moreover, yeast does not express any close Nrf2 homologue. While this allows for the advantage
of minimizing interference with endogenous Nrf2 regulation as it occurs in mammalian cells (i.e.,
yeast as a “living test tube”), this also has its limitations in that endogenous factors that may have
otherwise influenced the interaction or mechanism are not present, which may ultimately lead to
imprecise results. For instance, in our yeast model of Nrf2, Cul3 is not present to mediate the
Keap1-dependent ubiquitination of Nrf2 because the Keap1-Nrf2 pathway does not exist in yeast.
Additionally, the plasmids used in our genetic interaction studies were high-copy expression
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plasmids that result in protein overexpression in yeast cells. It is therefore possible that this
artificially high copy number introduces unforeseen variables regarding genetic and proteinprotein interactions. Nonetheless, many important discoveries that are relevant to this work have
been discovered using yeast. Quite notably, in 1999, a yeast two-hybrid screen using the Neh2
domain of Nrf2 as ‘bait’ led to the discovery of Keap1 a the canonical Nrf2 repressor [42]. This
highlights the strength of yeast as a tool for detecting protein interactions.

5.7.2 Chapter 3
To assess Nrf2 and Keap1 oxidative stress-induced protein inclusion formation, yeast and cultured
mammalian cells were used. Experiments were primarily conducted in HeLa cells, with minor
additional experiments in the 21MT-1 and SKBR3 breast cancer cell lines to confirm some results
observed in HeLa. It is important to note that all three cell lines are cancer cell lines and may thus
carry mutations or other aberrations, which could undermine experimental outcomes. Although
this inclusion formation was observed in yeast, future experiments must still be conducted in noncancerous cell lines and eventually animal models to verify that our findings are not cancer cellspecific. Additionally, due to the rapid growth of cells in artificial culture (especially cancer cells),
there is a high chance of mutation and genetic variation within the cell population (Hastings &
Franks, 1983). This may lead to heterogeneity within the cell population that cannot be easily be
distinguished, leading to inaccurate results. This is a limitation for all traditional cell culture
experiments in general, including those in Chapter 4.
As mentioned before, observations regarding the temporal formation and possible solubilization
of these protein inclusions were not yet determined. In our experiments, cells were treated with
hydrogen peroxide for a total of 3 h, but visualization after 30 mins and 1, 2 and 3 h of hydrogen
peroxide treatment (data not shown) but did not yield any significant differences, implying that
this oxidation event may be very rapid and more precise imaging methods are required. Finally,
although this study documented the formation of stress-induced protein inclusions that was
verified using three different models (yeast, mammalian cells, and purified protein) and different
forms of cell stress, functional analyses will need to be addressed in future studies.
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5.7.3 Chapter 4
The main limitation of Chapter 4 is that it is currently incomplete due to the restrictions imposed
by the COVID-19 pandemic starting in March 2020 that prevented laboratory access and hindered
some of my work. For this reason, the key experiment involving the proposed co-inhibition of
Hsp90 and GPx could not be performed. Additionally, the western blots using a total protein
internal loading control could not be completed. These experiments will be completed following
my Ph.D. defence for publication purposes.
With regards to experimental limitations, because this study involves the use of artificially cultured
cells, it is also subject to the limitations discussed in Section 5.7.2, namely the high likelihood of
mutations and resultant population heterogeneity. Additionally, because these cells are cultured in
a monolayer, cell-cell interactions and cell-cell signalling that may have existed between these
cells within a tumour cannot be accurately be recapitulated, making the results less transferable to
a clinically relevant scenario. This limitation may be addressed with the use of 3D cell culture
systems which have been gaining traction over the past decade for the advantages they provide
over traditional 2D cell culture (Ravi et al., 2015). Importantly for this study, this method allows
for the formation of scaffolds and matrices and more closely mimics the tissue architecture and
microenvironment of a tumour, thereby providing more accurate drug response studies (Ravi et
al., 2015). However, 3D cell cultures are time-consuming, labour-intensive, and expensive (Lee et
al., 2019) and therefore not a feasible option for all laboratories. An additional limitation is that
our RT-qPCR studies were limited to a select number of Nrf2 and Hsf1 genes rather than assessing
transcriptome-wide changes (e.g., by RNAseq (Wang et al., 2009)) due to the high associated
costs. Nrf2 and Hsp90 are involved in many cellular processes and regulate a vast array of proteins,
thus, additional off-target effects associated with Hsp90 inhibition could exist that go beyond what
is observed in this study. We are therefore dependent on future work and other research groups to
fill in these gaps.
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5.8

Future Directions

Many aspects of this work provide exciting trajectories to be explored in future studies. Regarding
the interaction between Nrf2 and Keap1 with Hsp90, although previous work has revealed that
Hsp90 prefers Kelch domains (Taipale et al., 2012) like those found in Keap1, the exact binding
between Nrf2 and Hsp90 and the underlying molecular mechanisms and functional outcomes are
still unknown. Future work could use the yeast model of Nrf2 to perform domain analyses, in
addition to biophysical techniques such as nuclear magnetic resonance (NMR) and isothermal
titration calorimetry (ITC) to determine the exact interaction sites for these two proteins.
Furthermore, the Nrf2 yeast model could be used to screen for small-molecule inhibitors or
compounds that modulate Nrf2 interactions with other proteins or to screen for additional genetic
and protein-protein interactions that have not yet been described. As Nrf2 is an intrinsically
disordered protein, it has the potential to bind to an unusually vast array of proteins, some of which
may still be unknown.
For our protein oxidation studies, live-cell imaging would be very informative, and expansion into
non-cancer cell lines and animal models, as well as the use of different oxidative stress compounds,
is important, as discussed above. Other key experiments would be to determine the functional
outcome of Nrf2 and Keap1 inclusion formation, particularly to determine if the Nrf2 antioxidant
response can still be activated if Nrf2 or Keap1 are included, and to determine the degree of
reversibility (i.e., by thioredoxin and/or molecular chaperones). Domain analyses may also reveal
if certain domains are more prone to misfolding than others, or if the full-length protein is
necessary for inclusion formation. We found that the Kelch domain of Keap1 alone is not sufficient
for inclusion formation, but the other domains remain to be studied. Finally, given the harsh
microenvironment of a rapidly dividing cancer cell where ROS is prevalent, it would be interesting
to determine if stress-induced Nrf2 and Keap1 inclusions are present in cancer patient samples
using immunohistochemistry (IHC). These results encourage us to start such pathological studies
in breast cancer.
For our Hsp90 inhibition studies in HER2+ breast cancer, short-term directions include completing
the remaining experiments to assess the co-inhibition of Hsp90 and GPx activity. Cell viability
and cell death assays will be used to determine the efficacy of Trastuzumab and chemotherapy
treatment with this co-inhibition. Western blots will also be completed. For long-term experiments,
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considering that cancer cells can develop resistance to therapy, it would be important to determine
if HER2+ breast cancer cells will become resistant to our proposed combined treatment regimen.
Resistance to Trastuzumab (Luque-Cabal et al., 2016; Li et al., 2018) and chemotherapy (Ji et al.,
2019; Lainetti et al., 2020) have been well documented; however, the question remains if resistance
will be delayed or inhibited with the co-inhibition of Hsp90 and GPx, or if cancer cells can develop
resistance to Hsp90 inhibitors in general. A single mutation in the N-terminal ATP-binding site of
Hsp90 has been found to result in resistance to Hsp90 inhibitors (Duerfeldt & Blagg, 2009) but
the mechanism remains unknown and it is unclear if this happens in a prolonged cancer treatment
scenario. Lastly, HER2 plays an important role in cancer cell proliferation and tumour metastasis
in other cancers apart from breast cancer, with HER2 overexpression being detected in pancreatic
cancer (Stoecklein et al., 2004) and HER2 as a predictor of poor prognosis in ovarian cancer (Luo
et al., 2018). If the results in HER2+ breast cancer turn out to be promising, they could be extended
into these other HER2+ cancer subtypes.

5.9

Overall Significance

The antioxidant and heat shock responses are often discussed independently as two separate
pathways regulating two different types of cellular stress. In this work, we show that there is
convergence and crosstalk between these pathways using a yeast model for Nrf2 and a human
breast cancer model for HER2-enriched breast cancer. We also examined aspects of protein folding
by investigating the misfolding of Nrf2 and Keap1 under oxidative stress conditions. Our findings
suggest that oxidative damage to Nrf2 and Keap1 and their interactions with Hsp90 alter their
regulation and function within the cellular antioxidant stress response. Taken together, we
explored aspects of two key cellular stress response pathways and considered their implications in
protein regulation, folding, and function, and suggest that investigating these key pathways in
parallel may provide an additional layer of knowledge that is relevant to both basic science and
clinical research.
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5.10 Graphical Summary

Figure 5.4: Graphical summary of Chapters 2, 3, and 4. A novel yeast model of Nrf2 detects
the interaction between Nrf2 and Keap1 with Hsp90. Furthermore, oxidative damage to Nrf2 and
Keap1 and their interactions with Hsp90 alter their regulation and function within the cellular
antioxidant stress response. This nexus between the antioxidant and heat shock responses is thus
an important area of research.
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Abstracts and Presentations
a) National/International Meetings
2020 Nov

Ngo, V., Karunatilleke, N., Song, Z., Brickenden, A., Krstic, M., Choy, W. Y., &
Duennwald, M. L. Oxidative stress-induced aggregation of Keap1 impairs Nrf2
regulation. Poster presentation at the 27th Annual Conference of the Society for Redox
Biology and Medicine (SfRBM). Virtual platform.
*Awarded a Young Investigator Award
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2019 Jun

Ngo, V., Krstic, M., Brickenden, A., Karunatilleke, N., Choy, W. Y., & Duennwald,
M. L. Novel crosstalk between the antioxidant and heat shock responses in cancer.
Selected for an oral presentation at the 62nd Annual Conference of the Canadian
Society for Molecular Biosciences (CSMB) Model Systems in Cancer Research.
Montreal, QC, Canada.

2019 Oct

Karunatilleke, N., Fast, C., Ngo, V., Brickenden, A., Duennwald, M. L., Konermann,
L., & Choy, W. Y. Nrf2, the key transcription factor that regulates the cellular
response to oxidative stress, is intrinsically disordered. Co-author for oral presentation
by N. K. at the 18th International Conference on Structural Biology. London, England,
UK.

2018 Jul

Ngo, V. & Duennwald, M. L. Oxidative stress-induced aggregation of Keap1 impairs
Keap1-dependent Nrf2 regulation. Selected for a lightning talk and poster presentation
at the FASEB Science Research Conferences: Protein Folding in the Cell. Olean, NY,
USA.

2018 Apr

Ngo, V. & Duennwald, M. L. Nrf2 regulation in the antioxidant response in cancer:
Stress-induced aggregation of Nrf2 and Keap1. Selected for a lightning talk and poster
presentation at the 11th Conference on Signaling in Normal and Cancer Cells. Banff,
AB, Canada.

b) Regional/Institutional Meetings
2019 Mar

Ngo, V., Krstic, M., Karunatilleke, N., Song, Z., Brickenden, A., Allan, A. L., Choy,
W. Y., & Duennwald, M. L. Oxidative stress-induced aggregation of Keap1 impairs
Keap1-dependent Nrf2 regulation. Selected for a platform presentation at Pathology
and Laboratory Medicine Research Day. London, ON.
*Awarded the Dr. M. Daria Haust Award for the Best Basic Science Presentation

2018 May

Ngo, V. & Duennwald, M. L. Nrf2 regulation in the antioxidant response in cancer.
Poster presentation at London Health Research Day. London, ON.

2018 Apr

Ngo, V. & Duennwald, M. L. Nrf2 regulation in the antioxidant response in cancer.
Poster presentation at Pathology and Laboratory Medicine Research Day. London,
ON.

2017 Mar

Ngo, V. & Duennwald, M. L. The interaction between p21 and Nrf2 regulates
oxidative stress in cancer. Selected for a platform presentation at Pathology and
Laboratory Medicine Research Day. London, ON.

2017 Mar

Ngo, V. & Duennwald, M. L. The interaction between p21 and Nrf2 regulates
oxidative stress in cancer. Poster presentation at Pathology and Laboratory Medicine
Research Day. London, ON.

2016 Apr

Ngo, V. & Duennwald, M. L. Nrf2 interactions with p21, prothymosin alpha, and
Keap1 in cancer. Poster presentation at Pathology and Laboratory Medicine Research
Day. London, ON.
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Ngo, V. & Duennwald, M. L. Nrf2 interactions with p21, prothymosin alpha, and
Keap1 in cancer. Poster presentation at London Health Research Day. London, ON.
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Tong, J., Ngo, V., & Goldreich, D. Testing a Bayesian model of perceptual length
contraction illusions. Poster presentation at the Southern Ontario Neuroscience
Association Conference. Niagara Falls, ON.
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Ngo, V., Tong, J., & Goldreich, D. Testing a Bayesian model of the tactile rabbit and
tau illusions. Poster presentation at the Lake Ontario Visionary Establishment
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Ngo, V., Tong, J., & Goldreich, D. Testing a Bayesian observer model of the
cutaneous rabbit illusion. Poster presentation at the NeuroXchange Conference.
Hamilton, ON.
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